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Abstract 
 
Rheumatoid Arthritis (RA) is a heterogeneous disease with variable outcomes. Its 
contemporary treatment has made remission a reality with an increasing 
proportion of patients achieving this target. The goal of this thesis was to improve 
knowledge of RA remission and its clinical implications. It had three aims. Firstly to 
define remission and sustained remission using an extended range of clinical, 
laboratory and radiological biomarkers. Secondly to identify clinical and 
laboratory predictors of remission. Thirdly, to assess the impact of remission on 
health-related quality of life.  
 
Systematically reviewing published early RA studies showed 17% achieved 
remission using the most stringent criteria and 33% using the least stringent 
criteria. Intensive treatment increased the frequency and structural benefits of 
remission. Modelling studies in early RA patients from an early RA trial and large 
observational cohort showed remission was predicted by age, gender, and tender 
joint count. Studies in a new, unique cohort of 104 RA patients with stable low 
disease activity followed for 12 months (REMIRA) showed remission was frequent 
with the least stringent criteria and rare with the most stringent ones. Only a 
minority of patients achieved sustained remissions. Ethnicity and conventional 
disease activity assessments predicted sustained remissions. Sustained remissions 
were also predicted by the multi-biomarker disease activity score and four of its 
components (highly sensitive C-reactive protein, serum amyloid-A protein, 
interleukin-6 and leptin). Finally, achieving sustained remission maximised quality 
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of life outcomes compared to low disease activity states throughout the study 
period. 
 
This thesis has made novel contributions towards the understanding of RA 
remission which has important impact in the clinical setting. The use of clinical and 
laboratory biomarkers can predict sustained remission and therefore guide 
treatment decisions. With the growing emphasis on personalised medicine, this 
thesis brings us one step closer to achieving individualised care in RA.  
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DMARDs   Disease Modifying Anti-Rheumatic Drugs 
 ERAN    Early Rheumatoid Arthritis Network 
ESR    Erythrocyte Sedimentation Rate 
 EMS    Early Morning Stiffness 
 EULAR   European League Against Rheumatism 
EGF    Epidermal growth factor  
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FACIT – F Functional assessment of chronic illness 
therapy – Fatigue 
FDA    Food and Drugs Administration 
FINRACO study  Finnish RA Combination Therapy 
HACA    Human anti-chimeric antibody 
HBSS    Hank’s Balance Salt Solution 
HRQoL   Health related quality of life 
hsCRP    High sensitive C-Reactive Protein 
IA    Intra-articular Injection 
ICC     Intraclass Correlation Coefficient  
IL 6    Interleukin 6     
IM    Intramuscular Injection 
InFoRM    The index of RA measurement study  
IQR    Inter-quartile range 
JIA    Juvenile Idiopathic Arthritis 
KCH    King’s College Hospital 
 LDAS    Low disease activity state 
MBDA score   Multi-biomarker disease activity score 
MCID    Minimum clinically important changes 
MCP1-5   Metacarpophalangeal joint 1-5 
MMP1    Matrix metalloproteinase 1  
MMP3    Matrix metalloproteinase 3  
MRI    Magnetic resonance imaging 
MTP    Metatarsophalangeal  joint 
MTX    Methotrexate 
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NICE National Institute of Health and Clinical 
Excellence  
NTT     Number needed to treat 
PBS    Phosphate buffered saline 
PIP     Proximal interphalangeal  
 RA    Rheumatoid Arthritis 
 RCT    Randomised Control Trial 
REMIRA study  Remission in Rheumatoid Arthritis study 
RF IgA    Rheumatoid Factor IgA isotype 
RF IgG    Rheumatoid Factor IgG isotype 
RF IgM   Rheumatoid Factor IgM isotype 
SAA    Serum amyloid A  
SD    Standard Deviation 
SF36 MCS Medical Outcomes Study 36-Item Short-Form 
Health Survey Mental component score 
SF36 PCS Medical Outcomes Study 36-Item Short-Form 
Health Survey physical component score 
SJC    Swollen Joint Count 
 SSZ    Sulfasalazine 
 TICORA study  Tight control for rheumatoid arthritis 
TJC    Tender Joint Count 
TNF-R1   Tumour necorsis factor receptor 1  
OR Odds Ratio 
 UHL    University Hospital Lewisham 
 VAS    Visual Analogue Score 
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VCAM1   Vascular cell adhesion molecule 1 
VEGF-A   Vascular endothelial growth factor – A  
vdH-SS   van der Heijde modification of the Sharp Score 
YKL-40    Human cartilage glycoprotein-39 
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1 Introduction 
1.1 Rheumatoid Arthritis 
Rheumatoid Arthritis (RA) is a chronic, multi-systemic, inflammatory disease 
characterised by uncontrolled proliferation of the synovial tissue. This leads to 
damage of the joints and ultimately loss of function and disability. It is the most 
common cause of chronic inflammatory joint disease, occurring in 0.8% of the 
adult population in the UK and is more common in women.  In addition to joint 
damage, RA can also cause extra-articular manifestations including vasculitis, 
anaemia, osteoporosis, pulmonary involvement and psychological disorders. It is 
also associated with an increased risk of cardiovascular disease.  
 
The economic burden of RA is considerable for patients as well as for the health 
care and social services (Pugner et al. 2000, Kobelt and Jonsson 2008). About 30% 
of patients are unable to work within 10 years of onset of RA and 50% after 20 
years (Scott et al. 1987, Wolfe, Hawley 1998). The total costs of RA in the UK, 
including indirect costs and work related disability have been estimated at 
between £3.8 - 4.75 billion per year (NICE 2009). 
 
In the last 10 years, there have been major advances in the treatment of RA. 
Studies have shown that early and aggressive treatment is important to improve 
clinical outcomes. In addition, when compared to DMARD monotherapy, 
therapeutic regimes using combination DMARD therapy or anti-TNF therapy 
combined with Methotrexate have been shown to be superior in terms of clinical 
and radiographic outcomes in early RA (Breedveld et al. 2006, Breedveld et al. 
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2004, Smolen et al. 2009a, Keystone et al. 2009) and established RA (Klareskog et 
al. 2004, Maini et al. 1998). The aim of RA therapy has now shifted from 
symptomatic control to strategies aiming at inducing and maintaining remission.  
 
1.2 Clinical presentations of RA  
RA is the most common chronic inflammatory joint disease. There are no single 
clinical sign, symptom, test nor histological finding which is pathognomoic of 
rheumatoid arthritis. It is a heterogenous disease diagnosed by applying a 
combination of clinical findings and laboratory tests. It has a highly variable 
disease onset and disease course. The presentation can vary from a gradual, 
insidious onset to explosive acute disease onset with fever, polyarthritis and extra-
articular features. Articular signs and symptoms include pain, swelling and 
stiffness in a symmetrical manner involving small joints of the hands and feet. The 
typical clinical finding of synovitis includes soft tissue swelling and tenderness 
(Figure 1.1). Concomitant bursitis, tenosynovitis and carpal tunnel syndrome 
maybe present. Systemic symptoms include generalized weakness, weight loss and 
low-grade fever.  
 
If patients are left untreated or under-treated, joint deformities can occur. These 
include Boutonniere’s deformity, swan neck, joint subluxation, ulnar deviation and 
tendon rupture (Figure 1.1). Atlantoaxial subluxation of the cervical spine is rare 
but potentially life-threatening complication of RA.  
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Figure 1-1: Clinical presentation of Rheumatoid Arthritis. 
A) Early RA. Symmetrical swelling of proximal interphalangeal joints, the 
metacarpophalangeal joint B) Established RA with chronic changes: ulnar 
deviation, Z-thumb and MPCJ subluxations. Picture courtesy of ACR image bank 
 
 
The incidence and prevalence of RA is 2-4 times higher in females than men. This 
ratio decreases with age. It can affect patients of any age but its incidence rate 
seems to increase with age up to a plateau of around 60 years. Elderly-onset RA is 
classified as patients with a diagnosis of RA after the age of 65.  
 
One variant of RA is palindromic rheumatism which presents with episodes of 
acute polyarthritis involving one or more large or peripheral joints.  These 
episodes last from hours to days and there is spontaneous resolution of symtoms 
and signs in between attacks. Approximately one third of patients will evolve into 
classical RA.  
 
The laboratory tests include elevated ESR and CRP. Thrombocyotosis, leucocytosis 
and anaemia are common. RF (rheumatoid factor) and ACPA (anti-citrullinated 
peptide antibody) are important serological tests are important for diagnosis and 
for prognosis. These serological biomarkers will be discussed in more details in 
(A) Early RA (B) Established RA 
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sections 1.5 and 1.6. Imaging is useful for the diagnosis of rheumatoid arthritis. 
Conventional radiographic examinations are still the gold standard for assessing 
joint damage. The use of ultrasound has become standard practice in clinics. It is of 
use at disease onset to detect subclinical synovitis of symptomatic joints. In 
addition, it also has a role in assessing erosions which may not be detectable on 
conventional x-rays. MRI has also been shown to be sensitive at detecting early 
synovitis. However, due to its costs and availability, its use in clinical practice is 
limited. These imaging modalities are discussed in more detail in sections 1.10. 
 
Extra-articular manifestations and RA-related comorbities include (EULAR 
textbook): 
1. Secondary osteoporosis 
2. Muscle weakness may be related to neuropathy, steroid use or joint 
involvement 
3. Secondary Sjogren’s 
4. Eye complications including Scleritis or episcleritis 
5. Increased risk of malignancy including lymphomas 
6. Vasculitis 
7. Pulmonary involvement including pleuritis, interstitial lung disease, or nodules 
8. Pericarditis 
9. Increased risk of coronary heart disease  
10.  Secondary amyloidosis 
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1.3 Classification of RA 
The classification for RA used in this thesis is the American Rheumatism 
Association (ARA) 1987 revised criteria (Arnett et al. 1988). They require four of 
the following: 
1. Early Morning Stiffness ≥1 hour before maximal improvement for >6 weeks 
2. Soft tissue swelling of ≥ 3 joint areas ≥ 6 weeks 
3. Symmetric arthritis ≥ 6 weeks  
4. Hand joint involvement (PIP/MCP/wrists) 
5. Subcutaneous nodules 
6. Positive test for rheumatoid factor 
7. Radiographic erosions or pericarticular osteopenia in hand or wrist 
 
After this thesis has started, the new 2010 ACR /EULAR criteria for RA were 
released (Aletaha et al. 2010). They require ≥6/10 points for a definitive 
classification of rheumatoid arthritis. The new criteria were not used in this thesis 
as patient recruitment preceded their publication. 
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Table 1-1 New 2010 ACR/EULAR criteria for RA (Aletaha et al. 2010) 
 
Patients who have at least 1 joint with definite clinical synovitis (swelling) with the 
synovitis not better explained by another disease* 
 
A. Joint involvement Score 
1 large joint 0 
2-10 large joints 1 
1-3 small joints (with or without involvement of large joints) 2 
4-10 small joints (with or without involvement of large joints) 3 
>10 joints (at least 1 small joint) 5 
B. Serology (at least 1 test result is needed for classification)  
Negative RF and negative ACPA 0 
Low-positive RF or low-positive ACPA 2 
High-positive RF or high-positive ACPA 3 
C. Acute-phase reactants (at least 1 test result is needed)  
Normal CRP and normal ESR 0 
Abnormal CRP or abnormal ESR 1 
D. Duration of symptoms  
<6 weeks 0 
≥6 weeks 1 
 
Patients have to score 6 or more to fulfil criteria for RA 
*The criteria are aimed at classification of newly presenting patients. In addition, patients with 
erosive disease typical of rheumatoid arthritis (RA) with a history compatible with prior fulfillment 
of the 2010 criteria should be classified as having RA. Patients with longstanding disease, including 
those whose disease is inactive (with or without treatment) who, based on retrospectively available 
data, have previously fulfilled the 2010 criteria should be classified as having RA. 
1.4 Pathogenesis of Rheumatoid Arthritis 
There is marked heterogeneity in RA in terms of clinical presentation, natural 
history, outcomes and responsiveness to treatment. The pathogenesis of RA is far 
from understood. On a background of genetic susceptibility, an external trigger (eg 
cigarette smoking, infection or trauma) triggers an autoimmune reaction leading to 
synovial hypertrophy and chronic joint inflammation.   
 
It is thought that triggers of the innate immune system activate peripheral 
dendritic cells. These antigen presenting cells then migrate to lymph nodes, where 
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they present the antigen to T-lymphocytes, forming a complex of antigen, class II 
major histocompatibility complex and T-cell receptor. Other co-stimulatory 
molecules such as cytotoxic T-lymphocyte-associated antigen-4 and CD28 are also 
involved in the interaction. B cells are also activated which then generates 
antibodies RF and ACPA. This process defines the activation of the adaptive 
immune system. Effector T lymphocytes (Th1 and Th17) then proliferate and 
migrate into the joints. Cell migration is enabled through increased expression of 
adhesion molecules and cheomokines within the synovial microvessels. This 
process of neoangiogensis is induced by local hypoxic conditions and cytokines. 
These changes within the synovium combined with synovial architectural 
reorganization and local fibroblast activation, permit the buildup of synovial 
inflammatory tissue in rheumatoid arthritis (Scott, Kingsley 2006, McInnes, Schett 
2011, Figure 1.2).  
 
Pro-inflammatory cytokines of importance in RA include TNF-, IL-1, IL-6 and IL-
17. This immune response is then amplified by stimulating mononuclear cells, 
synovial fibroblasts, chondrocytes and osteoclasts. Erosion of cartilage and bone is 
associated with the formation of a proliferating pannus. The interface between 
pannus and cartilage is occupied predominantly by activated macrophages and 
synovial fibroblasts that express matrix metalloproteinases (MMPs) and 
cathepsins, which are cartilage-degrading enzymes (Scott, Kingsley 2006, McInnes, 
Schett 2011).  
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Figure 1-2 Pathogensis of Rheumatoid Arthritis 
Innate and adaptive immune processes within the joint in Rheumatoid arthritis 
(McInnes, Schett 2011) 
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1.5 Rheumatoid Factor 
Rheumatoid Factor (RF) was the first serological biomarker to be identified in RA. 
It was first observed by Waaler in 1940 when a factor in sera of patients with RA 
agglutinated red blood cells sensitized with immunoglobulin IgG antibodies 
(Waaler 2007).  It binds to the γ2-γ3 cleft on the Fc portion of IgG. Though 
originally observed as an IgM antibody which agglutinated latex particles coated 
with human IgG, RF is known to also include both IgA and IgG isotypes. IgM isotype 
remains the most commonly analysed diagnostically. Numerous detection methods 
exist to detect RF, including latex and agglutination tests, as well as more 
quantitative ELISAs. It is present in 70-90% of patients with RA. RF remains an 
important criterion in the ARA criteria for the classification of Rheumatoid 
arthritis. With the newer ACR 2010 revised criteria for classifying RA (Aletaha et 
al. 2010), levels of RF titres (negative/low-positive/high-positive) are 
incorporated within this revised criterion. RF is detectable in a number of other 
autoimmune conditions, such as Sjögren’s syndrome (60-80%) and 
Cryoglobulinaemia (40-100%) as well as infectious diseases. Furthermore, RF has 
been found in healthy individuals, particularly with older age (5%). Nevertheless 
RF detection is still of clinical importance in RA. High titres have been associated 
with more a severe disease state, whilst the presence of both IgM and IgA isotypes 
has been demonstrated to have a high diagnostic value (Jonsson et al. 1998), and 
the presence of all three isotypes produced a positive predictive value of 96% 
(Swedler et al. 1997). Studies have suggested that IgA RF positivity is associated 
with more active RA, increased joint damage and a higher frequency of extra-
articular manifestations (Jonsson, Valdimarsson 1998). IgA RF positivity in healthy 
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people is also a predictor of the development of RA (Rantapaa-Dahlqvist et al. 
2003).  IgG RF is often present in sera and synovial fluid of patients with severe RA. 
Its role in monitoring response to therapy has been described in rheumatoid 
vasculitis (Scott et al. 1981). 
 
1.6 Anti-cyclic citrullinated peptide antibodies 
Antibodies to perinuclear factor (Nienhuis, Mandema 1964) and keratin (Young et 
al. 1979) have been previously shown to be highly specific for RA. These antibodies 
are directed against citrulline containing epitopes. Citrulline is a not a naturally 
occuring amino acid as it is not incorporated into proteins during protein 
synthesis. It is generated via post-translational modification of arginine residues 
by one of a family of enzymes called peptidylarginine deiminases (PAD). 
Subsequent studies have shown autoantibodies reactive to cyclic synthetic 
peptides containing citrulline detected using an ELISA based assay were highly 
specific to RA. This formed the basis of the anti-CCP test. In an effort to improve the 
sensitivity of this test, a dedicated library of synthetic citrulline-containing 
peptides were screened with RA sera and a new set of peptides (CCP2) was 
developed giving superior performance compared to the CCP1 test. Anti-CCP 
detection in the routine clinical laboratories is principally derived from the anti-
CCP2 assay, formed from a large scale screening of unknown citrullinated peptides 
using RA sera (Vossenaar, van Venrooij 2004). 
 
Anti-CCP antibodies are also termed anti-citrullinated peptide antibodies (ACPAs). 
It is present in approximately 70-80% of RA patients. The revised ACR/EULAR 
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2010 RA classification critiera has included the use of ACPA. A recent systematic 
literature review found the assay had specificity for RA, ranging from 81-100% 
and sensitivity ranging from 39-94% (Avouac, Gossec & Dougados 2006). ACPA 
can be present early in disease and may precede onset of symptoms by many 
years(Rantapaa-Dahlqvist et al. 2003). It can also predict the development of RA in 
patients with early undifferentiated arthritis (van Gaalen et al. 2004). ACPA has 
been reported as a better predictor of more severe disease than RF (Kastbom et al. 
2004) and the presence of ACPA is a predictor of radiographic damage at baseline 
and progression over 24 months (Vencovsky et al. 2003).  
 
1.7  Assessment of Disease Activity in Rheumatoid Arthritis 
The symptoms and signs of RA vary over time and between individual patients. 
Clinical variables range from early morning stiffness, joint pain, joint swelling and 
functional impairment to more general symptoms such as fatigue and impairment 
of general health. Because of this variety in disease expression, a selection of 
variables is needed to assess disease activity. In clinical trials, disease activity is 
based on sets of clinical variables developed by EULAR or ACR. The EULAR 
response criteria use the individual change in the composite score DAS28 and the 
level of DAS28 reached whereas ACR response measures percentage change. 
Despite their differences, they were found to be in reasonable agreement in the 
same set of clinical trials (van Gestel et al. 1999).   
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The advantages of DAS, DAS28 and EULAR response criteria include: 
1) DAS and DAS28 are continuous scales and reflect the degree of underlying 
inflammation whereas ACR response criteria are a measure of change.  
2) DAS has a Gaussian distribution and is easier to interpret in clinical trials.  
3) DAS is also sensitive enough to assess small effects.  
4) As it is an absolute number, responses to treatment in trials can be compared. 
5) Trial results can be expressed as a clinically meaningful outcome, which can be 
translated into the clinical setting. 
 
1.7.1 Disease Activity Score (DAS) 
The disease activity score (DAS) was developed on the basis of a large prospective 
study in which the decision of rheumatologists to start a DMARD because of 
disease activity or to stop treatment because of disease remission were equated 
with high and low disease activity, respectively (van der Heijde et al. 1990, van der 
Heijde et al. 1993). Data from early RA patients (< 3 yrs) were used.  Following this, 
a new DAS formula was developed using the same procedure and same cohort but 
with up to 9 years of follow-up (Prevoo et al. 1995). The resulting DAS was almost 
identical demonstrating that disease duration did not influence the construction of 
the DAS. The original DAS consists of the following composite variables: Ritchie 
articular index (RAI 0-78), 44 Swollen Joint Count (SJC, 0-44), Erythrocyte 
Sedimentation Rate (ESR) and general health assessment on a visual analogue 
scale (VAS, range 0-100), where the RAI is the sum of the grades of tenderness (0 = 
not tender, 1 = tender, 2 = tender and causes wince, and 3 = tender, causes wince 
and effort to withdraw) elicited by applying firm pressure over the joint margin of 
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articular joints. The joints involved include sternoclavicular, acromioclavicular, 
shoulder, elbow, wrist, MCP, PIP, knee, ankle, and MTP  
Its formula is as follows: 
0.53938*sqrt (Ritchie Articular Index) + 0.06465*(SJC) + 0.330*In(ESR) + 
0.00722*(General Health) 
 
The DAS uses the square-root and natural log transformation to provide a Gaussian 
distribution and is a continuous scale ranging from 0-10. As it also contains a 
patient’s global assessment of disease activity (VAS), it reflects patient-assessed 
disease activity as well. The level of disease activity is considered low (DAS <2.4), 
moderate (2.4-3.7) or high (>3.7). A DAS <1.6 corresponds to a state of remission 
according to the American Rheumatism Association (ARA) criteria.  
 
1.7.2 DAS28 
For reasons of convenience, a reduced DAS was created using fewer joints (Prevoo 
et al. 1995). It consists of 28 non-graded (compared to the RAI which is graded in 
terms of tenderness) Tender Joint Count (TJC, 0-28), 28 Swollen Joint Count (SJC, 
0-28), ESR and VAS (range 0-100). The DAS28 has a continuous scale ranging from 
0-9.4 and shows a Gaussian distribution in the RA populations. The 28 joints 
include all MCPs, PIPJs, wrists, elbows, shoulders and knees. 
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DAS and DAS28 values do not directly compare but the correlation was calculated 
to be 0.97. The level of disease activity can be interpreted as low (<3.2), moderate 
(3.2-5.1) or high (>5.1). A DAS28 <2.6 corresponds to being in remission according 
to the ARA criteria. This means that nearly all RA patients in remission have a 
DAS28<2.6 but not all patients with DAS28<2.6 are in remission. The DAS28 was 
validated using the data from the same cohort and data from a very similar cohort. 
Patients’ impressions of disease activity have been shown to correlate well with 
the DAS28 (Leeb et al. 2005). Furthermore, there is evidence from ultrasound 
studies that synovitis may be present in tender joints not considered to be swollen 
clinically (Scheel et al. 2005).  
 
1.7.3 DAS28-CRP 
An alternative formula for DAS28 has been developed which incorporates CRP 
instead of ESR. CRP correlates with disease activity, radiologic progression and 
treatment response (Nakamura 2000) and may be more preferable to ESR. DAS28 
CRP has been validated in cohorts of early (Hensor et al. 2010) and established 
(Wells et al. 2009) rheumatoid arthritis cohorts. The correlation coefficient 
between DAS28-ESR and DAS28-CRP was very strong (0.95). However, DAS28CRP 
threshold values were found to be lower at <2.3, 2.3-2.7 and > 4.1 corresponding to 
remission, LDA and high disease activity respectively (Inoue et al. 2007). 
 
Its formula is: 
0.56*SqrtTJC28+0.28*sqrtSJC28+0.36*In(CRP+1)+0.96 
+0.014*General Health 
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1.7.4 SDAI and CDAI 
The simplified disease activity index (SDAI) is a validated and sensitive assessment 
of disease activity and treatment response which is comparable with the DAS28 
and ACR response criteria (Smolen et al. 2003). It is an unweighted and 
untransformed index and therefore easy to calculate. It uses 5 variables: TJC28, 
SJC28, Patient VAS (PVAS; 10cm), physician VAS (PhVAS; 10cm) and CRP (mg/dl). 
It correlates highly with DAS28, physical function and progression of joint damage. 
The cut-offs for SDAI are ≤3.3, 3.3-11 and >26 corresponding to remission, LDA 
and high disease activity respectively. The SDAI can be further simplified in the 
form of the clinical disease activity index (CDAI) (Aletaha et al. 2005a) where the 
CRP is omitted. This also correlates well with HAQ and radiographic progression 
just as well as DAS28 and SDAI. The advantage of the CDAI is that assessments of 
disease activity in clinic can be carried out without the need for awaiting 
laboratory results. The cut-offs for CDAI are ≤2.8, 2.8-10 and >22 corresponding to 
remission, low disease activity (LDA) and high disease activity respectively.  
 
Their formulae are: 
SDAI = SJC28 + TJC 28 + PVAS + PhVAS + CRP 
CDAI = SJC28 + TJC 28 + PVAS + PhVAS 
 
1.7.5 ACR response 
In 1995, the ACR criteria (Felson et al. 1993) were developed as definitions of 
improvement aimed for use in clinical trials. Improvement is denoted as ACR 20, 
ACR 50 or ACR 70 reflecting an improvement to the 20%, 50%, or 70% level in 
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certain parameters.  These indices are now commonly used in clinical trials and 
this uniformity enables trials to be compared.  
 
ACR 20: 
 20% reduction in number of tender joints and swollen joints 
 Plus an improvement of at least 20% in at least 3 of: 
1. Patent’s assessment of pain 
2. Patient’s assessment of physical function 
3. CRP or ESR 
4. Patient global assessment of disease 
5. Physician global assessment of disease 
ACR 50: 
 50% reduction in number of tender joints and swollen joints 
 Plus an improvement of at least 50% in at least 3 of: 
1. Patent’s assessment of pain 
2. Patient’s assessment of physical function 
3. CRP or ESR 
4. Patient global assessment 
5. Physician global assessment of disease 
ACR 70: 
 70% reduction in number of tender joints and swollen joints 
 Plus an improvement of at least 70% in at least 3 of: 
1. Patent’s assessment of pain 
2. Patient’s assessment of physical function 
3. CRP or ESR 
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4. Patient global assessment 
5. Physician global assessment of disease 
1.7.6 Patient withdrawals for lack of efficacy and toxicity 
Despite an aim for uniformity in clinical outcome measures, there are still wide 
variations which are reported in different clinical trials. Choy et al., 2005 (Choy et 
al. 2005) investigated the use of patient withdrawals to assess lack of efficacy and 
adverse events in clinical trials. These outcome measures are routinely reported in 
clinical trials in accordance with CONSORT (Consolidated standards of reporting 
trials) guidelines (Begg et al. 1996). They found similar effects with these 
outcomes compared to ACR 20 and 70, therefore, confirming their validity. 
 
1.7.7 Multi-biomarker disease activity (MBDA) test for RA 
Clinical tools of disease activity have a critical role in guiding treatment decisions, 
but they are not without flaws. The clinical components are subject to intra and 
inter assessor variability (Uhlig, Kvien & Pincus 2009, Marhadour et al. 2010) and 
can be confounded by co-morbidities such as fibromyalgia (Leeb et al. 2004) and 
joint damage. The biomarkers within these clinical disease activity measures are 
non-specific and can be elevated in a number of conditions eg age, anaemia, 
infection and malignancy. It can also be normal in patients with active disease 
(Keenan, Swearingen & Yazici 2008, Sokka, Pincus 2009).  
 
A multi-biomaker disease activity test for rheumatoid arthritis has been developed 
to quantitatively and objectively characterize RA disease activity (Curtis et al. 
2012, Centola et al. 2013). Multiple serum biomarkers have been reported to have 
a role in assessing disease activity. A multiple-stage approach was taken to identify 
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suitable biomarkers. DAS28CRP was chosen as the gold-standard rather than 
DAS28-ESR as CRP measurements can be standardized in archived samples from 
multiple centres. Out of 396 candidate biomakers from the literature, 130 were 
considered to have adequate measurability. From these, 4 feasibility studies were 
carried out to prioritise the biomarkers. These yielded a set of 25 biomarkers. 
These were entered into the development phase. To ensure that the assays were 
suitable for use as a clinical diagnostic test, the assays were optimized to function 
in a multiplex environment with precision across time, instruments, operators and 
reagent lots. 703 patients in the The index of RA measurement study (InFORM) 
cohort were used for algothrim training. The final MBDA algorithm uses 12 
biomarkers to generate an MBDA score between 1 to 100. This has been shown to 
have the criterion and discriminant validity as an objective measure of RA disease 
activity and has been validated in several large RA cohorts (the index of RA 
measurement observational (InFoRM) study, Brigham and women’s hospital RA 
sequential study (BRASS) registry and the Leiden early arthritis clinic cohort.  This 
score appears to be independent of co-morbidities.  
The final algorithm consisted of 12 serum biomakers (Figure 1.3 and 1.4): 
1. YKL-40 (human cartilage glycoprotein-39) 
2. Interleukin 6 (IL 6) 
3. Serum amyloid A (SAA) 
4. Epidermal growth factor (EGF) 
5. Tumour necrosis factor receptor 1 (TNF-R1) 
6. Vascular endothelial growth factor – A (VEGF-A) 
7. Matrix metalloproteinase 1 (MMP1) 
8. Matrix metalloproteinase 3 (MMP3) 
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9. Resistin 
10. Leptin 
11. High sensitivity C-Reactive Protein (hsCRP) 
12. Vascular cell adhesion molecule 1 (VCAM1) 
These 12 biomarkers measure different biological pathways involved in the 
pathogenesis of RA and can be broadly grouped into acute-phase response (SAA, 
hsCRP, IL6), hormones (leptin and resistin), growth factors (VEGF and EGF), 
adhesion molecules (VCAM1), skeletal-related proteins (YKL-40), matrix 
metalloproteinases (MMP1, MMP3) and cytokine related proteins (TNFR1). The 
formulae used to predict TJC28, SJC28 and PGA are found in the appendix (11.4). 
The MBDA (multi-biomarker disease activity) thresholds for disease activity 
categories were determined by translating the DAS28-CRP thresholds to the 
corresponding MBDA scores based on the linear relationship between DAS28CRP 
and MBDA score as follows: 
 Remssion ≤ 25 
 Low Disease Activity Score 26 – 29 
 Moderate disease activity > 29 & ≤ 44 
 High disease activity > 44 
This assay, named Vectra-DA®, is now commercially available (Crescendo 
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Figure 1-3: MBDA Score Algothrim. 
Determination of the MBDA score from 12 serum biomarkers. The Venn diagram 
indicates which biomarkers are used to predict TJC, SJC and PGA scores. The resulting 
predictions (PTJC, PSJC, PPGA) are then combined with the CRP in the BMDA score 
equation shown which is analogous to that used to determine the DAS28-CRP. (Curtis 
et al. 2012) 
 
 
Figure 1-4 The Role of MBDA Biomarkers in RA 
Network map of MBDA biomarker roles in cellular communication in RA. (Centola et 
al. 2013) 
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1.7.8 C-X-C motif chemokine 10  
CXC motif chemokine 10 (CXCL10), also known as Interferon gamma-induced 
protein 10 (IP10) or small-inducible cytokine B10. It is a 10 kDa protein encoded 
by the CXCL10 gene. It belongs to the CXC subfamily chemokine containing a single 
and variable amino acid between the first 2 highly conserved cysteine amino acid. 
CXCL10 is considered to have potent inhibitors of angiogensis properties (Belperio 
et al. 2000). Its expression is increased in a wide range of autoimmune diseases 
incluing Autoimmune Thyroiditis, Graves’ Disease, Type 1 diabetes, systemic lupus 
erythematous, systemic sclerosis, cryoglobulinaemia as well as Rheumatoid 
Arthritis (Antonelli et al. 2013).  
 
It exerts its function through binding to chemokine (CXC motif) receptor 3 
(CXCR3), a seven transmembrane receptor coupled to G proteins. Its secretion by 
CD4+, CD8+, Natural Killer (NK) and NKT cells is dependent on Interferon gamma 
(IFNg). High levels of CXCL10 are therefore a marker of host immune response 
especially T helper 1 (Th1) cells which is of pathogenic importance in RA. CXCL10 
has been detected in synovial fluid, synovial tissue and serum of RA patients 
(Hanaoka et al. 2003). Serum levels have also found to be high in active disease 
and significantly reduced with response to treatment (Kuan et al. 2010). A phase II 
clinical trial using an anti-CXCL10 monoclonal antibody (MDX-1100) reported 
increased ACR20 response rate at week 12 compared to the placebo group in 
active RA patients who have failed Methotrexate treatment (Yellin et al. 2012). No 
differences were seen in ACR50 or ACR70 responses between the treatment and 
placebo arms.  
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CXCL10 was discarded from the MBDA panel was it was only high ranking in terms 
of performance in 1 out of 4 feasability studies (Curtis et al. 2012, Centola et al. 
2013).  
 
1.7.9 Calprotectin  
Calprotectin, a 36.5 kDa protein, is also known as S100A8/A9, MRP-8/MRP-14, 
calgranulin A/calgranulin B, cystic fibrosis antigen and L1. It is a major leucocyte 
protein, constituting 40-60% of the soluble cytosolic protein content in 
neutrophilic granulocytes, as well as being a major monocyte/macrophage protein. 
The protein is released during cell activation and turnover. It has been named an 
“alarmin’ which is an endogenous molecule that signals the early phase of tissue 
and cell damage (Andres Cerezo et al. 2011).  
Calprotectin is one of the calcium binding proinflammatory S100 proteins. The 
protein is released during the interaction of monocytes with inflammatory 
activated endothelium, probably at sites of local inflammation (Frosch et al. 2000) 
and it binds to endothelial cells to modulate transendotheial migration of 
leucocytes (Vogl et al. 2004). Unlike the acute phase proteins which are mainly of 
hepatic origin, calprotectin is locally releasied at the site of inflammation. 
Calprotectin was excluded from the MBDA panel as the assay did not meet the 
performance criteria required for clinical testing. 
 
Faecal calprotectin is routinely used for the detection of inflammatory bowel 
disease and is recommended by NICE for screening (NICE). In addition, high 
correlations between calprotectin and clinical measures have been found in 
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several inflammatory disease eg juvenile rheumatoid arthritis (Frosch et al. 2000), 
psoriatic arthritis (Kane et al. 2003), spondyloarthropathy (Kane et al. 2003), 
reactive arthritis (Hammer et al. 1995) and systemic lupus erythematous (Haga et 
al. 1993).  
 
In RA, calprotectin has been described within the synovial tissue (Youssef et al. 
1999) and high concentrations have been found in synovial fluid and blood of RA 
patients (Berntzen et al. 1991). The protein has been described as a good measure 
of disease activity and joint inflammation in RA (Madland et al. 2002). Moreover, 
Calprotectin was found to be an independent predictor of x-ray damage cross-
sectionally and longitudinally (Hammer et al. 2007, Hammer et al. 2010). Recently, 
it has been shown to correlate with ultrasound assessments which are 
independent of disease activity (Hammer et al. 2011).  
The role of calprotectin has been explored in juvevnile idiopathic arthritis (JIA) 
patients. Not only has it been shown to correlate strongly with disease activity 
(Frosch et al. 2000) but it also plays an important role in predicting good response 
to Methotrexate treatment (Moncrieffe et al. 2013) and predicting flares with drug 
tapering (Gerss et al. 2012). However, there is little in the literature describing 
calprotectin in low disease activity in RA. In early RA, normalisation of calprotectin 
levels has been reported in patients with treatment. It was found to be a predictive 
marker for improvement in swollen joints (Andres Cerezo et al. 2011). 
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1.8 Health Related quality of life assessments (HRQoL) 
1.8.1 HAQ 
The Health assessment questionnaire disability index (HAQ-DI) is a disease 
specific questionnaire for the assessment of Rheumatoid Arthritis. The 
questionnaire is a patient reported outcome (PRO) which is usually self-
administered by the patient. (a sample questionnaire is shown in the appendix 
11.15). 
The following categories are assessed by the HAQ-DI: 







8. Common Daily Activities 
The patients report the amount of difficulty they have in performing some of these 
activities. Each question asks on a scale ranging from 0 to 3 if the categories can be 
performed without any difficulty (scale 0) up to cannot be done at all (scale 3). The 
HAQ score represents the mean of the highest values within each single domain, 
and therefore, is located on a scale from 0 to 3, where higher values represent 
worse function and vice versa. Four domains are related to dexterity (dressing, 
eating, reach and grip) and four to mobility (rising, walking, hygiene, and errands 
and chores).  
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The HAQ is a validated instrument for the measurement of functional status used 
in clinical trials (Fries et al. 1980) and is sensitive to clinically relevant changes in 
function. It has been shown to predict several outcomes in RA such as mortality 
(Pincus, Sokka 2001), work disability (Sokka, Pincus 2001) and hip replacement 
surgery (Wolfe, Zwillich 1998). It has also been shown to correlate with 
inflammation (Devlin et al. 1997).  Gossec et al. (Gossec et al. 2004) followed 191 
patients with early RA (disease duration less than 1 year) for 5 years and reported 
that patients with a baseline HAQ score <1.25 had an OR of 2.8 for the occurrence 
of sustained remission between the third and fifth years of monitoring. Eberhardt 
et al also found that a lower HAQ score was a predictor of remission for patients 
with disease duration less than 2 years at initial evaluation (Eberhardt, Fex 1998) .  
 
In the literature, the HAQ score accepted as consistent with a remission state is 0.5, 
representing hardly any difficulties in daily activities. HAQ of 1.0 represents mild 
disability with some difficulties in all activities [(Molenaar, Voskuyl & Dijkmans 
2002)].  However, disease duration must be considered as the reversibility of HAQ 
decreases with longer disease duration (Aletaha, Smolen & Ward 2006). 
 
1.8.2 EuroQol 
EuroQol also known as EQ-5D is a standardized instrument for use as a generic 
measure of health outcome. It is an indirect preference-based health-related 
quality of life (HRQoL) instrument increasingly being used for economic evaluation 
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of clinical interventions and health programmes. Specifically for this study, we 
used the EQ-5D-3L which measures health-related quality of life states consisting 
of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, 
anxiety/depression) each of which can take one of 3 responses. The responses 
record 3 levels of severity (no problems/some or moderate problems/extreme 
problems) within each dimension. The combination of the five dimensions with the 
three answering categories produces 243 possible health states described as 
vectors ranging from 11111 (no problems in any domain) to 33333 (severe 
problems in all five domains) (e.g. 11231 corresponds to no problems walking 
around, no problems with self-care, some problems with performing usual 
activities, extreme pain or discomfort and not anxious or depressed). The EuroQol 
can also be reported as a preference-based, single index number. The latter is 
calculated by applying algorithms that link the five-digit health state description to 
average values for members of the general population by the time trade-off 
method. The EQ-5D allows for negative utility values, which theoretically 
correspond to health states worse than death. In addition, there is also a EQ VAS 
which is a 20cm vertical VAS that generates a self-rating of health-related quality 
of life (Anonymous1990, Brooks 1996).  
 
1.8.3 SF36 
The SF-36 (Ware, Sherbourne 1992) as patient-reported outcome measurement 
constitutes a questionnaire compromising 36 items. Different sets of items are 
organized into eight domains whose scores are obtained via summation and 
transformation of item values into a scale between 0 and 100, where higher values 
represent better health status. Domains and the respective number of comprising 
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items are as follows: physical function (PF; 10 items), physical role (RP; 4 items), 
bodily pain (BP; 2 items), general health perception (GHP; 5 items), vitality (VT; 4 
items), social function (SF; 2 items), emotional role (RE; 3 items) and mental health 
(MH; 5 items). One single item that is not summarized is measuring the change of 
health status compared with the preceding year (health transition; HT). 
Furthermore, domains can be aggregated into two summary measures: the 
physical component score (PCS; including PF, RP, BP and GHP) and the mental 
component score (MCS; VT, SF, RE and MH).  For norm-based scoring, scores of SF-
36 and its summary measures are transformed to a mean of 50 (S.D.10), achieving 
the same mean and S.D. across the domains and summary scores. This method 
enables more useful and easier interpretation of all scores.  The SF-36v2® Health 
Survey is a multi-purpose, 36-item health survey yielding a profile of two health 
component summary measures and eight health domain scales. It can be used 
across all adult patient and non-patient populations for a variety of purposes, such 
as screening individual patients, monitoring the results of care, comparing the 
relative burden of diseases, and comparing the benefits of different treatments. In 
the early 1990's, studies were initiated to address problems with meaning of 
words in some items and address well-documented shortcomings of the two role 
functioning scales, in version 1 of the tool. The result of the efforts was the 
development of the SF-36v2® Health Survey. Without increasing the number of 
questions, the SF-36v2® Health Survey improvements substantially increase the 
reliability and validity of scores and make the survey easier to understand and 
complete. Further, the norm-based scoring (NBS) algorithms make it possible to 
compare results across both versions of the SF-36v2® Health Surveys, eliminating 
concerns about loss of comparability. The NBS algorithms are useful to interpret 
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scores across the eight health domain scales of the SF-36v2®, to compare those 
domains with the two component summary measures.  
 
1.8.4 FACIT-F 
Fatigue is a prevalent and debilitating symptom in rheumatoid arthritis (Wolfe, 
Hawley & Wilson 1996). Fatigue is most often associated with pain, negative illness 
perceptions, sleep disturbances and low mood. It is also rated highly as an 
important RA outcome from the patients’ prespective. It has been identified by the 
OMERACT group as an important core outcome measure for the assessment of RA 
(Kirwan et al. 2007). Its absence is used as part of certain criteria for remission 
(Pinals, Masi & Larsen 1981).  
 
Many tools for assessing fatigue exist but none are specific to RA. Scales with 
evidence of validation for the measurement of fatigue in RA include 
Multidimensional assessment of fatigue (MAF), Global Fatigue index (GFI), Ordinal 
scores, visual analogue score, the multi-dimensional Functional Assessment of 
Chronic Illness Therapy Fatigue (FACIT-F), Profile of mood states (POMS) and 
SF36 vitality subscale (Hewlett, Hehir & Kirwan 2007). In this thesis, fatigue will 
be measured using a simple fatigue visual analogue score (VAS) and FACIT-F. 
FACIT-F is a well-validated quality-of-life instrument widely used for the 
assessment of chronic illnesses. Both have been validated for use in RA (Cella et al. 
2005, Hewlett, Hehir & Kirwan 2007). FACIT-F (Yellen et al. 1997) is a 13-item 
questionnaire that assesses self-reported fatigue (range 0-52). Its use is common 
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amongst clinical trials (Strand et al. 2012, Cohen et al. 2006, Keystone et al. 2008a, 
Weinblatt et al. 2003). A fall of disease activity is associated with improvement in 
fatigue in these trials suggesting that disease activity and fatigue are closely linked. 
Although, the study by Pollard et al., 2006 has suggested that high fatigue levels are 
associated more with pain and depression and that the association with disease 
activity may be secondary (Pollard et al. 2006).   
 
1.9 Radiographic outcome measures 
1.9.1 Radiographs in Rheumatoid Arthritis 
Conventional radiography remains an important part of the evaluation of patients 
with RA. Radiographic joint damage is one of the main outcomes in RA and is 
associated with functional impairment (Drossaers-Bakker et al. 1999). It occurs 
early in disease course. It is persistent and progressive, especially within the first 2 
years of disease onset (Fuchs et al. 1989, Wolfe, Sharp 1998).  
 
Radiographic examinations of the hands and feet are important at diagnosis as part 
of disease monitoring. NICE guidelines have advised that early RA patients should 
receive annual radiographs to monitor radiographic progression (NICE 2009). The 
characteristic changes seen are bone erosions and joint space narrowing (Figure 
1.5).  In advanced RA, the radiographs changes can also include misalignment, 
subluxation, dislocation, sclerosis and ankylosis. A variety of joints can be affected 
by RA including metacarpophalangeal (MCP) and proximal interphalangeal (PIP) 
joints in the hands, metatarsophalangeal (MTP) joints in the forefoot as well as 
joints in the mid-foot and hindfoot, the wrist, the knees, the glenohumeral joiunt at 
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the shoulder, the elbow and the cervical spine. The presence of erosions is part of 
the ACR/EULAR 2010 classification criteria for RA. Patients with erosive disease 
typical of rheumatoid arthritis (RA) with a history compatible with prior 
fulfillment of the 2010 criteria should be classified as having RA. 
 
Figure 1-5: Erosion in RA.  
(A) normal MCP, (B) thinning of cortex on radial side of proximal head of MCP with 
minimal JSN (C) marginal erosion with JSN.  Picture courtesy of ACR image bank 
 
 
Objective measures of damage have been developed to assess radiographic 
progression in clinical trials. A variety of scoring systems exists and all are based 
on plain radiographs of hands and feet. These include Sharp Score, van der Heijde 
modification of Sharp Score (vdHSS) and Larsen-Dale score.  
The relationship between disease activity and radiographic progression in early 
RA remains a topic of debate. The follow-up study of Cohen, et al found that 
sustained clinical remission correlated with stability of radiological damage in 
most patients (Cohen et al. 2007a). However, there was radiological progression in 
a proportion of patients (16.7%) in sustained remission (DAS <1.6 at 3 and 5 
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years), and 20% developed erosions in a previously unaffected joint between the 
third and fifth years. Other trials have also found radiological progression in 
patients in remission (Molenaar et al. 2004, Brown et al. 2008). It is therefore 
uncertain whether radiographic progression is wholly dependent on joint 
inflammation (Boers 2008). Another explanation may be that current assessment 
tools for disease activity are insensitive at low levels of inflammation and fail to 
detect ongoing disease activity. Radiographic remission is not considered within 
the remission criteria used in clinical practice. With the newest ACR/EULAR 
Boolean remission criteria, radiographic remission was used as a tool for testing 
predictive validity of their criteria.  
 
1.9.2 Ultrasound in Rheumatoid Arthritis 
The use of ultrasound for the management of patients with early arthritis has 
increased over recent years in both clinical practice and research settings. The 
advantages of ultrasound are that it is relatively inexpensive, non-invasive and 
allows many joints to be assessed at any one time. It can be done in real time 
within the clinic and yields instant information. The main disadvantage is its 
dependency on the skills of the operator and potential problems with 
reproducibility.  
 
Ultrasound has the capability to directly visualize both synovitis and bone damage. 
The 2 parameters of synovitis: Synovial Hypertrophy (SH) and Power Doppler 
(PD) (Figure 1.6). 
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Figure 1-6: Ultrasound of Metacarpalphalangeal Joint.  
(A) Synovial hypertophy (B) Power Doppler 
 
High resolution grey-scale ultrasonography (Fig 1.6A) allows morphological 
structures of the joints and surrounding tissues to be seen. Fluid and solid 
structures can be differentiated in their echotexture – solid structures (eg bone) 
are hyperechoic, whereas fluid appears anechoic. High-frequency transducers (6-
14 MHz) should be used for the examination of small joints and low-frequency 
transducers for large joints (5-10 MHz for hip and 8-14 MHz for the knee, elbow 
and shoulder).  
 
Doppler ultrasonography (Fig 1.6B) allows the blood flow to be visualized by the 
change in frequency of sound waves reflected by moving objects (The Doppler 
shift). PDUS is able to detect slow velocity flow signals eg typical for inflammation 
within joints and tendons.  
 
The presence of erosions can also be assessed which is defined as a break in the 
cortex visualized in both longitudinal and transverse planes. 
 
In research settings, assessments of both parameters of synovitis can be 
undertaken applying semi-quantitative scores or quantitative scores. The majority 
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of the studies use a semi-quantitative scoring system graded from 0 to 3.  The 
number of joints evaluated can differ greatly ranging from 7 to 78 joints. In a 
systematic review of the reliability of ultrasound findings, good inter-observer and 
intraobserver reliability of still-images were found (Cheung, Dougados & Gossec 
2010). However, few studies looked at the image acquisition reliability and 
therefore more research is still needed in this field.  
 
Ultrasound has been shown to detect synovitis with greater precision than clinical 
examination in small joints of the hands and feet (Naredo et al. 2005, Filer et al. 
2011). It also correlates with DAS28 and CRP (Dougados et al. 2010).  Ultrasound 
is able to detect damage to the joints in patients with normal radiographs 
(Backhaus et al. 1999). It was also found to be more sensitive than MRI at detecting 
synovitis (Backhaus et al. 1999).  There is also increasing evidence that ultrasound 
has a role in predicting radiographic progression. One study showed that baseline 
GS and US parameters were able to predict further radiographic damage at 2 years 
(OR 3.14 and 2.79 respectively) (Dougados et al. 2013).  
 
1.9.2.1 Ultrasound and remission 
Several studies have reported on the presence of subclinical synovitis in cohorts of 
remission patients. The Leeds group found that most patients classified to be in 
remission by their rheumatologists had evidence of synovitis on ultrasound 
(Brown et al. 2006), even after anti-TNF therapy (Wakefield et al. 2007). 
Ozgocmen et al also found a significant proportion of patients in remission (DAS28 
and ACR remission) with PD signal (Ozgocmen et al. 2008).  
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The presence of power Doppler signal is a powerful predictor of radiographic 
progression (Brown et al. 2008, Foltz et al. 2012) and flare (as defined by 
increased treatment, Saleem et al. 2012) over 1 year. However, a major criticism of 
their remission cohort is that the inclusion criteria were not stringent and 23% of 
the patients had moderate or high disease activity at baseline. Scire et al also found 
the presence of PD to be a predictor of flare (within 6 months). But in addition, also 
found that the absence of a PD signal was associated with stable remission for 24 
months. In their inception cohort of 104 patients, only 43 were in remission (Scire 
et al. 2009). Yoshimi et al found in their small cohort of 22 patients in remission, 
PD signal was associated with radiographic progression (Yoshimi et al. 2013). All 
these studies suggest that subclinical synovitis is ongoing in patients with clinical 
remission. 
 
More stringent criteria may be more closely associated with less sub-clinical 
synovitis. Balsa et al., 2010, showed the superiority of SDAI over DAS28 remission 
criteria in the assessment of ultrasound-classified remission (Balsa et al. 2010). A 
more recent study using the new ACR remission criteria also demonstrated less PD 
signal in patients with more stringent remission criteria (Sakellariou et al. 2013). 
However, this was not substantiated in a study by Saleem et al., 2011 which 
showed similar PD signal between DAS28, SDAI and Boolean remission (Saleem et 
al. 2011).   
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1.9.3 Magnetic resonance imaging (MRI) in Rheumatoid Arthritis 
MRI of joints can also be used for early diagnosis of rheumatoid arthritis and 
staging of disease (Figure 1.7). 3 parameters are assessed on MRI as markers in 
RA: Bone marrow oedema/osteitis, synovitis and erosions. Synovitis can be seen 
when MRI is performed with gadolinium contrast.  Bone marrow oedema is a 
predictor of erosive progression on x-rays (Boyesen et al. 2011a, Boyesen et al. 
2011b).  
1.9.3.1  MRI and Remission 
Studies have shown subclinical synovitis on MRI is present in patients with clinical 
remission and LDA states (Brown et al. 2008, Gandjbakhch et al. 2014). 
Gandijbakhch et al., 2014 reported that even in these clinical states, evidence of 
synovitis based on MRI findings are significant predictors of erosive progression 
(Gandjbakhch et al. 2014).  
 
 
Figure 1-7 MRI of Wrist Joint  
(A) T1-weighted image after gadolinium administration showing contrast 
enhancement of the synovium (arrow) and the sheath of the extensor carpi ulnaris 
tendon (arrowhead) of the wrist.  (B) Coronal STIR image showing bone marrow 
oedema in the hamate bone and ulnar head (arrows). (Boyesen et al. 2011a) 
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1.10  Treatment of Rheumatoid Arthritis 
1.10.1 Combination Disease Modifying Anti-Rheumatic Drugs (DMARDs) 
DMARDs used in routine clinical practice include Methotrexate (MTX), 
Sulfasalazine (SSZ), Leflunomide, Hydroxychloroquine (HCQ) and Ciclosporin 
(CsA).  
 
Methotrexate resembles folic acid and is a competitive inhibitor of folate-
dependent enzymes eg dihydrofolate reductase (DHFR). These enzymes are 
involved in the pyrimidine synthesis and the de novo purine synthesis of DNA and 
RNA. The mechanisms by which MTX exerts its effects are complex. Most studies of 
immune function in patients with RA show only marginal effects on humoral and 
cellular immune responses on T and B cells, monocytes, neutrophils and 
fibroblasts (EULAR textbook).  
 
Leflunomide is an isoxazole derivative and inhibits de novo pyrimidine synthesis, 
resulting in diverse antiproliferative and anti-inflammatory effects such as 
suppression of TNF-induced cellular responses and inhibition of matrix 
metalloproteinases and osteoclasts. (EULAR textbook).   
 
Cyclosporin A (CsA) has complex effects on T cell function including inhibition of 
interleukin-2 release and subsequent activation of T cells. It is an effective DMARD 
but its toxicities (hypertrichosis, tremor, gum hyperplasia, hypertension and dose-
related loss of renal function) has limited its use in clinical practice (EULAR 
textbook). .  
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Sulfasalazine is a 5 aminosalicylic acid derivative which is metablolised via the 
volonic intestinal flora to sulfapyridine and 5-aminosaligylic acid (5-ASA). After 
absorption, it is metaoblised further. Sulfapyridine is the active moiety in RA,  
although its mechanism of action has not been identified (EULAR textbook). . It is 
mainly excreted in the urine, either as unchanged drug or via its metabolites.  
 
Hydroxycholorquine, a 4-aminoquinoline derivative, is an anti-malarial agent. Its 
precise machanism of action is unknown (EULAR textbook). . It concentrates inside 
cells, within acidic cytoplasmic vesicles, resulting in changes in acidity and 
interference with the processing of autoantigenic peptides. It can interact with 
nucleic acids and inhibit endosomal toll-like receptor (TLR) activation, suggesting 
a potential mechanism to modulate activation of the innate immune system.   
 
Glucocorticoids are a unique class of drugs with well-defined effects. It has 
pleiotrophic well-characterised anti-inflammatory and immunosuppressive effects.  
 
As the DMARD agents have different mechanisms of action, it is logical to combine 
these agents. Evidence for the benefits of treating RA during the early phase of the 
disease is accumulating (Goekoop-Ruiterman et al. 2007). Improvement in clinical 
and radiological outcomes has been observed. However, the optimal regimen for 
treating early RA has not been established. Treatment strategies are diverse, 
including double, triple or even quadruple combinations and may involve a step-
down or step-up approach (Boers et al. 1997, Grigor et al. 2004, Mottonen et al. 
1999a). 
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1.10.2 Biological therapies in rheumatoid arthritis 
With the advent of biological therapies, treatment of RA has been revolutionised. 
These biological therapies consist of monoclonal antibodies and soluble receptors 
able to block key cytokines (TNF, IL-1, IL-6), delete or modulate lymphocyte 
subsets (B cells or T cells).  The biological therapies currently available include 
TNF inhibitors (Infliximab, Etanercept, Adalimumab, Certolizumab and 
Golimumab), IL-1 antagonist (Anakinra), T cell costimulation blocker CTLA-4Ig 
(Abatacept), B cell depleter (Rituximab) and IL-6 signal inhibitor (Tocilizumab). 
These treatments have significantly improved the signs and symptoms of disease, 
decreased the progression of joint damage, improved physical function and 
improved health-related quality of life (Lipsky et al. 2000, Klareskog et al. 2004, 
Keystone et al. 2004, Bresnihan et al. 2004, Smolen et al. 2009a, Kremer et al. 2003, 
Edwards et al. 2004, Genovese et al. 2008, Keystone et al. 2009, Keystone et al. 
2008b).   
 
The first part of this thesis compares the efficacy of combination DMARDs with 
anti-TNF with MTX therapies at inducing remission. Therefore, anti-TNF agents 
will be discussed in more detail in the next section. 
 
1.10.2.1 Anti-TNF blocking agents 
Amongst these biologic agents, TNF antagonists have the largest safety data set in 
RA as they have been available for the last 15 years. Infliximab is a chimeric 
human-murine IgG1 anti-TNF monoclonal antibody. It consists of a human 
immunoglobulin Fc portion and a murine TNF binding variable region. It binds to 
soluble and membrane-bound TNF and inhibits its effect by blocking TNF and 
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receptor interactions. Infliximab is also cytotoxic for TNF-expressing cells (Scallon 
et al. 1995). It is administered as an intravenous infusion. Etanercept is a 
recombinant souble p75 TNF receptor:Fc fusion protein. It consists of 2 TNF 
binding domains linked to the Fc portion of human Ig. It binds to TNF, preventing 
its interaction with its receptor. It also targets TNF (lymphotoxin)(Mohler et al. 
1993). It is given by weekly subcutaneous injections. Injection site reaction has 
been reported in 34-37% of patients compared to 7-10% of placebo (Fleischmann, 
Yocum 2004). Adalimumab is a fully human recombinant IgG1 monoclonal 
antibody. It binds to human TNF with high affinity and therefore stops it binding 
to its receptors. It is given by fortnightly or weekly subcutaneously injections. 
Injection site reaction occurs in 19.5% of patients compared to 11.6% of placebo 
(Fleischmann, Yocum 2004). Both Infliximab and Adalimumab can induce 
neutralizing anti-globulin response that reduces their efficacy (Radstake et al. 
2009).  Golimumab, the newest available anti-TNF agent, requires only monthly 
subcutaneous injections (Keystone et al. 2009). It has also been shown to be 
effective in patients who have failed other anti-TNF agents (Smolen et al. 2009b).  
 
Certolizumab pegol is a novel type of TNF inhibitor. It consists of a humanized Fab’ 
fragment fused to a 40-kd polyethylene glycol (PEG) moiety. Certolizumab pegol 
binds to TNF and prevents its interaction with specific receptors therefore 
neutralizing it. Its unique structure reduces immunogenicity by shielding the 
protein from recognition by the immune system. This leads to reduction in anti-
drug antibody formation and therefore secondary failures. PEGylation also 
increases the half-life and therefore the drug can be administered less frequently. 
In animal models, PEGylation has also been shown to preferentially distribute in 
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inflamed tissues (Nesbitt A, et al. 2007). Certolizumab pegol does not have an Fc 
portion and therefore avoids potential Fc-mediated effects seen in vitro, eg 
complement-dependent or antibody dependent cell-mediated cytotoxicity or 
apoptosis (Nesbitt A et al. 2007). In addition, Certolizumab pegol is synthesized by 
fed-batch fermentation in Escherichia Coli. The benefits of this method of 
production include lower cost, rapid production cycle of 2-3 days, higher yield and 
a more reliable drug supply.  
 
Anti-TNF agents have shown major clinical efficacy in established RA. Currently, in 
accordance with the NICE guidelines, anti-TNF can only be used in the UK when 2 
or more DMARDS have failed. But with remission as the ultimate goal of therapy, 
the use of anti-TNF blockade in early RA seems a logical progression. Therefore, 
interest is now focused on treatment with anti-TNF agents in early RA to induce 
long-term impact on outcome. This will be discussed in the next section. 
 
The use of anti-TNF blocking therapies has been limited by rare but clinically 
significant side effects. These include reactivation of latent mycobacterium 
tuberculosis, increased risk of other infections, infusion reactions, malignancies, 
induction of auto-antibodies, and worsening of severe heart failure. Some 
individuals also produce antibodies against the agents themselves. These human 
anti-chimeric antibodies (HACA) can neutralize the agent concerned and result in a 
gradual reduction of efficacy.  This can lead to secondary failures.  
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1.10.3 Treating early disease is important 
There is accumulating evidence that the course of RA is determined early. 
Radiographic damage is seen in more than 70% of patients with RA within the first 
2 years of disease and progression is greater in the first year (Fuchs et al. 1989). 
Studies have shown that early and aggressive treatment significantly reduces 
radiographic progression and improves clinical outcomes (Nell et al. 2004, Stenger 
et al. 1998). In addition, a short delay in initiation of DMARD therapy has been 
shown to result in more rapid joint destruction and loss of function in patients 
with early RA (van Aken et al. 2004). Consequently the concept of  a ‘therapeutic 
window of opportunity’ has been developed, which requires both early diagnosis 
and early intensive DMARD therapy to reduce disease progression. 
 
Numerous trials have examined the benefit for intensive treatment in early 
rheumatoid arthritis. These include the use of combination DMARD therapies 
(Boers et al. 1997, Choy et al. 2008a, Ma, Kingsley & Scott 2010, Grigor et al. 2004) 
and anti-TNF therapy with Methotrexate (Emery et al. 2009, Breedveld et al. 2004, 
Breedveld et al. 2006, Ma, Kingsley & Scott 2010). All have shown improvement in 
disease activity, radiological outcomes and HRQoL outcomes over DMARD 
monotherapy.  
 
1.10.4 Tight Control Treatment Regimes 
Not only is aggressive treatment important in early disease to suppress disease 
activity, it is also important to maintain low disease activity. Welsing et al., 2004 
investigated the longitudinal relationship between disease activity and radiological 
progression in 2 independent follow-up cohorts (Welsing et al. 2004). Fluctuating 
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high DAS and fluctuating low DAS showed similar rates of radiological progression 
to patients with a constant high DAS. Persistent low levels of rheumatoid 
inflammation (DAS28 <3.2) are associated with up to 50% less progression of joint 
damage. Disease activity (DAS) was also found to be an important factor 
influencing functional capacity (HAQDI) for patients with disease duration up to 6 
years (Welsing, Fransen & van Riel 2005). These data support the systematic 
monitoring of disease activity in clinical practice to achieve persistent low disease 
activity. This approach is called ‘tight control’ regime.  
 
The advantages of tight control regimes are: 
1. There is a predefined treatment protocol to which treatments of individual 
patients are adjusted.  
2. It is an orderly process.  
3. It is useful for assessing if the treatment chosen is necessary and effective  
4. It can ensure that patients are not over-treated.  
 
Five RCTs have investigated the effects of tight control: FINRACo trial (Mottonen et 
al. 1999b), TICORA trial (Grigor et al. 2004), Fransen et al., 2005 (Fransen et al. 
2005), BeST study (Goekoop-Ruiterman et al. 2007) and CAMERA study 
(Verstappen et al. 2007). 4 used early RA patients (<5 years). These studies 
showed that clinical and radiological outcomes are more favourable in the tight-
control regime group. The range of remission rates were 37-68% vs 16-41% in the 
tight control group compared to normal group. This improvement in clinical and 
radiological outcomes did not appear to be at the cost of increased drug toxicity. 
Interestingly, health economic assessment of the TICORA trial showed that there 
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was an increased outpatient cost for the intensive strategy but this was offset by 
increased community healthcare and inpatient cost in the routine care group. 
Ultimately, the intervention was cost neutral.  
 
BeST study used the concept of tight control in all 4 treatment groups and 
compared different treatment strategies. The groups using initial combination 
therapies with prednisolone or anti-TNF showed faster clinical improvement, 
however, at 2 years, there were no statistical differences between any treatment 
strategies. This finding was further supported by the observational trial by 
Verschueren et al., 2008 (Verschueren, Esselens & Westhovens 2008). They also 
found more remissions initially in the step up group compared to step down group 
but this effect had disappeared by 2 year. This showed that it was the tight-control 
regime principal that was important rather than the agents used for clinical 
outcomes. However, this is not reflected in the radiological outcomes. The initial 
combination groups achieved less radiological progression than the monotherapy 
or step-up groups. Less radiographic progression has been noted at each disease 
activity state in patients treated with anti-TNF therapy against conventional 
DMARDs (Keystone 2008). This suggests that the aim of therapy may need to be 
stricter for certain treatment regimes e.g DMARD monotherapy than anti-TNF 
therapy.  
 
Tight control regimes are perceived as aggressive forms of treatments however, 
they also allow treatment reduction and hence reduce drug toxicity. CAMERA trial 
showed that 56% of patients in the intensive group had reduction in treatment 
because of sustained response. Also, the BeST trial showed that by end of 2 years, 
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31% of patients of step-up therapy, 36% of initial combination with prednisolone 
and 53% of patients on initial combination with anti-TNF had reduced their 
treatment to monotherapy. This will therefore minimise any potential drug toxicity 
of over-treatment.  
 
The NICE guidance (NICE 2009) emphasise on treatment reduction when patients 
have controlled disease activity. However, currently, there is no guidance on how 
to reduce treatment. It is likely that more clinical, radiological or laboratory tools 
are required to guide treatment reductions. 
 
1.11 Definitions of Remission 
Remission has many meanings. In some medical contexts it indicates lessened 
disease severity. In other contexts it implies the disease has disappeared or 
evidence of disease activity is absent. Concepts of remission in rheumatoid 
arthritis (RA) reflect both models. Some definitions only indicate low disease 
activity states. Other definitions suggest the absence of disease, with undetectable 
symptoms, signs and disease markers. Critically, remission differs from “cure”, 
which implies RA will never return. Current opinion favours restricting remission 
to patients with either no or minimal synovitis, without long-term structural or 
functional sequelae. The seminal paper by Pinals et al in 1981 concluded 
“complete” RA remission indicates the “total absence of articular and extra- 
articular inflammation and immunological activities” (Pinals, Masi & Larsen 1981). 
However, many years later, uncertainties still remain as to how to define true 
biological remission states.  
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The introduction of new therapeutic options and strategies over the past decade 
has made remission an achievable goal, and in clinical practice a realistic one. An 
immediate consequence of this perspective is the need for an accurate and uniform 
way to identify remission. Although there are many definitions, remission does not 
yet have an internationally accepted gold standard. Remission criteria differ 
between studies and remission rates vary depending on the remission criteria 
used. Some remission criteria use categorical descriptions; the original American 
College of Rheumatology (ACR) remission criteria are one important example 
(Pinals, Masi & Larsen 1981) (Table 1-2). However, these criteria are very 
stringent and too few patients achieve this goal to make the definition a useful 
outcome to discriminate between patients in clinical trial settings, or to make it a 
realistic outcome in the routine clinic setting. It has been reported that the 
majority of healthy individuals above the age of 50 do not fulfil ACR remission 
criteria (Sokka et al. 2007). Consequently many variants have been described. 
Continuous composite measures are often used to define remission (Table 1-2); 
the most commonly used are the low scores calculated using the Disease Activity 
Score (DAS, (Prevoo et al. 1996)) or its modifications such as DAS28-ESR (Fransen, 
Creemers & Van Riel 2004). The newer criteria include Simplified Disease Activity 
Index (SDAI, (Aletaha et al. 2005b)), Clinical Disease Activity Index (CDAI, (Aletaha 
et al. 2005a)) and the ACR/EULAR Boolean criteria. The newest criteria, the 
ACR/EULAR Boolean criteria, were developed to provide a more uniform 
definition which can be widely used (Felson et al. 2011). It was tested for its ability 
to predict good functional and radiological outcomes. However, the Boolean 
criteria have been criticised as possibly being too stringent. In particular, the 
patient global visual analogue score (PtVAS) of less than 1cm (on a 10cm scale) has 
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proved difficult to achieve (Studenic, Smolen & Aletaha 2012). It may not even 
reflect disease activity as it may be more related to functional limitations, low back 
pain and fatigue (Masri et al. 2012).  
 
The US Food and Drug administration (FDA) criteria for remission or complete 
clinical response in RA specify that patients must meet the ACR remission criteria 
and have radiographic arrest over a continuous 6-month period whilst not taking 
any antirheumatic drugs, or in the case of complete clinical response, while 
continuing anti-rheumatic drug therapy. This is not used routinely in clinical 
practice.  
 
Table 1-2: Table of Remission Criteria 
ACR = American College of Rheumatology, EULAR = European League Against 
Rheumatism, SDAI = Simplified Disease Activity Index, CDAI = Clinical Disease Activity 
Index, DAS28 = Disease activity Score 28 joints, CRP = C-Reactive Protein, ESR = 
Erythrocyte Sedimentation Rate, MBDA = multi-biomarker disease activity score, FDA 
= Food and Drugs administration 
 
Index Remission criteria 
ACR/EULAR Boolean TJC, SJC, CRP, PGA all ≤1 
SDAI ≤ 3.3 
CDAI ≤2.8 
DAS28-CRP < 2.32 
DAS28-ESR <2.6 
MBDA score ≤ 25 
FDA 
Old ACR remission criteria  
Plus no radiographic progression off treatment for 6 
months 
Old ACR remission 
criteria 
5 or more over 2 consecutive months: 
 No joint swelling or soft tissue swelling of 
tendon sheaths 
 No joint tenderness or pain on motion 
 ESR <30 women, <20 men 
 Early Morning Stiffness <15 minutes 
 Absence of joint pain by history 
 No Fatigue (not included in modified version) 
  70 
 
 
The remission criteria that have evolved over the last two decades all reflect a 
similar underlying theme. Namely, changes in clinical variables assessed by 
clinicians such as joint counts, physician global scores and inflammatory blood 
markers like the erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) 
(Inoue et al. 2007). Despite attempts to define remission in many different forms, 
the definition of true remission still remains elusive. A significant proportion of 
patients classified in clinical remission still continue to develop radiographic 
progression (Proudman et al. 2007, Makinen et al. 2005a, Vazquez et al. 2007, 
Machold et al. 2007). This suggests ongoing sub-clinical disease in some patients 
apparently in remission. Radiological markers such as MRI or ultrasound may be 
more sensitive in detecting sub-clinical disease, though there are challenges in 
standardising these techniques between clinicians and centres.  
 
Finally, there are 2 outstanding features of remission that need to be clarified. 
First, there is very little information about how long remission should last to be 
significant. Meeting criteria for remission on a single occasion is likely to be 
insufficient. A full clinical picture requires integrating disease states with time. 
Second, as more patients achieve low disease activity states, there will be more 
opportunities for drug tapering and withdrawal. Studies are urgently needed to 
determine which characteristics of remission most accurately predict those 
patients who are able to withdraw therapy.  
 
In an era where treatments are increasingly targeted at a molecular level, it is 
important that monitoring treatment responses progresses to reflect such specific 
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therapies. Laboratory biomarkers, beyond ESR and CRP, are likely to play crucial 
roles in defining disease activity and remission in the future. It is likely that 
addition of radiological and laboratory biomarkers to clinical variables will help 
clarify the kaleidoscope-like appearance of existing remission criteria. This will 
give a clearer picture of what true remission entails. 
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1.12  Rationale of the thesis 
Remission means the absence of a disease. It is conventionally assumed to mean 
there are undetectable or minimal symptoms and signs of the disease and that 
laboratory markers of active disease have returned to normal. Periods of remission 
can be followed by flares and subsequent periods of active disease. Due to the 
heterogeneous nature of RA outcomes, these periods of remission and flares are 
currently unpredictable.  
 
The introduction has outlined the limitations of current knowledge about RA 
remission. Although several criteria have been developed to enable clinicians to 
judge whether or not remission is present, there is uncertainty about which 
criterion is the most useful as an aid for decision making in clinical practice. There 
is also uncertainty about the impact and clinical relevance of the length of 
remission. Meeting criteria for remission on a single occasion is likely to be 
insufficient. True remission suggests that patients are in stable remission over 
time. In addition, remission needs to be characterised in more detail and it is likely 
that addition of radiological and laboratory biomarkers to clinical variables will 
help clarify the concept of true remission. 
 
1.13  Overall Aims of thesis 
The overall goal of this thesis is to improve the knowledge of remission states and 
the clinical implications of achieving of remission in RA. The research spans three 
broad aims:  
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The first broad aim was to characterise in detail the definition of remission and 
sustained remission using an extended range of clinical, laboratory and 
radiological biomarkers. 
 
The second broad aim was to identify predictors of remission, both for remission 
at single time points and also for remission sustained over periods of time. This 
aim reflects the disease heterogeneity of RA, the growing emphasis on 
personalised medicine, and the opportunity to individualise care using risk 
stratification to guide treatment decisions,  
The third broad aim was to assess the impact of different levels of remission on 
aspects of RA directly relevant to patients. These include pain, fatigue and 
disability, which are characteristic features of established RA. Over time the 
disability associated with RA has considerable impacts on health-related quality of 
life (HRQoL) and these effects have been evaluated for both sustained and 
incomplete remission. 
Delivering these overall aims has been achieved by focusing on five specific 
research objectives. These objectives have included research based on 
systematically reviewing the existing literature, using previously collecting clinical 
research data from both an observational study and a clinical trial, and establishing 
a large prospective cohort of RA patients in remission for this thesis. 
 
1.14  Objectives of the thesis 
The first specific objective of the thesis was to assess the frequency of remission in 
the published literature. A detailed systematic review was carried out to assess the 
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remission rates in observational and randomised controlled trials as defined by 
different remission criteria and to assess the impact of treatment on remission 
rates.  
 
The second specific objective was to develop a predictive model for 24-month 
remission in early RA patients. Clinical baseline variables from a RCT comparing 
Methotrexate, steroids and combination DMARDs were used to develop this model 
(CARDERA study)(Choy et al. 2008a). The predictive model was then validated 
using data from a UK cohort - the Early RA Network (ERAN, (Kiely et al. 2009). 
Finally the clinical model was combined with serological biomarkers to develop 
predictors of response to different DMARD treatment regimens. 
 
The third specific objective was to develop a cohort of RA patients with features of 
stable low disease activity states. This was the REMIRA cohort - REMission In RA. 
This cohort was used to assess the prevalence of sustained remission over 1 year 
and to develop predictors of sustained remission using clinical, serological and 
radiological biomarkers.  
 
The fourth specific objective was to define an objective molecular signature of 
point remission and sustained remission and to develop molecular biomarkers in 
predicting sustained remission. Serum biomarkers from the REMIRA cohort will be 
used. These will include the MBDA score and its components as well as CXCL10 
and calprotectin. 
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The last specific objective of the thesis was to assess the impact of remission on 
health-related quality of life. The impact of baseline remission and sustained 
remission on diability, fatigue and quality of life over 1 year were both assessed.  
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2 Methods and Materials 
The methods and materials section is a summary of the different methods and 
techniques used within this body of research. Since they varied extensively, they 
are also summarised within each results chapter.  
 
2.1 Systematic reviews 
2.1.1 Search Terms 
Pubmed, EMBASE and Medline were searched using the following search terms: 
Early Rheumatoid Arthritis or Early RA combined with Remission, Treatment, anti-
TNF or DMARD. The search was limited to 1996 – 2008, English and Clinical trials.  
 
2.1.2 Selection criteria 
Studies were selected for inclusion using the following criteria: 
1. Randomised Controlled Trials or Observational Studies 
2. Patients fulfilled the 1987 ACR classification of RA 
3. Disease duration less than 3 years of diagnosis.  
4. Remission used as an outcome measure 
5. Enrolled more than 40 patients  
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2.1.3 Outcomes 
We included DAS (and its modifications) or ACR (and its modifications) remissions 
as the clinical outcome measure. Radiological outcomes of patients in remission 
were also assessed.  
 
2.1.4 Quality of trials 
The quality of the trials was judged using the Jadad Scoring System (Jadad et al. 
1996). The Jadad scoring system, also known as The Jadad scale or the Oxford 
quality scoring system, is a procedure to independently assess the methodological 
quality of a clinical trial. It consists of 3 elements: Randomisation, blinding and 
withdrawals/dropouts. It ranges from 0-5, 0 being the weakest and 5 being the 
strongest. See appendix 11.3 for the calculations.  
 
2.1.5 Data Extraction 
Studies were assessed for eligibility and extracted data on year of publication, 
population source, study design, study size and follow-up period. When there were 
differences between observers (Margaret Ma and Ian Scott), they reviewed the 
papers together and came to a joint conclusion. 
 
2.2 Autoantibody analysis 
For the CARDERA and REMIRA samples, I had carried out the assays myself. RF 
IgM, IgA and IgG measured in relative units per ml (RU/ml) using commercially 
available ELISA kits (Euroimmun). Testing was performed according to the 
manufacturer’s instructions, at a sample dilution of 1:200. The upper limit of the 
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normal range recommended by Euroimmun is 20 RU/ml. Anti-CCP antibodies 
(IgG) were measured using an ELISA based kit from Axis-Shield which detects 
autoantibodies towards a synthetic cyclic peptide containing modified arginine 
residues (CCP2 peptides).  Testing was performed according to the manufacturer’s 
instructions, at a sample dilution of 1:100. The cut-off value for anti-CCP antibody 
positivity was 5 U/mL.  
 
2.3 REMIRA cohort 
This is a unique cohort which I had collected. This included applying for Ethics, 
R+D, setting up Remission clinics at 3 sites (GSTT, KCH and UHL), patient 
recruitment, patient assessments, processing of laboratory samples and data 
analysis. I also set-up and maintained a REMIRA database on ACCESS.  
 
Adult RA patients diagnosed according to the 1987 revised ACR criteria were 
recruited into the REMIRA (REMission in RA) study. Inclusion criteria restricted 
disease duration to <10 years (as defined by date from diagnosis). We chose this as 
a cut-off as we were particularly interested in patients who were more likely to 
have had contemporary treatment of RA. To ensure all recruited study subjects 
were in stable LDA, we also included the following criteria: stable DMARDs therapy 
> 6 months and DAS28-ESR ≤3.2 for at least 1 month.  Three centres across south 
London participated in this study: Guy’s and St Thomas’ Hospital, King’s College 
Hospital and University Hospital Lewisham NHS Foundation Trusts. The study was 
approved by the local ethics committee and conducted according to the guidelines 
of the Declaration of Helsinki (REC:09/H0803/154, Wandsworth Research Ethics 
Committee).  Local Research and Development (R&D) approval was obtained from 
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all sites.  Written informed consent was obtained from all participants.  Summary 
of REMIRA study in Appendix 11.17.   
 
2.3.1 Clinical measures 
2.3.1.1 Patient assessments 
Clinical data including demographics, smoking, disease duration (as defined as from 
date of diagnosis) and treatment were collected. Extended 68-tender joint (TJC68) 
and 66 -swollen joint (SJC66) counts were performed (see appendix 11.5 – 12) for 
consent form, patient information leaflet and assessment form). For the evaluation 
of pain, fatigue, patients’ as well as evaluators’ global assessment of disease activity, 
100mm visual analogue scales (VAS) were used. Early morning stiffness (EMS) was 
recorded in minutes. Erythrocyte Sedimentation Rate (ESR) was collected from 
routine clinical laboratory results.  For the evaluation of remission, DAS28ESR, 
DAS28CRP, SDAI, CDAI and ACR/EULAR Boolean remission criteria were used. 
Patients were assessed 3 monthly for 1 year.  
 
2.3.1.2 Patient reported outcome measures 
Health Assessment Questionnaire Disability Index (HAQ-DI) ranged from 0-3 with 
higher scores indicating more disability. The Medical Outcomes Study 36-Item 
Short-Form Health Survey (SF36) assesses health-related quality of life. It comprises 
of 8 domains: physical function (PF), physical role (RP), bodily pain (BP), general 
health perception (GH), vitality (VT), social function (SF), emotional role (RE) and 
mental health (MH). These domains are then generated into two summary 
measures: the physical component score (PCS; including PF, RP, BP and GHP) and 
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the mental component score (MCS including VT, SF, RE and MH). The scores are 
transformed to have a mean with S.D. of 10. Both range from 0-100. EuroQol also 
known as EQ-5D is a standardized instrument for use as a measure of health 
outcome. There are 5 dimensions which are combined to generate a single index of 
quality of life range between −0.594 to 1. In addition, there is also a EQ VAS which is 
a 20cm vertical VAS that generates a self-rating of health-related quality of life.  The 
Functional Assessment of Chronic Illness Therapy (FACIT-F, (Yellen et al. 1997)) is a 
13 item questionnaire that assesses self-reported fatigue (range 0-52). With the 
SF36, EurQol and FACIT-F, the greater the number, the better the reported outcome. 
These were all measured 3-monthly for the length of the study. (see appendix for 
PROMs questionnaires). 
 
2.3.2 Radiographic outcomes 
2.3.2.1 Radiographs of hands and feet 
Posterior-Anterior conventional radiographs of the hands and feet were taken at 
baseline and 12 months. Erosive progression is defined as new erosions or 
worsening of existing erosions over 1 year.  
2.3.2.2 Ultrasound assessments 
Ultrasound examination was carried out in all patients at baseline and 12 months. 
All sonographic assessments were performed using high-sensitivity ultrasound 
equipment (GE Logiq 9), with a 2D M12L transducer. Sonographic assessments 
were performed using a frequency of 14MHz, Gain 50, Depth 2.0cm, Frame Rate 
24. When performing power doppler (PD) evaluation, frequency of 7.5 MHz and 
pulse repetition frequency was set between 500 to 800 Hz. The receiver gain 
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settings were systematically increased and decreased to achieve the highest gain 
without the appearance of artifacts. An experienced blinded sonographer (Dr Toby 
Garrood), without access to clinical or laboratory data, scanned 6 joints of each 
hand (1-5 Metacarpophalangeal joints and wrists) for both synovial hypertrophy 
(SH) and intraarticular PD signals (Ozgocmen et al. 2008). All included joints were 
scanned for SH and PD in the dorsal aspect using longitudinal midline as in 
accordance with OMERACT guidelines (Wakefield et al. 2005). In addition, 2 other 
views of the wrists were obtained longitudinal (ulnocarpal and radiocarpal). MCPs 
and wrists are the most commonly used joints for ultrasound and we have 
therefore opted to use these joints. Due to limited time, we were unable to scan 
more number of joints. Grading of the scans were carried out retrospectively using 
saved images. Still were saved for grey scale and 3 second cine-loops were 
recorded for power doppler assessments. SH and PD were graded using a 4-grade 
semiquantitative scoring system from 0-3 according to the method developed by 
Wakefield (Wakefield et al. 2005). In SH, Grade 0 = no hypertrophy, Grade 1 = 
minimal: below the level of bony joint line, Grade 2 = above the level of bony joint 
line but without distension of joint capsule (forming concavity of the upper joint 
surface) and Grade 3 = severe: above the level of bony joint line with distension of 
joint capsule (forming convexity or flattening of upper surface). In PD, Grade 0 – no 
flow in synovium, Grade 1 – up to 3 single spots OR up to 2 confluent spots OR 1 
confluent and 2 single spots, Grade 2 – more than grade 1 but <50% of gray scale 
area and Grade 3 – vessel signals >50% gray scale area (see Figures 2.1-2.8 for 
representative images of MCPs and all 3 views of the wrists). The total SH score 
and total PD score are the sums of the average of all 3 views of the each wrist plus 
each of the MCPs. 










Figure 2-1: Representative images of SH of MCP SH (Synovial Hypertrophy - Grades 0-3)  
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Grade 2 Grade 3 










Figure 2-2 Representative Images of Grading of PD of MCP (Power Doppler Grades 0-3) 
  
Grade 0 Grade 1 
Grade 2 Grade 3 









Figure 2-3 Representative Images of Grading of SH of the Dorsal Wrist (Synovial Hypertrophy - Grades 0-3)  
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Figure 2-4 Representative Images of Grading of PD of the Dorsal Wrist (Power Doppler Grades 0-3)  
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Grade 2 Grade 3 









Figure 2-5 Representative Images of Grading of SH of Radiocarpal Joint (Synovial Hypertrophy - Grades 0-3)   
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Figure 2-7 Representative Images of Grading of SH of Ulnocarpal Joint (Synovial Hypertrophy - Grades 0-3) 
  














Figure 2-8 Representative Images of Grading of PD of Ulnocarpal Joint (Power Doppler - Grades 0-3)
Grade 0 Grade 1 
Grade 2 Your own  Grade 3 
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2.3.3 Blood sampling 
2.3.3.1 At baseline visit 
 4 x sodium heparin GREEN TOP tubes 40ml 
 2 x plain BRICK RED TOP tubes for serum 16ml 
 2 x PAX gene tube for whole blood RNA 8ml  
 2 x Tempus tubes for whole blood RNA 6ml 
2.3.3.2 At follow-up: 3, 6 and 9 month visit 
 4 x sodium heparin GREEN TOP tubes  
 2 x plain BRICK RED TOP tubes for serum  
 2 x Tempus gene tube for whole blood RNA  
 
2.3.3.3 At end of study: 12 month visit 
 4 x sodium heparin GREEN TOP tubes - for PBMCs  
 2 x PAX gene tube for whole blood RNA  
 2 x Tempus tubes for whole blood RNA  
 2 x plain BRICK RED TOP tubes for serum  
 1 x Paxgene DNA tube 
 
2.3.4 Protocol for blood sample processing 
The bloods samples were all processed on the same day as sampling. Courriers 
were used to transport samples from KCH (King’s College Hospital) and UHL 
(University Hospital Lewisham) to the lab. The protocols used for blood sampling 
and processing are summarized below: 
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2.3.4.1 PBMC isolation and freezing 
Materials required 
 2 x 50ml Leucosep tubes  
 Hank’s Balance Salt Solution (HBSS, Sigma) 
 Sterile Phosphate Buffered Saline  (PBS, Fisher) 
 Lymphoprep (Axis Shield) 
 Cell culture grade DMSO (Sigma) 
 RNeasy Protect cell (Qiagen) 
 AB serum (PAA) 
 Coolcell freezing containers (VWR) 
 
Protocol 
1. Dilute blood in sterile HBSS (1:1) in 50 ml Corning tubes  
2. Aliquot 15ml Lymphoprep in all Leucosep tubes  
3. Centrifuge Leucocep tubes for 30 seconds at 1000g at RT 
4. Pour 35ml of diluted blood into each of 2 X Leucosep tubes  
5. Spin in centrifuge (10min, 1000g, no brake, RT)  
6. Check for interphase 
7. Using Pastuer pipette, remove plasma layer fraction up to a minimum remnant 
of 5 to 10 mm above the interphase to remove contamination of the enriched 
cells with platelets.  
8. Harvest the enriched cell fraction using a pastuer pipette or by pouring the 
supernatant above the porous barrier into another tube 
9. Wash with ice-cold Phosphate-buffered saline (PBS) – make up to 50ml 
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10. Spin in centrifuge (10 min, 1600rpm, brake, RT) 
11. Check for cell pellet and discard supernatant 
12. Wash pellet in sterile ice-cold 10ml PBS again  
13. Spin in centrifuge (10 min, 1200rpm, brake, RT) 
14. Add 2 ml ice-cold PBS to cell pellet  
15. Count cells using cell counter 
16. Take out 5x106 cells for RNA (see RNA section for further instructions) 
17. Add 3mls of PBS to cell suspension (making it up to 5ml)  
18. Spin down cells in a cold centrifuge at 1200 rpm.  Decant supernatant and flick 
tube gently to loosen cell pellet. 
19. Place freezing medium – (i) neat filtered AB serum and (ii) mix of 80% filtered 
AB  serum + 20% high purity DMSO – on ice for at least 10 minutes. Place 
cryovials also on ice. 
20. Add 500ml neat AB per 0.5-1x107 cells.  The cells were not frozen any denser 
than this. Pipette gently to minimize shear force 3 times and avoid bubbles.  
21. Add equal volume of AB serum/DMSO and mix slowly with each drop; add 
dropwise over 1-2 minutes, repeatedly swirling tube gently to mix. 
22. Pipette 1ml into cryovials. Work quickly if there are many cryovials.  
23. Transfer to CoolCell and into -80oC freezer for 24 hours then to Liquid nitrogen. 
 
2.3.4.2 Protocol for storing PBMC RNA  
1. 1.5x106 PBMCs were used for RNA storage. 
2. Add 5 volumes of RNAprotect Cell Reagent (Qiagen) to 1 volume of cell-culture 
medium or storage solution. 
3. Mix by shaking, pipetting, or vortexing. 
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4. Note: The medium or storage solution must not exceed 1 ml.  
2.3.4.3 Protocol for storing whole blood RNA and DNA 
1. PAXgene and Tempus tubes contain buffer to ensure immediate lyses of the 
blood cells and stabilisation of the RNA. 
2. Incubate the blood in vacutainers at room temperature for 2 hours  
3. Store tubes at -20oC for at least 24 hours  
4. Transfer to -80oC until further processing  
 
2.3.4.4 Protocol for serum 
1. Blood in the vacutainers are kept in the fridge whilst awaiting processing. 
2. Spin in vacutainer at 1200rpm, 10min. 
3. Harvest serum  
4. Spin serum repeatedly until no red cell pellet is visible (1200rpm, 10min). 
5. Freeze aliquots in -80oC  
 
2.3.5 Serum biomarkers 
All 14 biomarkers were measured by Crescendo Bioscience laboratories. The 
development of the MBDA score has been discussed in the introduction (see 
section 1.7.8). The concentrations of 12 serum proteins—serum amyloid A (SAA), 
IL-6, TNF receptor superfamily member 1A (TNF-R1), VEGFA, MMP1, human 
cartilage glycoprotein 39 (YKL40), MMP3, epithelial growth factor (EGF), vascular 
cell adhesion molecule 1 (VCAM1), leptin, resistin and CRP—were measured by 
customized immunoassays, quantified on a Sector Imager 6000 (Meso Scale 
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Discovery, Gaithersburg, MD, USA) and transformed to the power 0.1 to achieve 
approximately normal distributions. 
 
CXCL10 and Calprotectin were measured by using commercially available ELISA 
kits according to the manufacturers’ protocols. The Calprotecit assay was from 
Buhlmann (MRP 8/14 ELISA Product Code EK-MRP8/14). For CXCL10, a modified 
version of the R&D Systems Human CXCL10/IP-10 Quantikine ELISA (Product 
Code: DIP100) was used. For this ELISA assay, in-house manufactured pre-diluted 
standards and controls were used. A 2-fold dilution of samples was carried out. 
The rest of the procedure was performed per the manufacturer’s protocol. 
 
2.4 Statistical analysis 
Statistical analyses are described within each chapter separately. 
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3 Remission in Early Rheumatoid Arthritis: Systematic Review 
3.1 Introduction 
The advent of intensive treatment regimens has made remission a realistic 
treatment goal in early rheumatoid arthritis (RA) (Boers et al. 1997, Choy et al. 
2008). These intensive treatments including combinations of disease modifying 
anti-rheumatic drugs (DMARDs) and DMARDs with biological therapies such as 
tumour necrosis factor (TNF) inhibitors (Allaart et al. 2006, Grigor et al. 2004, 
Breedveld et al. 2006, Mottonen et al. 1999) and they are associated with higher 
rates of remission. These regimes are now part of the standard treatment of care in 
RA with remission as the main treatment goal. Despite remission being a key goal 
of RA treatment, its frequency on treatment has not been evaluated methodically. 
 
Several classification criteria have been developed for remission. Some criteria use 
categorical descriptions of remission whilst others are continuous composite 
measures are also used to define remission. These have been described in the 
introduction (see section 1.11). Radiological progression is not considered in these 
remission criteria in spite of its importance in long-term disability (Scott et al. 
2000). 
 
The first step of the thesis was therefore to systematically review observational 
and randomised controlled trials in early RA with three aims. Firstly, to identify the 
differences in the frequency of remission dependant on the criteria by which it is 
judged. Secondly, to determine how the frequency of remission is influenced by 
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different treatment strategies. Finally, to review the effects of remission on 
radiological outcomes.  
 
3.2 Methods 
3.2.1 Search Terms 
Pubmed, EMBASE and Medline were searched using the following search terms: 
Early Rheumatoid Arthritis or Early RA combined with Remission, Treatment, anti-
TNF or DMARD. The search was limited to 1996 – 2008, English and Clinical trials.  
 
3.2.2 Selection criteria 
Studies were selected for inclusion using the following criteria: 
1. Randomised Controlled Trials or Observational Studies 
2. Patients fulfilled the ACR classification of RA 
3. Disease duration less than 3 years of diagnosis.  
4. Remission used as an outcome measure 
5. Enrolled more than 40 patients  
 
3.2.3 Outcomes 
DAS (and its modifications) or ACR (and its modifications) remissions were used 
as the clinical outcome measure. Radiological outcomes of patients in remission 
were also assessed.  
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3.2.4 Quality of trials 
The quality of the trials was judged using the Jadad Scoring System (Jadad et al. 
1996). The Jadad scoring system, also known as The Jadad scale or the Oxford 
quality scoring system, is a procedure to independently assess the methodological 
quality of a clinical trial. It consists of 3 elements: Randomisation, blinding and 
withdrawals/dropouts. It ranges from 0-5, 0 being the weakest and 5 being the 
strongest. See appendix 11.1 for the calculations.  
 
3.2.5 Data Extraction 
I had carried out the data extraction. For the purpose of publication, Dr Ian Scott 
acted as the second observer. Studies were assessed for eligibility and extracted 
data on year of publication, population source, study design, study size and follow-
up period. When there were differences between observers, they reviewed the 
papers together and came to a joint conclusion. 
 
3.2.6 Statistical Analysis 
Data from all studies were analysed descriptively. RCTs were analysed using 
Review Manager 4.2.8 (Cochrane Collaboration, Oxford, United Kingdom). The 
random effects odds ratio (OR) model based on DerSimonian and Laird’s method 
was used to estimate the pooled effect sizes (DerSimonian, Laird 1986); this gives 
more equal weighting to studies of different precision in comparison to a simple 
inverse variance weighted approach, thereby accommodating between study 
heterogeneity. It was reported with 95% confidence intervals (CI). For all meta-
analyses, Cochran's Chi-Squared test was performed to assess between study 
heterogeneity and quantified the I2 statistic (Hardy, Thompson 1998, Higgins et al. 
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2003). We considered a p-value less than 0.05 as significant. The number needed 
to treat (NNT) was calculated and reported with 95% CI. 
 
In RCTs with more than one ‘control’ arm or ‘treatment’ arm, the arm with the best 
outcome was selected for analysis.  
 
3.2.7 Update In 2014 
The initial systematic review was undertaken in 2009 and 2010 and was published 
in 2010 (Ma et al. 2010). In the ensuing four years several new studies have been 
published on remission in RA. In order to retain the original peer-reviewed 
published systematic review and to ensure this thesis is up to date, details of these 
new studies have been collated as an addendum to the chapter. They used identical 
methods, although the dates for the search were extended.  
 
3.3 Results 
3.3.1 Study Selection 
1660 citations were identified for review, 52 were evaluated in detail and 37 
studies were included in the final analysis.  These comprised 17 observational 
studies and 20 RCTs (Figure 3.1). The baseline characteristics of the observational 
studies and RCTs are described in Tables 3.1 and 3.2 respectively. From the 
available data, the patients enrolled into the RCTs appeared to have higher disease 
activity.  
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Figure 3-1: Search Strategy of the systematic review 
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The 17 observational studies (Table 3.1) followed patients for 2-10 years: 16 
reported end point remissions and 1 reported remissions over 6 months at any 
point during follow-up. 4762 patients entered these observational studies (3653 
completing full follow-up); 972 (27%) achieved remissions.  
 
The 20 RCTs (Table 3.2 and 3.3) followed patients for 1-3 years. Their average 
Jadad score was 3.5 (range 1-5). 19 RCTs reported end-point remissions and 1 
reported remission at any time point. Four trials evaluated DMARD monotherapies 
(2 monotherapy vs placebo/NSAID; 2 different monotherapies). 13 trials 
compared monotherapy with combination therapies. 3 trials reported different 
combination strategies. 4290 patients entered these trials; 1312 (31%) achieved 
remissions. 
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Table 3-1 Patient Characteristics and Remission in Observational Studies 
Table shows remission rates at the end of the study * remission over 6 months at any point, Results are mean values unless denoted by suffix “i” indicating median data; ii DAS 
 
 






















Prevoo et al., 1996 ACR <12 55i 63 78 - - 72 Monotherapy 227 49 15 (31%) 
Eberhardt and Fex 1998 ACR <24 - 63 75 29 - 60 Monotherapy 183 176 37 (20%)* 
Young et al 2000 ACR 8 - 66 63 - - 60 Monotherapy 941 732 94 (13%) 
Makinen et al 2005 ACR 5 56 61 54 - - 60 Monotherapy 127 111 19 (17%) 
Möttönen et al 1996 ACR <24 46 75 63 30i - 72 Combination 142 142 45 (32%) 
Lindqvist et al 2002 ACR <24 - 63 75 - - 120 Combination 183 163 30 (18%) 
Sanmarti et al 2003 ACR <24 52 78 - 45 5.8 12 Combination 65 60 12 (20%) 
Fransen et al 2004 ACR <12 55 66 76 - - 72 Combination 424 77 9 (12%) 
Cantagral et al 1999 DAS <12 - - 71 - - 24 Not stated 108 108 15 (14%) 
Tengstrand et al 2004 DAS <12 57 64 58 - 5.1 24 Monotherapy 844 844 279 (33%) 
Vázquez et al 2007 DAS <24 55 81 74 40 5.7 24 Monotherapy 115 105 34 (32%) 
Khanna et al 2007 DAS <14 51 - 100 43 5.5 24 Monotherapy 200 101 33 (33%) 
Gossec et al 2004 DAS <12 51 73 81 40 4.1ii 60 Combination 191 165 38 (23%) 
Forslind et al 2007 DAS ≤12 58 64 60 - 5.3 60 Combination 698 608 234 (39%) 
Proudman et al 2007 DAS <24 56 76 61 42 5.3 36 Combination 61 52 28 (54%) 
Sanmarti et al 2007 DAS <24 55 81 74 40 5.7 24 Combination 115 105 34 (32%) 
Machold et al 2007 DAS ≤3 51 75 - - - 36 Combination 138 55 16 (29%) 
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Table 3-2 Patient Characteristics in the Clinical Trials.  
Results are mean values. RF = rheumatoid factor 
 











(%) ESR DAS28 
Monotherapy 
Eberhardt et al 1996 53 63% 80% 36  - 50 52% 67% 32 -  
Rau et al 1997 54 60% 68% 41  - 57 72% 54% 41 -  
Van Jaarsveld et al  2000 56 69% 67% 42  - 57 64 65 41  - 
Choy et al  2002 58 74% 54%  - DAS 5.3 57 76% 58%  5 
Monotherapy vs Combination Therapy 
Boers et al  1997 49 52% 72% -  -  50 66% 78% - -  
Möttönen et al 1999 48 66% 66% 39 -  47% 58% 70% 37 -  
Proudman et al 2000 50 55% 79% 31.4 5.1 51% 65% 80% 39.1 5.4 
Ferraccioli et al  2002 59 86% 55% 43 -  59 86% 73% 52 -  
Gerards et al 2003 51 70% 97% 46  - 53 62% 93% 53  - 
Wassenberg et al 2005 50 65% 47% 40  - 53 75% 43% 44.5  - 
St Clair et al  2004 50 75% 71% 43 6.7 50 68% 73% 44 6.7 
Svensson et al 2005 59 63% 66% - 5.4 51 65% 66% - 5.28 
Allaart et al  2006 54 68% 67% - DAS44 4.5 54 66% 64% - DAS44 4.3 
Breedveld et al 2006 52 74% - - 6.3 52 72%  - 6.3 
Choy et al  2008 54 67% 66% - 5.8 55 67% 72% - 5.6 
Emery et al  2008 52 73% - 49 6.5 51 74% - 47.8 6.5 
Hetland et al 2006 51 70% 59% 27 5.5 53 64% 70% 28 5.3 
Combination vs Combination therapy 
Verstappen et al 2007 53 66% 62 39 - 54 69% 66% 36 - 
Saunders et al  2008 55 79% 72% 45 6.9 55 76% 69% 36 6.8 
Verschueren et al** 2008 55 65% 52%  - DAS28 CRP 4.76 45 63% 79% - DAS28 CRP 5.28 
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Cases Treatment Remission Rate Cases Treatment Remission Rate 
Monotherapy 
Eberhardt et al 1996 24 24 ACR derivative 22 Placebo 5 (12%) 21 D-Penicillamine 4 (12%) 
Rau et al 1997 16 12 ACR derivative 87 MTX 10 (12%) 87 GSTM 21 (24 %) 
Van Jaarsveld et al 2000 <12 24 ACR derivative 107 HCQ 29 (27%) 105 MTX (short lag) 25 (24%) 
Choy et al 2002 <12 12 DAS28 55 Diclofenac 0 62 SSZ 0 
Monotherapy vs Combination therapy 
Boers et al 1997 <24 12 ACR 76 SSZ 19 (24%)* 79 SSZ/MTX/Pred 24 (32%)* 
Möttönen et al 1999 <24 24 ACR 98 SSZ or MTX 18 (18%) 97 MTX/SSZ/HCQ/Pred 36 (37%) 




Ferraccioli et al 2002 16 36 ACR 42 SSZ 3 (7%) 42 MTX/CsA 4 (9%) 
Gerards et al 2003 <36 12 ACR 60 CsA 4 (7%) 60 CsA/MTX 6 (10%) 
Wassenberg et al 2005 <24 24 ACR 86 DMARD 8 (9%) 80 DMARD/Pred 13 (16%) 
St Clair et al 2004 <36 12 DAS28 245 MTX 37 (15%) 325 MTX/Infliximab 101 (31%) 
Svensson et al 2005 <12 24 DAS28 126 DMARD 42 (33%) 116 DMARD/Pred 65 (56%) 
Allaart et al 2006 <12 24 DAS44 126 DMARD 58 (46%) 128 MTX/Infliximab 54 (42%) 
Breedveld et al 2006 <36 24 DAS28 257 MTX 64 (25%) 268 MTX/Adalimumab 131 (49%) 
Choy et al 2008 <24 24 DAS28 117 MTX 21 (18%) 116 MTX/CsA/Pred 32 (28%) 
Emery et al 2008 <24 12 DAS28 263 MTX 73 (28%) 265 MTX/Etanercept 132 (50%) 
Hetland et al 2006 <6 12 DAS28/ACR 68 MTX/IASteroid 23 (34%)/19 (28%) 69 MTX/CsA/IASteroids 30 (43%)/24 (35%) 
Combination vs Combination therapy 
Verstappen et al,  2007 <12 24 ACR derivative 148 Usual MTX/CsA 55 (37%) 151 Intensive MTX/CsA 76 (50%) 
Sauders et al 2008 Mean 12  12 DAS28 44 Step up 21 (45%) 47 Parallel 16 (33%) 
Verschueren et al** 2008 <12 12 DAS28 17 Step up No values 46 Step down No values 
 
Cases at end of follow-up, *achieving remission at some point during follow-up (probable and definite remissions included), ** Not randomised. GSTM = Gold Sodium Thiomalate, MTX = 
Methotrexate, HCQ = Hydroxychloroquine, SSZ = Sulphasalazine, Methylpred = Methylprednisolone, Pred = Prednisolone, CsA = Ciclosporin A ¶ = inclusion criteria of symptoms < 5 years but 
mean disease duration <12 months (SD  <12 months). 
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3.3.2 Remissions In Observational Studies 
Eight studies reported remissions using 1986 ACR criteria; 5 excluded fatigue and 1 
used low levels of pain (<10mm on a 100mm VAS scale).  The overall remission rate 
was 261/1501 (17%). The maximum disease duration ranged from 5 to 24 months. 
The mean remission rate of patients with <1 year disease duration was 18% and < 2 
years disease duration was 23%. The follow-up period ranged from 1 to 10 years. 
When these were sub-divided into groups (<3 years, <6 years and >6 years), the mean 
remission rates were similar (20%, 21% and 18% respectively). 
 
Four studies reported ACR remission rates in patients receiving only DMARD 
monotherapies; 165/1068 (15%) of these patients achieved remission. Four studies 
reported ACR remission in patients also receiving combination therapies; 96/442 
(22%) patients achieved remission.  
 
Nine studies used DAS based remission criteria: 2 used DAS ≤ 1.6 and 7 DAS28 ≤ 2.6. 
The overall rate of remission was 711/2143 (33%). The maximum disease duration 
ranged from 3 to 24 months. The mean remission rate of patients with <1 year disease 
duration was 29% and <2 years disease duration was 36%. The follow-up period 
ranged from 1 to 6 years. When these were sub-divided into groups (<3 years and <6 
years), the mean remission rates were 32% and 31% respectively. Three studies 
reported DAS remissions in patients receiving only DMARD monotherapies; 328/1057 
(31%) achieved remission. Five studies reported remissions in patients receiving 
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combination therapies; 350/985 (36%) achieved remission. One study did not 
describe the treatments used (Cantagrel et al. 1999).  
 
3.3.3 Remissions In Clinical Trials Of DMARD Monotherapies 
Four RCTs evaluated remissions with DMARD monotherapies: one compared DMARD 
(D-Penicillamine) with placebo; one compared SSZ with NSAIDs; and two compared 
different DMARD monotherapies. Three RCTs used categorical remission criteria 
based on ACR remission (ACR derivative). 5/22 (12%) achieved remissions with 
placebo therapy. There were 89/469 (19%) patients in remission using DMARD 
monotherapy. One RCT used DAS-based remission criteria but did not identify 
remissions with DMARD monotherapy or NSAIDs (Choy et al. 2002). 
 
3.3.4 Remissions In Clinical Trials Of Combination Therapies 
Thirteen RCTs compared DMARD monotherapy with combination DMARD therapy 
(including biologics). Six used ACR-based remission criteria: two excluded fatigue; one 
excluded morning stiffness. They reported 75/472 (16%) patients achieved 
remissions with monotherapies and 112/467 (24%) with combination therapies. 
Maximum disease durations were from 12-36 months. The mean remission rate of 
patients with <1 year disease duration was 19% with monotherapies and 24% with 
combination therapies, < 2 year disease duration was 15% with monotherapies and 
24% with combination therapies and <3 year disease duration was 7% with 
monotherapy and 10% with combination therapy. The follow-up period ranged from 
1-3 years. When these were sub-divided into groups (<1 years, <2years and <3 years), 
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the mean remission rates were similar (17%, 14%, 7% with monotherapies and 23%, 
27% and 9% with combination therapies). Meta-analysis (Table 3.4, Figure 3.2) 
showed the random effects OR for remission with combination therapies compared 
with monotherapies was 1.69 (95% CI 1.21, 2.36). There was no evidence of 
significant heterogeneity. The NNT was 12 (95% CI 8, 33).   
 
Seven RCTs used DAS remission criteria. 318/1202 (26%) patients achieved 
remissions with monotherapies and 545/1287 (42%) with combination therapies. 
The maximum disease duration ranged from 6 to 36 months. The mean remission rate 
of patients with <1 year disease duration was 26% with monotherapies and 41% with 
combination therapies, <2 year disease duration was 40% with monotherapies and 
49% with combination therapies and <3 year disease duration was 22% with 
monotherapy and 39% with combination therapy. The follow-up period ranged from 
1 to 2 years. When these were sub-divided into groups (<1 years and <2 years), the 
mean remission rates were 26% and 31% respectively with monotherapies and 41% 
and 44% respectively with combination therapies). Meta-analysis showed the random 
effects OR for remission with combination therapies compared with monotherapies 
was 2.01 (1.46, 2.78) with DAS remissions criteria. There was significant 
heterogeneity within the studies. The NNT was 6 (95% CI 5, 8). One trial reporting 
DAS and ACR remissions was included in both ACR and DAS remission analysis 
(Hetland et al. 2006). The effects of steroids, anti-TNF therapy, combination DMARD 
therapies and tight-control regimes were also investigated by using meta-analysis 
(table 3.4).  The random OR were similar in all subgroups (1.51 – 2.23). 





Figure 3-2: Forrest plot showing the meta-analysis of RCTs comparing combination treatment and monotherapies 
(A) DAS remission criteria; (B) ACR remission criteria, n = number of patients in remission, N = number of patients in treatment arm  
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Table 3-4 Meta-Analysis of Remission Rates in RCTs 










Cases Remission Cases Remission 
DAS remission 7 1202 318 1287 545 2.01 (1.46, 2.78) 19.1 p = 0.004 
ACRRemission 7 472 75 467 112 1.69 (1.21, 2.36) 2.8 p = 0.84 
Steroids 3 328 91 315 132 1.95 (1.39, 2.73) 1.99 p >0.05 
Anti-TNF 4 928 226 1383 390 2.05 (1.26, 3.34) 17.18  p = 0.0006 
Combination DMARDs 10 841 200 953 294 1.51 (0.99, 2.31) 28.33  p = 0.0008 
Tight control regimes 2 246 95 248 142 2.23 (1.26, 3.97) 2.39 p > 0.05 
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Three trials reported different combination strategies. One trial compared step-up 
and step-down combinations regimens but was not randomised (Verschueren, 
Esselens & Westhovens 2008); remission rates were similar with both treatments but 
no values were reported. Two RCTs reported ACR or DAS-based remissions in 33-50% 
of patients. Remission by any criteria occurred in 168/395 (43%) patients.  
 
3.3.5 Remissions And Radiological Progression 
Four observational studies reported radiological outcomes in patients in remission 
(Table 3.5). All showed some radiological progression (19%-54% patients over 3-5 
years) using varying radiological assessment methods. Three studies compared 
erosive progression in patients achieving remission to other cases: one study 
(Machold et al. 2007) reported lower erosive progression with lasting remission 
defined as DAS28 < 2.6 for > 1 year (19% vs 72%); two studies found no differences. 
 
Two RCTs reported the effects of remission on radiological outcomes (Allaart, 
Breedveld & Dijkmans 2007, Svensson et al. 2005). Both showed less radiological 
progression with combination treatments compared to monotherapies in patients in 
remission (Table 3.6).  
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Table 3-5 Radiographic Outcomes In Observational Trials In Remission 
*Lasting remission = DAS28 < 2.6 for > 1 year 





Makinen et al 2005 ACR 111 
Radiological remission (no new/increased 
erosions) at 5 years in 66 patients (55%) 
Vázquez et al 2007 DAS 105 
Increase in Larsen score > 4 at 2 years: 
Remission 9/34 (27%) 
No remission 23/71 (34%) 
Proudman et al 2007 DAS 61 
Increase in erosion score at 3 years: 
Remission 15/28 (54%) 
No remission 14/24 (58%) 
Machold et al 2007 DAS 55 
New erosions over 3 years: 
Lasting remission* 3/16 (19%); 
No lasting remission 28/39 (72%). 
 
 
Table 3-6 Summary of Radiographic Outcomes in RCTs in Remission 
 
Study Year Monotherapy  Combination Therapy  
Svensson et al  2005 
Median change in Larsen 
Score at 2 years  
Remission 2.5 (IQR 0.5-8.0) 
Median change in Larsen Score at 
2 years 
Remission 1.0 (IQR 0-3.5)  
Allaart et al  2006 
Continuous Remission 
25% damage progression  
Continuous Remission 
3% damage progression 
 
  
  111 
3.4 Addendum: Studies Published Since 2010 
3.4.1 Explanation 
As outlined in the methods section (see 3.2.7), since the systematic review was 
completed and published, several new studies have appeared. These are summarized 
in this addendum.  The methods used in this update were identical to those in the 
main review. As the initial review included studies published until the end of 2008 in 
this update studies were included that were published between January 2009 and 
December 2013. 
 
3.4.2 Studies Identified 
The update identified 77 new citations and 19 these were selected for review. 11 were 
excluded as they did not fulfill selection criteria: 6 studies had <50 patients within the 
study (Kita et al. 2012, Bejarano et al. 2010, Sakellariou et al. 2012, Benbouazza et al. 
2012, Picchianti Diamanti et al. 2012), 4 were follow-up reports of previously 
included studies (Rantalaiho et al. 2010b, Rantalaiho et al. 2010a, Rantalaiho et al. 
2009, Svensson, Hafstrom 2011), one included undifferentiated arthritis patients 
(Gremese et al. 2013) and one RCT did not report remission rates per treatment arm 
(Schipper et al. 2011). A further 4 RCTs were identified through hand searching 
(Soubrier et al. 2009, Moreland et al. 2012, Detert et al. 2013, Kavanaugh et al. 2013). 
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3.4.3 Observational Studies 
Two new observational studies were identified (Sagawa et al. 2011, Benbouazza et al. 
2012). These are summarized in Table 3.7. Both studies included the use of DMARD 
combinations. DAS28 remission rates ranged from 35% to 44%. This is higher than 
the studies in the original systematic review (33%). Sagawa et al (Sagawa et al. 2011) 
reported the highest remission rate but the drop-out rate was very large at the end of 
the 24 months period. This makes the results difficult to intepret.  
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Table 3-7 Remissions In Observational Studies (2009-2013) 
 






















Sagawa et al 2010 DAS28 20 52 84 - 47 4.90 24 Combination 81 16 7 (43.8%) 
Benbouazza et al 2011 DAS28 <12 47 89 63 57 6.90 24 Combination 51 45 16 (34.8%) 
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3.4.4 Randomised Controlled Trials 
There were 6 new RCTs reporting on remission rates (Table 3.8). Five compared 
DMARD monotherapy with combination treatment: 3 of which used anti-TNF 
(Adalimumab) with Methotrexate (Soubrier et al. 2009, Kavanaugh et al. 2013, Detert 
et al. 2013) and 2 used combination DMARDs (Kawai et al. 2011, Montecucco et al. 
2012). One trial compared combination DMARDs vs anti-TNF and Methotrexate 
(Moreland et al. 2012). All 6 RCTs reported DAS28 remission (Table 3.8-3.9). One trial 
reported DAS28CRP rather than DAS28ESR remission and the cut-off was 
unconventional at <2.6. 2 studies also report SDAI remission (Kavanaugh et al. 2013, 
Montecucco et al. 2012). The DAS28 remission rates for the monotherapy arms 
ranged from 17% - 39% and for the combination arms ranged from 34% - 59%. The 
SDAI remission rates were lower at 10%-16% and 20%-30.8% for monotherapy and 
combination arms respectively. The RCT comparing 2 different combination regimes 
reported similar remission rates in both arms (57% to 59%). From all 6 RCTs, in total: 
142/674 (21%) patients achieved DAS28 remission with monotherapies and 
498/1098 (45%) with combination therapies. This was similar to the original 
systematic review. No RCTs reported on ACR/EULAR Boolean remission.  
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Table 3-8 Summary of Inclusion Criteria of Clinical Trials 























Monotherapy vs Combination Therapy 
Soubrier et al.,  2009 2 49 81 77 35 6.15 46 78 70 39 6.13 
Kawai et al et al  2011 3 50 81 - 46 - 47 90 - 45 - 
Montecucco et al., 2012 3 62 63 - 23.5 5.20 57 65 - 28 5.00 
Detert et al.,  2013 4 53 67 59 36 6.3 47 61 55 33 6.2 
Kavanaugh et al.,  2013 4 50 74 89  6.00* 51 74 87  6.00* 
Combination vs Combination therapy   
Moreland et al.,  2012 2 49 77 92 33 5.8 51 74 89 37 5.8 
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§Cases Treatment Remission §Cases Treatment Remission 
Monotherapy vs Combination therapy 












1) 25 (27.8%) 
2) 14 (16%) 
96 MTX/pred 
1) 43 (44.8%) 
2) 30 (30.8%) 




Kavanaugh et al 2013 12 6 
1) DAS28CRP <2.6 
2) SDAI 
460 MTX 
1) 78 (17%) 




1) 158 (34%) 
2) 93(20%) 
Combination vs Combination therapy 
Moreland et al 2012 36 24 DAS28ESR 132 
MTX/HCQ/
SSZ 





§= Cases at end of follow-up, * = Achieving remission at some point during follow-up,  MTX = Methotrexate, Pred = Prednisolone, DMARDs = disease modifying anti-rheumatic 
drugs
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Only 2 RCTs reported radiographic outcomes (Table 3.10). Montecucco et al 
(Montecucco et al. 2012) showed that there were significantly more clinical remission 
(DAS28 <2.6) and ultrasound remission (PD negativity) with combination therapy 
than monotherapy. The OPTIMA study showed similar rates of SDAI remission in the 
non-radiographic progression group suggesting that aiming of a stringent target is 
more important than regimes used (Kavanaugh et al. 2013).  
 
3.4.5 Combining the addendum RCTs to the original meta-analysis 
5 RCTs compared remission rates between monotherapy and combination therapy 
arms. All of the new studies reported DAS remission. When these were combined with 
the orginial RCTs, the meta-analysis (Figure 3.3) showed the random effects OR for 
remissions with combination therapies compared with monotherapies was 2.15 (95% 
CI 1.75, 2.63). There was no evidence of significant heterogeneity. This result was very 
similar to the original meta-analysis.  
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Table 3-10 Summary of Radiographic Outcomes in RCTs 
§ Combined clinical and ultrasound remission = DAS28 <2.6 and PD negativity 
* = p <0.05 between treatment arms 
 
Study Year Monotherapy  Combination Therapy  
Montecucco et al  2012 
PD negativity: 53.3% (48/90)* 
Combined clinical and ultrasound remission§: 15.8% 
(14/90)* 
PD negativity: 69.8% (67/96)* 
Combined clinical and ultrasound remission§:  
35.5% (48/96)* 
Kavanaugh et al 2013 
No radiographic progression at 26 weeks 
1) DAS28CRP remission: 71% (17/24)  
2) SDAI remission: 93% (28/30) 
No radiographic progression at 26 weeks 
1) DAS28CRP remission: 83% (52/63)  
2) SDAI remission: 96% (54/56)  
 
  




Figure 3-3 Forrest plot showing the meta-analysis of combined RCTs  
Using DAS remission criteria 
  120 
3.5 Discussion 
This systematic review showed that remission is becoming a realistic therapeutic 
target in early RA. Observational studies showed an overall remission rate of 17% 
with ACR remission criteria and 33% with DAS remission criteria. Many patients in 
clinical remission showed ongoing radiological progression. The RCTs showed that 
more patients achieved remission when combination treatments were used (random 
OR 1.69–2.01 compared to DMARD monotherapies). Radiological progression was less 
in patients receiving combination therapies who were in remission. The newer studies 
in the addendum showed similar results.  
 
The ACR remission criteria and DAS28 remission criteria were derived using different 
methods, leading to differences in their definitions.  Clinicians need to either agree on 
one measure of remission or, if agreement proves impractical, report both. One crucial 
difference between these criteria is the reliance placed on fatigue by the ACR criteria. 
Wolfe and colleagues highlighted the disproportionate impact of fibromyalgic 
rheumatoid on fatigue despite patients with this subtype having no more synovial 
inflammation (Wolfe, Hawley & Wilson 1996). Consequently, using fatigue to assess 
RA remission may disproportionally affect the assessment of fibromyalgic RA. Pain 
and fatigue are common in the general population and Sokka and colleagues 
suggested most people aged over 50 years in the general population will not fulfil ACR 
remission criteria for RA due to these symptoms (Sokka et al. 2007). The majority of 
the trials in this systematic review that used ACR remission criteria excluded fatigue. 
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Despite this, the ACR remission criteria are more stringent than DAS28-based criteria 
as no swollen nor tender joints are permitted in ACR remission criteria.  
 
With DAS-based criteria, there is uncertainty about differentiating remission from low 
disease activity. The DAS-based remission criteria are derived from studies that 
showed that DAS≤1.6 best reflects ACR remissions (Prevoo et al. 1996). However, its 
conversion into DAS28≤2.6 is controversial (Landewe et al. 2006); other levels of 
DAS28 have been suggested to better reflect remission (Makinen et al. 2005b, 
Fransen, Creemers & Van Riel 2004). Conversely, patients in remission may have 
falsely higher scores due to fibromyalgia or co-morbidities which can affect ESR, 
tender joint scores and patient global scores. DAS is not the only continuous 
assessment of disease activity and remission; other more stringent examples include 
the simple disease activity index (SDAI) and the clinical disease activity index (CDAI). 
Current cut points for remission have been defined as 3.3 for SDAI and as 2.8 for CDAI 
(Aletaha, Smolen 2005, Aletaha et al. 2005b). The SDAI has been reported in some of 
newer studies in the addendum. A final issue is the value of repeated assessments for 
determining remission; it is uncertain how many times patients need to be assessed 
and over what period; for instance, is remission on a single occasion important or 
does it need to be sustained for 6 or 12 months? 
 
The relationship between disease activity and radiographic progression in early 
rheumatoid arthritis remains a topic of debate. The follow-up study of Cohen et al., 
found that sustained clinical remission correlated with stability of radiological 
damage in most patients (Cohen et al. 2007a). However, there was radiological 
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progression in a proportion of patients (16.7 %) in sustained remission and 20% 
developed erosions in a previously unaffected joint between the third and fifth years. 
Other trials have also reported radiological progression in patients in remission 
(Molenaar et al. 2004, Brown et al. 2008).  It is therefore uncertain whether 
radiographic progression is wholly dependent on joint inflammation (Boers 2008). 
Another explanation may be that current assessment tools for disease activity are 
insensitive at low levels of inflammation and fail to detect ongoing disease activity. As 
a key goal of treatment is to prevent joint damage, radiological remission should be 
considered as a criterion for remission. The effect of treatment on radiological 
outcomes in patients with remission is unclear. The meta-analysis identified 2 RCTs, 
which reported radiographic outcomes in remission groups. They both found that 
combination therapy is associated with less radiographic progression in patients in 
remission when compared to monotherapy (Allaart, Breedveld & Dijkmans 2007, 
Svensson et al. 2005).  Prednisone or anti-TNF were used in the combination arms of 
those trials in which there was reduced radiological progression. It is inappropriate to 
extrapolate results from these two trials to all combination DMARD regimens. 
Interestingly, a recent post-hoc analysis of the PREMIER study found that once 
patients are in sustained remission, there was no difference in radiographic 
progression across the treatment groups (Aletaha et al. 2009).  
 
To conclude, remission is now a realistic treatment goal in early RA, particularly with 
the increased focus on patients receiving intensive combination treatment regimens. 
Currently, multiple remission criteria exist but DAS28 remission criteria appears 
easier to achieve. The absence of a single standard for assessing clinical remission is a 
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major hurdle in its use as a standardised outcome measure. In addition, radiological 
remission is currently not considered routinely in clinical trials, which is key to 
preventing long-term disability. Patients in true remission should be in clinical as well 
as radiological remission. Currently, there is an urgent need for international 
consensus on assessing and reporting true remission states. This will be further 
explored in chapters 5-7. 
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4 Predictors of Remission at 24 months  
4.1 Introduction 
Chapter 3 demontrated that remission, particularly with the use of combination 
therapies, is now becoming a possibility in the treatment with RA. However, RA 
remains a heterogeneous disease with variable long-term outcomes that are difficult 
to predict. Its course ranges from drug free remission to severe joint damage and 
extra-articular manifestations (Scott, Steer 2007). Early intensive treatment has 
improved both clinical and radiological outcomes (Donahue et al. 2008, Ma, Kingsley 
& Scott 2010, Katchamart et al. 2008). This approach is now widely adopted as first-
line treatment in routine clinical practice both nationally and internationally (NICE 
2009, Singh et al. 2012, Smolen et al. 2010). Optimising therapeutic strategies to 
induce remission requires an understanding of the initial clinical characteritics that 
predict remission; currently no suitable model exists.  
 
In the era of personalised medicine where treatment should be more individualised, it 
is unclear from the current literature whether all RA patients benefit from such 
intensive therapies to the same extent. Serological biomarkers including rheumatoid 
factor (RF) and anti-citrullinated peptide antibodies (ACPA) play an important role in 
the diagnosis of RA (Aletaha et al. 2010). The presence of these antibodies are 
associated with radiographic damage, high disease activity and extra-articular 
manifestations (Nell et al. 2005, Smolen et al. 2006, van der Helm-van Mil et al. 2005). 
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There is emerging evidence that serological status can predict treatment response in 
biological therapies (Klaasen et al. 2011, Braun-Moscovici et al. 2006). 
 
Accordingly, I set out to: 
1)  To develop a predictive model for 24-month remission in early RA patients. Data 
from an RCT comparing Methotrexate, steroids and combination DMARDs will be used 
to develop this model (CARDERA study)(Choy et al. 2008a). The predictive model will 
then be validated using data from a UK cohort - the Early RA Network (ERAN, (Kiely et 
al. 2009). These datasets provide a unique comparative assessment of remission in 
both a clinical trial and routine practice settings in patients seen across a large 
number of UK specialist centres.  
 
2) To explore the use of the above model and serological biomarkers as predictors of 
response to DMARD intensive treatment. Since serum samples are only available in 
the CARDERA RCT, this part of the study is limited to patients enrolled in the RCT 
only. 
 
4.2 Patients and Methods 
This study was a post-hoc analysis of already collected data (CARDERA and ERAN 
cohorts). I carried out the autoantibody assays myself.  
4.2.1 Clinical Trial Patients 
The CARDERA trial recruited patients with RA from across 42 specialist rheumatology 
centres in England and Wales with less than 2 years disease duration who had 
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evidence of clinically active disease (Choy et al. 2008a). 467 patients were recruited 
and 378 patients remained on trial treatment and had full datasets at 24 months. 358 
of these patients had available baseline serum samples. Patients were assessed 
initially and then 6 monthly for 24 months. The trial compared four treatment 
regimens, which were allocated randomly to across 4 equal treatment arms. These 
regimens comprised Methotrexate monotherapy, Methotrexate and Ciclosporin, 
Methotrexate and prednisolone, and Methotrexate, Ciclosporin and prednisolone. 
Methotrexate dose was 7.5-15mg, Ciclosporin dose was 100mg escalating to 3mg/kg 
and Prednisolone was 60mg aimed to stop by 34 weeks. For the purposes of this 
study, the double therapies were combined for analysis. 
 
4.2.2 Observational Cohort Patients 
The Early RA Network (ERAN) is an inception cohort of patients with newly diagnosed 
RA recruited in 19 UK centres. It reflected contemporary routine care of early RA 
patients(Kiely et al. 2009). We analysed data collected from 2002-2007. The 194 
patients who completed 24 months follow-up at the time of analysis were evaluated. 
Patients were assessed at first presentation, at 3-6 months, and at 12 and 24 months. 
Treatment was determined by the supervising clinician. 94% of patients received 
initial DMARD monotherapy, comprising Methotrexate (47%), Sulfasalazine (42%), 
Hydroxychloroquine (7%), Leflunomide (2%), gold injections (1%) and Ciclosporin 
(0.5%). 4% of patients received two DMARDs initially and 2% started initial triple 
DMARD therapy. Oral or intramuscular steroids were used in 70% of patients.  
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4.2.3 Clinical Variables 
Remission was defined as DAS28 scores of less than 2.60 (Prevoo et al. 1995). The 
following initial variables were present in both the clinical trial and the observational 
study: age, gender, rheumatoid factor positivity, rheumatoid nodules, health 
assessment questionnaire (HAQ) scores, tender joint counts for 28 joints (TJC), 
swollen joint count for 28 joints (SJC), erythrocyte sedimentation rate (ESR) and 
patient global assessments (PGA). Initial Larsen scores (as an assessment of 
radiographic progression) and SF36 scores were also available in the clinical trial.  
 
4.2.4 Autoantibody analysis 
Serum samples were taken at baseline and stored at -20oC prior to analysis. The 
autoantibody assays have been described in Chapter 2. 
 
4.2.5 Statistical Analysis 
Data were analysed using STATA version 10 (StataCorp, Texas, 2007) and IBM SPSS 
20. Individual variables were assessed descriptively as median values and 
interquartile ranges. Categorical data were represented as percentages (%) and 
analysed using Chi-squared test if the n ≥10 patients or Fisher’s exact test if n ≤10.  
 
In assessing predictors of remission, analyses were restricted to those individuals 
with complete data at 24 months (n=378). Point remission at 24 months was used as 
the outcome as this was the study endpoint when the patients would have had 
maximal treatment. Univariate and multivariable logistic regression models were 
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used to estimate the associations between baseline variables that are potential 
predictors of remission at 24 months.  In this analysis, variances were adjusted for 
inter-site effect using Huber-White sandwich (robust) estimator. All continuous 
measures were entered into the models in this format. The results were presented as 
univariate and multivariate odds ratios (OR) with 95% confidence interval, p-values 
were two-tailed throughout. Those variables that had p values ≤ 0.05 in the univariate 
analysis were carried forward into multivariate analysis. We also assessed whether 
variables were colinear for the final model; we considered variables were correlated if 
their correlation coefficient was >0.5. The regression coefficient (β) of the variables 
from the final model was used to estimate the score.  The predictive model was 
calculated to be: (β1x V1)+ (β2 x V2) + (β3 x V3)…..+ α + ℮, where V = independent 
variables and α= constant, ℮= error. This was similar to the method which was used 
to derive the prediction model for patients with undifferentiated arthritis who then 
develops rheumatoid arthritis, published by van der Helm-van Mil (van der Helm-van 
Mil et al. 2007). We also derived a simplified remission score, based on the factors 
identified in the regression analysis; details are given in the results section. The area 
under the curve from Receiver Operating Characteristic (ROC) was used to assess the 
model’s ability to discriminate between remission and non-remission patients.  
 
In assessing predictors of response to intensive therapy, analyses were restricted to 
the 358 individuals with complete data at 24 months and available serum samples. 
Gender, age and tender joint count were dichotomised: Male/Female, age under 
50/over 50, TJC: 5 or less / 6 or over. The cut-off for TJC 5 or less/ 6 or over was 
chosen as this is considered the threshold for active disease in clinical trials. Logistic 
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regression models were used to estimate the associations between treatment 
regimens and point remission at 24 months when stratified by these clinical 
predictors and serological biomarkers. The effects of treatment on remission rates 
were first explored. This showed no difference between double vs monotherapy (OR 
0.852 95% CI 0.435 – 1.67, p = ns). The effect of triple therapy compared to 
monotherapy was OR 2.22 95% CI 1.11-4.46 (p = 0.025). The models were therefore 
restricted to monotherapy vs triple therapy with adjustment for treatment centre.  To 
explore the interaction between clinical and serological status, serological status 
models were also adjusted for baseline DAS28, gender and age. Multiple testing was 




4.3.1 Patients and Remission Rates 
The baseline characteristics of the 378 patients with full datasets were: 259 (68%) 
were females; median age was 54 years (IQR 46, 64); 82 (22%) had rheumatoid 
nodules. 74 (20%) were in remission at 6 months, 15% were in remission at 12 
months and 21% at 24 months. The number of patients who did not achieve remission 
at any point during the study was 65%. 14% achieved remission at one time-point, 
8% at 2 time-points and 7% had sustained remission over all time points. 9% 
achieved sustained remission between 12 and 24 months. 
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The observational cohort had enrolled 194 patients who had completed 24 months 
follow-up. They comprised of 140 (72%) females, their median age was 56 years (IQR: 
47,66 years); 72% were rheumatoid factor positive and 28% had nodules. 24% 
achieved remission at 6 months, 20% at 12 months and 30% patients achieved 
remission at 24 months. 23% achieved remission at one time-point, 12% at 2 time-
points and 4% had sustained remission over all time-points. The baseline 
characteristics of these 2 cohorts were similar with the exception of the baseline 
disease activity, which was expectedly higher in the RCT. The demographics of both  
patient populations are summarized in table 4.1. 
 
Table 4-1: Patient Characteristics (CARDERA and ERAN) 
Summary of the Clinical Trial (CARDERA) And Observational Cohort (ERAN) 
Characteristics Full dataset at 2 year 




Female n (%) 259 (68) 140 (72) 
Median Disease Duration (IQR) in months 2 (0, 5) 2 (1, 2) 
Median Age at onset (IQR) in years 56 (46, 64) 55 (47, 64) 
Clinical Rheumatoid Factor (%) 259 (68) 134 (72) 
Rheumatoid Nodules (%) 82 (22) 54 (28) 
Median Baseline DAS28 (IQR) 5.78 (4.88, 6.77) 4.77 (3.75, 5.77) 
Median Baseline HAQ (IQR) 1.16 (0.12, 2.12) 1.25 (0.59, 1.75) 
Median Larsen Score (IQR) 6.5 (2.5, 16.5) - 
Erosions at baseline (%) - 56 (29) 
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4.3.2 Predictors of Remission at 24 months 
4.3.2.1 Multivariate Remission Score 
Regression Analysis Of Clinical Trial Data 
Univariate analysis showed significant associations (p < 0.05) between remission at 
24 months and age, gender, baseline HAQ, 28 tender joint count (TJC28), 28 swollen 
joint count (SJC28) and patient global scores. Multivariate logistic regression analyses 
showed only age, gender and TJC28 remained independently associated with 
remission at 24 months. Clinical rheumatoid factor, nodules, and baseline Larsen 
score did not affect remission (Table 4.2). The final model was assessed for 
correlations between variables to exclude colinearity; all the correlation coefficient 
was less than 0.5. 
 
Developing Multivariate Remission Score Using Clinical Trial Data 
A Multivariate Remission Score was generated using the coefficients from 
multivariable logistic regression analysis (Table 4.2). The Remission Score was = 0.37 
+ [-0.03 x age] + [1.1 x gender (1 for males and 0 otherwise] + [-0.07 x Baseline 
28TJC]. A higher value indicates a higher probability that the patient will achieve in 
remission at 24 months. Remission Scores were calculated for each patient with a full 
dataset in the clinical trial. The area under the ROC curve was 0.71 (95% CI 0.63-0.77, 
Figure 4.1). When the "cut point" for the probability of identifying those patients in 
remission was set at 50% or more, the positive predictive value of the model was 69% 
and the negative predictive value was 81%.  
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Table 4-2: Predictors of Remission at 24 Months 
Baseline Variables Predictive Of Remission At 24 Months In Clinical Trial (CARDERA) Using Univariate And Multivariate Logistic 
Regression 
 
 Univariate Multivariate 
 OR (95%CI) P-value OR (95%CI) P-value Co-efficient (ß) 
Age 0.98(0.96,1.00) 0.049 0.97(0.95,0.99) 0.014 -0.03 
Male 2.91(1.75,4.85) <0.001 3.14(1.80,5.46) <0.001 1.1 
Rheumatoid Factor (Clinical) 0.96(0.57,1.62) 0.884 - - - 
Nodules 0.64(0.34,1.24) 0.186 - - - 
Health Assessment Questionnaire 0.67(0.47,0.96) 0.027 1.07(0.66,1.72) 0.79 - 
Larsen score 0.98(0.96,1.00) 0.057 - - - 
Tender Joint Count 0.93(0.90,0.97) <0.001 0.94(0.90,0.98) 0.006 -0.06 
Swollen Joint Count 0.95(0.91,1.00) 0.03 1.00(0.95,1.05) 0.89 - 
Erthrocyte Sedimentation Rate 0.99(0.98,1.00) 0.144 - -  
Patient Global Assessment 0.99(0.98,1.00) 0.041 0.99(0.98,1.00) 0.23 - 
SF-36 Mental Component Score 1.02(1.00,1.03) 0.081    
SF-36 Physical Component Score 1.02(1.00,1.05) 0.097    
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Replicating Multivariate Remission Score Using Observational Data 
Applying the Multivariate Remission Score to patients in the observational study gave 
an area under the ROC curve of 0.70 (95% CI 0.62, 0.78 Figure 4-1). The model 
correctly classified 71% of patients with a poor sensitivity of 29% but good specificity 




Predictive Model Using Multivariate Remission Score 
 
The Multivariate Remission Score was applied to predict the likelihood that patients 
would achieve remission at 24 months in both CARDERA and ERAN (Figure 4-2). 
Using the Multivariate Remission Score, the more negative the scoring the higher the 
likelihood that the patient would not achieve remission at 24 months. Overall this 
approach correctly classified 80% of patients but had a poor sensitivity (13%) despite 
good specificity (98%). With low remission scores, patients were unlikely to achieve 
remission at 24 months. 
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Figure 4-1 ROC curves for The Remission Score  
Receiver operating characteristics (ROC) curves using  
(A) Clinical Trial dataset (CARDERA) And (B) Observational Cohort (ERAN)  
ROC Curve: 
0.70 (95% CI 0.62, 0.78) 
 
ROC Curve: 
0.71 (95% CI 0.63, 0.77) 
A  B 
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Figure 4-2.Predictive Ability of the “Multivariate Remission Score” 
The Clinical Trial (CARDERA) And Observational Cohort (ERAN).  This figure shows the % of patients who achieved remission at 24 
months stratified according to the Multivariate remission score. The more negative the scoring the higher the likelihood that the patient 
would not achieve remission at 24 months.  
  
4.3.2.2 Simplified Remission Score 
As clinicians may not be keen to employ mathematical formulae when assessing 
patients, a simplified clinical tool was devised.  
 
Firstly, patient divided by gender then by age (< 50 and > 50 years) and finally by 
baseline tender joint counts (<5, 6-19 and >20). The likelihood of achieving 
remission at 24 months was compared in the combined data from CARDERA and 
ERAN datasets. The results of this comparison are shown in Figure 4.3. Males aged 
under 50 years who had 5 or fewer tender joints when initially seen had the 
highest chances of achieving remission at 24 months (71% of patients). In contrast, 
females aged over 50 years who had more than 15 tender joints when first seen 
had the lowest chance of remission (11% of patients). Secondly, a Simplified 
Remission Score was devised by scoring 1 point for being male, 1 point for being 
aged < 50 years, 2 points for  < or equal to TJC 5 and 1 point for 6-15 TJC. This 
simplified remission score showed a high correlation with the multivariate 
remission score (Spearman’s correlation coefficient 0.80). For the purposes of 
comparison, we evaluated the likelihood of achieving DAS28 remission, low 
disease activity (DAS28 under 3.2) and having high disease activity (DAS28 5.1 or 
more). The results are shown in Figure 4.4. High Simplified Remission Scores (3 
and 4), which were seen in 22% of patients, gave high chances of remission (37-
72%). They also gave high chances of low disease activity (47-78%) and low 
chances of persisting high disease activity (12% or less). In contrast, low Simplified 
Remission Scores (0 and 1), which were seen in 41% of patients, gave low chances 
of remission (7-14%) and low chances of low disease activity (10-20%) and high 
chances of persisting high disease activity (34-67%).  




Figure 4-3. Relationship Of TJC28, Age And Remission According To Gender 
The likelihood of achieving remission at 24 months was compared in the combined 
data from CARDERA and ERAN datasets. The patients were divided firstly by 
gender then by age and finally by baseline tender joint counts. The percentages of 
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 Figure 4-4: Simplified Remission Score and Disease Activity 
The Ability Of “The Simplified Remission Scores” At Predicting Different Disease 
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4.3.3 Predictors of response to treatment 
4.3.3.1 Remission rates according to treatment groups 
The followings section was based on post-hoc analysis of the CARDERA cohort 
only. The baseline characteristics of the CARDERA cohort with available serum are 
shown in Table 4.3. RF IgM and ACPA results were available for 358 and 351 
patients. 89% were RF IgM positive and 73% were ACPA positive. These were 
representative of the total cohort. In total, 16/87 patients (18%), 29/180 (16%) 
and 30/90 (33%) patients achieved remission at 24 months using monotherapy, 
double therapy and triple therapy respectively.  
 
Table 4-3 Baseline CARDERA Patient Characteristic with Available Serum 
358 Patients had Complete 2 Year Data and Available Serum Samples. IQR = 
interquartile range, HAQ = Health assessment questionnaire, RF-IgM = Rheumatoid 
factor IgM isotype, ACPA = antibiodies to citrullinated protein antigens 
 
 
Clinical Features Baseline Data 
Female n (%) 245 (68%) 
Median Age at onset (IQR) 54 (46, 63) 
Rheumatoid Nodules n (%) 80 (22%) 
Median Baseline DAS28 (IQR) 5.78 (4.88, 6.76) 
Median Baseline HAQ (IQR) 1.62 (1.12, 2.03) 
Median Larsen Score (IQR) 6.5 (2.3, 16) 
RF-IgM positivity n (%) 313 (87%) 
ACPA positivity n (%) 258 (72%) 
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4.3.3.2 The remission score and clinical predictors of remission by treatment group 
The mean (SD) Remission Score was -1.7 (0.84). The Remission Score predicted 
treatment response in monotherapy, double and triple therapy (OR 3.07 95% CI 
1.35-6.96 p=0.007, OR 1.99 95% CI 1.19, 3.32 p = 0.008 and OR 4.42 95% CI 1.90 – 
8.94, p <0.0001 respectively). This was adjusted for treatment centre. 
 
The individual clinical predictors were then dichotomised: Gender – Male or 
Female, age - < 50 or ≥ 50 and TJC - < 6 or ≥ 6. 245 patients were female, 113 
patients were male, 122 were < 50, 236 were ≥ 50, 88 had less than 6 tender joints 
and 270 had 6 or more tender joints. Figure 4.5 shows treatment responses when 
stratified to different clinical predictors. Females achieved low levels of remission 
across all treatment arms and responded to a similiar extent regardess of whether 
they received mono-, double or triple therapy [8/14 (14%), 17/131 13%, 13/57 
23% respectively, p >0.05]. Males responded better to triple therapy [17/33, 52%] 
compared to mono [8/31 26%, 12/49 25%]. Patients with lower TJCs responded 
to a similar extent across all the treatment groups: mono [6/19, 32%], double 
[12/44, 27%] and triple [10/24, 42%, p = ns] therapies. Patients with more than 6 
TJCs achieved higher remission rates with triple therapy (20/66, 30%) when 
compared to mono (10/68 15%) and double (17/136 13%) therapies. Patients 
under 50 achieved similar high rates of remission across all the treatment groups: 
mono (11/32, 34%), double (14/61 23%) and triple (11/29 38%) p = ns) 
therapies. Patients over 50 years of age achieved higher remission rates using 
triple therapy (19/61, 31%) when compared to mono (5/55, 9%) and double 
(15/119, 13%) therapies. 
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Using logistic regression analysis, patients who were male, over 50 or had ≥ 6 TJC 
were more likely to achieve remission at 24 months using triple therapy compared 
to monotherapy (OR 2.99, 4.95 and 2.71 respectively, Table 4.4).  There were no 
differences in response to monotherapy and triple therapy if patients were female, 
under 50 or had less than 6 tender joints (Table 4.4).  
 
Table 4-4. Predictors of Remission When Stratified to Treatment Regimes  
Predictive Value Of Achieving Remission At 24 Months Using Triple Therapy 
(Methotrexate, Ciclosporin and Prednisolone) When Compared To Methotrexate 




Predictors Of Response Odds Ratio 95% CI P Value 
Female 1.80 0.68 – 4.78 NS 
Male 2.99 1.01 – 8.90 0.049 
Over 50 4.95 1.66-14.75 0.004 
Under 50 1.09 0.38 – 3.16 NS 
≥ 6 TJC 1.56 0.43-5.63 0.028 
<6 TJC 2.71 1.11-6.60 NS 
RF-IgM Negative 1.49 0.17, 12.46 NS 
RF-IgM Positive 2.28 1.08, 4.85 0.032 
ACPA Negative 1.03 0.25, 4.30 NS 
ACPA Positive 2.99 1.29, 6.97 0.011 
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4.3.3.3 Serological predictors of remission by treatment group 
When stratified according to different treatment groups, serological status did 
have an impact on remission rates (Figure 4.5). In RF-IgM –ve patients, there was 
no difference in point remission rates between mono, double and triple therapies 
respectively [2/11 (18%), 5/23 (22%) and 3/10 (30%) p > 0.05]. In RF-IgM +ve 
patients, fewer patients achieved remission using monotherapy and double 
therapy (14/76, 18% and 24/157, 15%) when compared to triple therapy (27/80, 
34%, p = 0.02). In ACPA -ve patients, 5/24 (21%), 4/42 (10%) and 5/22 (23%) 
achieved remission using mono, double and triple therapies respectively (p >0.05). 
In ACPA +ve patients, more patients achieved remission using triple therapy 
(25/67, 37%) than monotherapy (11/63, 17%) and double therapy (24/132, 18%) 
(p=0.007). 
 
The level of seropositivity was next explored. Patients were stratified into low-
levels (< 3 x upper limit of normal) and high-levels (≥ 3 x upper limit of normal) of 
seropositivity as according to thresholds adopted in the ACR/EULAR criteria for 
Rheumatoid Arthritis in 2010 (12). In low-positive RF-IgM, there was no difference 
between remission rates in the different treatment groups: monotherapy 2/8 
(25%), double therapy 0/15 (0%) and triple therapy 1/3 (33%, p = ns). In high-
positive RF-IgM, more patients achieved remission with triple therapy 26/77 
(33.8%) than monotherapy 12/68 (17.6%) and double 24/142 (16.9%, p = 0.01).  
In low-positive ACPA, there was no significant difference in remission rates 
between the treatment groups: monotherapy 3/5 (60%), double therapy 1/13 
(7.7%) and triple therapy 2/9 (22%, p = ns). In contrast, in the high-positive ACPA 
group, more patients achieved remission with triple therapy 23/58 (39.7%) when 
  143 
compared to monotherapy 23/76 (13.8%) and double 23/119 (19.3%, p = 0.001) 
groups. 
 
The associations of treatment regimens and remission according to serological 
status are summarised in Table 4.4. The benefit of triple therapy is only apparent 
in RF IgM +ve (OR 2.28, 95% CI 1.08-4.85) and ACPA +ve (OR 2.99, 95% CI 1.29-
6.97). Their effects size increased when adjusted for clinical factors (DAS28, age 
and gender) suggesting that the effects of the clinical and serological biomarkers 
were cumulative (OR 2.54 and 3.52 respectively Table 4.5).  
 
Table 4-5: Serological Predictors Adjusted For Clinical Variable 
The Use Of Serological Status To Predict Remission At 24 Months 
Using Triple Therapy (Methotrexate, Ciclosporin and Prednisolone) Compared To 
Methotrexate Monotherapy. Adjusted For Treatment Region, Baseline DAS28, Gender 
And Age 
 
Predictors of response OR 95% CI P Value 
RF-IgM Negative 1.17 0.58, 23.9 NS 
RF-IgM Positive 2.54 1.12, 5.76 0.026 
ACPA Negative 0.91 0.19, 4.28 NS 
ACPA Positive 3.52 1.37, 9.03 0.009 
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Figure 4-5: Effect of Clinical and Serological Predictors on Treatment Response  
Showing Remission rates at 24 months in different treatment groups according to clinical and serological predictors. 
(A) Gender, (B) Tender joint count, (C) Age, (D) RF-IgM and (E) ACPA.  Multiple testing was adjusted by using bonferroni method. Monotherapy = 
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4.3.3.4 Serological Status And ACR Core Set Remission Measures 
To explore the effects of the individual components of DAS28, the threshold levels 
for remission according to the ACR core set measures were used (12, 20). At 24 
months, in total, 44.7% of patients achieved TJC28 ≤ 1, 22.9% had no swollen 
joints, 56.2% had ESR ≤ 20 and 23.2% had PGA ≤ 10. There were no differences 
between monotherapy and triple therapy in any of the 4 components at 24 months 
between RF-IgM positive and negative patients (Table 4.6). In ACPA +ve patients, 
more patients achieved TJC28 and SJC28 thresholds of remission in the triple 
therapy group than monotherapy groups at 24 months than ACPA negative 
patients (Table 4.6). 
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Table 4-6 Effects of Monotherapy and Triple Therapy on DAS28 Components 
Assessing the rate of remission at 24 months when stratified according to serological status withinin the individual DAS28 components 






TJC28 at 24 months SJC28 at 24 months ESR at 24 months PGA at 24 months 
≤1 p value <1 p value ≤20 p value ≤10 p value 
RF IgM 
Negative 








Triple 4/8 (50%) 3/4 (75%) 8/15 (53%) 2/6 (33%) 
RF IgM 
Positive 








Triple 50/87 (58%) 26/42 (62%) 47/89 (53%) 24/41 (59%) 
ACPA 
Negative 








Triple 11/25 (44%) 5/10 (50%) 15/27 (56%) 6/13 (46%) 
ACPA 
Positive 








Triple 43/70 (61%) 24/36 (67%) 39/76 (51%) 20/34 (59%) 
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4.4 Discussion  
In the first part of this study, we developed a remission score using simple clinical 
assessments that correctly classifies over 70% of patients. The score is equally 
applicable in a clinical trial and routine practice setting. Three variables – gender, 
age and initial tender joint counts – are all that is required. There was a marked 
difference in the likelihood of remission between different groups. Males who are 
under 50 years of age with less than 6 tender joints were the most likely to be in 
remission at 24 months. Clinical rheumatoid factor, rheumatoid nodules and x-ray 
damage did not contribute to the likelihood of remission. The Simplified Remission 
Score is readily applied in routine practice, and is similar in approach to the 
Simplified Disease Activity Index (Gaujoux-Viala et al. 2012). In the second part of 
this study, we explored these clinical factors as well as serological status in 
predicting treatment response to different treatment strategies.  Our study 
suggests that triple therapy approach is only superior to monotherapy in certain 
subsets of patients. Stratifying patients according to gender, age, tender joints, RF 
isotypes positivity and ACPA positivity can predict response to intensive 
treatment.  
 
The remission score is intended to identify those patients who are most likely to 
achieve remissions at 24 months using any treatment.  We used similar prediction 
methods to those employed to predict the progression of RA from undifferentiated 
inflammatory arthritis (van der Helm-van Mil et al. 2007) and the likelihood of 
radiographic progression in RA (Vastesaeger et al. 2009). Our remission score was 
equally applicable in patients treated in a clinical trial and in routine practice, 
suggesting it is likely to be generalisable.  
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Gender, initial DAS28 scores and age have all been previously reported as 
important determinants of remission (Verstappen et al. 2005, Forslind et al. 2007, 
Schipper et al. 2010, Vazquez et al. 2007, Katchamart et al. 2010, Gossec et al. 
2004). Interestingly, we found that it was tender joint counts rather than swollen 
joint counts or ESR values that were the defining clinical predictor of remission. 
The reason for this is uncertain. It might reflect greater levels of agreement 
between observers when assessing tender compared with swollen joint counts 
(Scott et al. 1996). Other possible explanations include the greater weighting of 
tender joint counts within the DAS28 score and the inter-relationship between 
tender joint counts and fibromyalgic RA (Leeb et al. 2004). Although we chose to 
use the individual components of the DAS28 rather than the DAS28 score itself to 
predict remission, using DAS28 instead of the tender joint count in the Multivariate 
Prediction Model gave a similar area under the ROC curve. Expectedly, patients 
with more tender joints (>=6) responded better to more intensive therapy. This 
study also showed that intensive therapy is not necessary in patients with milder 
disease as indicated by fewer tender joints as they responded with equal efficacy 
to monotherapy.  
 
The impact of gender is so striking that treatments might need to be adjusted for 
gender; this is particularly relevant to the analysis of the outcomes of clinical trials 
where analyses should be separately carried out for different genders. Different 
risk stratifications by gender are recognised in a range of medical disorders, 
particularly in cardiovascular diseases (Lerner, Kannel 1986).  The purpose of 
identifying patients’ subsequent chances of remission when they are first seen is to 
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enable treatment to be personalised so that those patients with the least chance of 
remission can be targeted for more intensive treatment.  However, given the 
findings from the second part of the study, females did not respond to a more 
intensive approach using triple therapy. Other approaches using different agents 
or tight-control regime should be considered. 
  
The effect of age is more complex. The risk of remission was reduced in the elderly 
but they appear to respond to triple therapy better than monotherapy. However, in 
treating elderly patients more intensively, one should take into account of 
potential co-morbidities and adverse events (Wijnands et al. 1990) .  
 
Intensive DMARD therapies are associated with increased drug toxicity (Ma, Cope 
& Scott 2010). Not all patients with RA require identical treatment. Instead, 
therapy should be individualized on the basis of risk factors assigned to each 
patient.  A personalised, tailored approach to treatment, where each patient 
receives the appropriate intensity of treatment for as long as needed is the goal of 
treatment. This study suggests that males respond better to triple therapy 
compared to monotherapy whereas females respond equally but less well to all 
treatment regimes. Conversely, patients over 50 and with more than 6 TJC respond 
better to triple therapy than monotherapy but younger patients with a lower TJC 
respond well to all treatment regimes. 
 
Several prediction matrices using serological status exist to predict risk of rapid 
radiological progression (RRP) using different DMARD and biological treatment 
regimes (Vastesaeger et al. 2009). Other studies have shown conflicting results 
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using serological status to predict anti-TNF response (Klaasen et al. 2011, Braun-
Moscovici et al. 2006). However, no model exists for predicting clinical response to 
DMARD treatment regimes. This is the first study demonstrating the difference in 
response to intensive DMARD therapy between seronegative and seropositive RA 
patients.  
 
In conclusion, remission in early RA can be predicted using three initial 
independent predictors – gender, age and tender joint counts. We created a 
multivariate remission score as well as a simplified remission score using these 3 
predictors. These can be combined in a remission score which is best at predicting 
those patients who are unlikely to achieve remission at 24 months. This was 
validated in an independent observational cohort to improve the robustness of our 
study. It is premature to base current treatment on our remission score; further 
work is required to optimise this approach. However, the concept of a predictive 
remission score would be useful to tailor treatment regimes at an individual 
patient level. It is likely that a broader range of potential predictors need to be 
examined, particularly extended imaging and laboratory biomarkers, before such 
predictive assessment is adopted in routine practice. In addition, this study shows 
the importance of serological biomarkers to predict treatment response to 
combination DMARD therapy. ACPA in particular was shown to be the best 
biomaker for predicting treatment response. Although this is unlikely to be the 
only predictor of response, this study brings us a step closer to achieving 
personalised medicine in RA.  
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5 Clinical and radiological predictors of sustained remission  
 
5.1 Introduction 
The research in this chapter builds upon three themes. Firstly, the heterogeneous 
nature of RA outcomes; these were outlined in Chapter 1. Secondly, the increasing 
frequency of point remission states (Ma et al. 2010) which were considered in 
Chapter 3. Finally, the many different criteria used to define remission in patients 
with RA.  
Many definitions of remission are based on continuous composite measures; one 
commonly used method is the Disease Activity Score (DAS, (Prevoo et al. 1996)) 
and its modifications, including DAS28-ESR (Fransen, Creemers & Van Riel 2004) 
and DAS28 CRP (Wells et al. 2009). Newer, stricter criteria are based on the 
Simplified Disease Activity Index (SDAI, (Aletaha, Smolen 2005) and Clinical 
Disease Activity Index (CDAI, (Aletaha et al. 2007). The most stringent of remission 
criteria, the ACR/EULAR Boolean remission criteria (Felson et al. 2011), was 
designed to differentiate remission from low disease activity. All these criteria 
describe point remission (remission at one time-point) and none include the 
concept of time within their definitions.  
The use of clinical and serological biomarkers as predictors of point remission at 
24 months was evaluated in Chapter 4. The prediction model had good specificity 
but poor sensitivity. This suggests that other laboratory biomarkers are likely to be 
required. A more complete clinical picture of disease activity necessitates 
integrating data points over time. True remission should mean that patients are in 
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sustained remission over time. Sustained remission has also been shown to arrest 
radiographic progression irrespective of treatment used in the PREMIER study 
(Aletaha et al. 2009). Currently in the literature, sustained DAS28 remission is 
reported infrequently in studies. Moreover, sustained remission using the more 
contemporary remission criteria have been described in only 2 studies to date 
(Svensson et al. 2013, Prince et al. 2012).  
The systematic review carried out in Chapter 3 showed that radiographic 
progression still occurred. Several studies have reported on the presence of 
subclinical synovitis in cohorts of remission patients (Ten Cate et al. 2000). 
Furthermore, the presence of power Doppler signal have been shown to be a 
powerful predictor of radiographic progression (Brown et al. 2008, Foltz et al. 
2012) and flare (Saleem et al. 2012, Peluso et al. 2011, Scire et al. 2009) in 
remission states. Data on the ability of ultrasound to differentiate between LDAS 
and different remission states is conflicting. Balsa et al., 2010, reported superiority 
of SDAI over DAS28 remission criteria in the assessment of ultrasound-classified 
remission (Balsa et al. 2010). However, this was not confirmed by another study 
which showed similar PD signal between DAS28, SDAI and Boolean remission and 
low disease activity (Saleem et al. 2011). 
 
To explore further whether laboratory or radiological biomarkers could be 
included to better characterise low disease activity states, and how these relate to 
longer term outcomes such as sustained remission or radiographic progression, a 
new cohort of RA patients was established with features of stable low disease 
activity states; the REMIRA cohort (REMission In RA). It had two main goals. 
Firstly, determining the prevalence of sustained remission over 1 year using the 
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different remission criteria. Secondly, assessing the value of combining clinical, 
serological and radiological biomarkers as predictors of sustained remission in 
patients who have already achieved low disease activity states. 
 
5.2 Methods and Patients 
5.2.1 REMIRA cohort 
Adult RA patients diagnosed according to the 1987 revised ACR criteria were 
recruited into the REMIRA (REMission in RA) study. Inclusion criteria restricted 
disease duration to <10 years (as defined by date from diagnosis). We chose this as 
a cut-off as we were particularly interested in patients who were more likely to 
have had contemporary treatment of RA. To ensure all recruited study subjects 
were in stable LDA, we also included the following criteria: stable DMARDs 
therapy > 6 months and DAS28-ESR ≤3.2 for at least 1 month.  Three centres 
across south London participated in this study: Guy’s and St Thomas’ Hospital, 
King’s College Hospital and University Hospital Lewisham NHS Foundation Trusts. 
The study was approved by the local ethics committee and conducted according to 
the guidelines of the Declaration of Helsinki (REC:09/H0803/154, Wandsworth 
Research Ethics Committee).  Local Research and Development (R&D) approval 
was obtained from all sites.  Written informed consent was obtained from all 
participants.  
 
5.2.2 Clinical assessments 
Clinical data including demographics, smoking, disease duration and treatment 
were collected. For the evaluation of pain, fatigue, patients’ as well as evaluators’ 
global assessment of disease activity, 100mm visual analogue scales (VAS) were 
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used. Early morning stiffness (EMS) was recorded in minutes. Erythrocyte 
Sedimentation Rate (ESR) and C-reactive protein (CRP) were collected from 
patient records (within the month of clinical assessment).  For the evaluation of 
remission, DAS28-ESR, DAS28-CRP, SDAI, CDAI and ACR/EULAR Boolean 
remission criteria were collected. Patients were assessed every 3 months for 1 
year.  
 
5.2.3 Autoantibody analysis 
Serum samples at baseline were obtained for autoantibody testing. The 
commercial kits used to determine RF and anti-CCP status were the same as those 
described in chapter 4.  
 
5.2.4 Radiographs of hands and feet 
Posterior-anterior conventional radiographs of the hands and feet were taken at 
entry of study and 12 months. Erosive progression was defined as new or larger 
erosions over 1 year. This was scored by me as first reader and Prof David Scott as 
second reader.  The second reader read a selection of 10% of radiographs.  
 
5.2.5 Ultrasound assessments 
Ultrasonography was carried out in all patients at baseline and 12 months. This 
has been described in Chapter 2.3.2.2. This was scored by me as first reader and Dr 
Toby Garrood as second reader. The second reader scored 20% of patients at one 
timepoint, selected at random, to assess inter-observer reliability. Intra-observer 
reliability was assessed by selecting the same images as the second reader. These 
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were read 6 months later. Scoring was carried out retrospectively on acquired 
images to ensure that both ultrasound scorers were blinded to clinical findings.  
 
5.2.6 Statistical analysis 
STATA 11.2 (StataCorp, College Station, TX, USA) was used for statistical analysis. 
Point remission at baseline was defined as DAS28-ESR <2.6, DAS28-CRP <2.32, 
SDAI ≤ 3.3 and CDAI ≤ 2.8. ACR/EULAR Boolean remission was defined as TJC, SJC, 
CRP (mg/dl) and patient VAS (0-10cm) all ≤1. Sustained remission (SR) was 
defined as achieving remission at all five study visits, intermittent remission (IR) 
as achieving remission on at least 1 study visit but not all. No remission (NR) was 
defined as not achieving remission at any study visit during the one year of follow 
up. Low disease activity (LDAS) was defined as no remission by any criteria and 
NR is defined as no remission at all time-points; for DAS28-ESR these would 
include study subjects whose disease activity remains in the > 2.6 to < 3.2 range. 
Individual variables were assessed descriptively as median values and 
interquartile ranges (IQR). Agreement between the different remission criteria 
was assessed using Cohen’s kappa test.  Intra- and inter-reader reliability for 
scoring ultrasound was assessed using Intraclass Correlation Coefficient (ICC). 0 is 
defined as ‘non-existing’, between 0 and 0.2 = ‘slight’, between 0.2 and 0.4 = ‘fair’, 
between 0.4 and 0.6 = ‘moderate’, between 0.6 and 0.8 = substantial, between 0.8 
and 1.0 ‘almost perfect’. Categorical data were analysed using Chi-squared test.  
 
Ethics approval was not in place at the start of the study to collect data on Euroqol 
(n=17) and FACIT-F (n=14). Therefore, T3 data were used as baseline data for 
these sujects. If there were missing data at baseline in the other parameters, the 
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mean values for the year for that particular patient were used. Last observation 
carried forward (LOCF) was used for missing data for follow-up visits.  
 
Extended analyses were limited to DAS28-ESR, SDAI and Boolean remission. CDAI 
and DAS28CRP were excluded as their agreements were similar to SDAI and 
DAS28ESR respectively. Univariate logistic regression models was used to estimate 
the associations between variables that are potential predictors of sustained 
remission. The odds ratio (OR) and 95% confidence intervals (95% CI) represent 
the increased or decreased risk associated with a 1-unit change in the predictor 
variable for continuous variables. For dichotomous variables, the OR represents 
the risk associated with having the characteristic compared to the risk of not 
having it.  With continuous variables, it can be difficult to intepret the actual 
differences amongst variables because variables can be scaled in different units. 
The standardized odds ratio, or the odds ratio per 1-SD change, allows comparison 
between predictor variables using common units.  Standardised OR is defined as 
Exp(B x SD) where B = B co-efficient and SD = standard deviation. Unforunately, 
multivariate logistic regression analysis could not be carried due to the small 
numbers in each of the groups.  
 
5.3 Results 
5.3.1 Patient Cohort 
372 patients were identified in LDAS or remission states. 222 patients did not 
fulfill criteria the inclusion criteria and 46 patients declined to participate. 104 
patients were enrolled in the observational study: 4 dropped out; 100 patients 
completed 12 months follow up. The drop-outs were all due to patients’ choice.  
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The baseline features of the patients enrolled in the study are summarised in Table 
5.1. Their median age was 56 years and median disease duration was 45 months; 
63% were female, 88% were IgM RF positive and 72% were ACPA positive. Median 
scores for DAS28-ESR, DAS28-CRP, SDAI and CDAI were all low, in the range 2.10 
to 3.60. Most patients (87%) were receiving Methotrexate. Between 4% and 31% 
were receiving other DMARDs (sulphasalazine, Hydroxychloroquine and 
Leflunomide). Only 3% were being treated with prednisolone and 16% were 
treated with TNF inhibitors. 57% were on DMARD monotherapy, 36% on DMARD 
double therapy and 7% on DMARD triple therapy. 
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Table 5-1 Baseline Characteristics Of The REMIRA Cohort 9 (n = 104) 
 
Baseline Characteristics  
Age, Median (IQR) years 56 (47-69) 
Disease Duration In Months, Median (IQR) 45 (23-75) 
Female, Percent 63% 
Igm RF+Ve, Percent 88% 





TJC28, Median (IQR) 0 (0,1) 
SJC28, Median (IQR) 0 (0,1) 
ESR, Median (IQR) 8 (4.75 – 16) 
Patient Global, Median (IQR) (0-100mm) 18 (10, 35) 
DAS28ESR, Median (IQR) 2.10 (1.40-2.78) 
DAS28ESR Remission, Percent  66 
DAS28CRP, Median (IQR) 2.15 (1.79-2.72) 
DAS28CRP Remission, Percent 59 
SDAI, Median (IQR) 3.60 (1.70-7.56) 
SDAI Remission, Percent 46 
CDAI, Median (IQR) 3.20 (1.20 – 7.20) 
CDAI Remission, Percent 46 
Boolean Remission Criteria, Percent 30% 
HAQ, Median (IQR) 0.125 (0, 0.75) 
EQ5D, Median (IQR) 0.80 (0.69 – 0.88) 
EQ5D VAS, Median (IQR) 80 (70-90) 
FACIT-F, Median (IQR) 42 (35-47) 
SF36 MCS, Median (IQR) 52 (44-58) 
SF36 PCS, Median (IQR) 44 (38-52) 
Erosive Disease, Percent 52% 







Combination therapy 43% 
TNF Inhibitors 16% 
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5.3.2 Baseline Remissions 
At baseline 67/102 (66%) were in DAS28ESR remission and 35/102 (34%) were 
in LDAS states. In addition 58 (59%) were in DAS28CRP remission, 45 (46%) in 
SDAI remission, 47 (46%) in CDAI remission and 30 (30%) in Boolean remission. 
Comparing agreement between remission states using kappa statistics (Table 5.2) 
showed close agreement between Boolean, SDAI and CDAI remission criteria 
(84%-99%). By contrast DAS28ESR remissions had lower levels of agreement, 
particularly with Boolean remissions.  
 
Table 5-2 Agreement Between Baseline Point Remission Criteria 
Results Shown For Cohen’s kappa 
 
 Boolean SDAI CDAI DAS28CRP 
SDAI 85%    
CDAI 84% 99%   
DAS28CRP 70% 86% 87%  
DAS28ESR 60% 69% 69% 80% 
 
5.3.3  Intermittent And Sustained Remissions 
The frequencies of intermittent and sustained remissions are shown in Figure 5.1. 
Intermittent remissions occurred in 38% to 45% of patients, depending on the 
remission criteria used. Intermittent DAS28ESR remissions were seen in 44 (42%) 
patients, DAS28 CRP remissions in 43 (41%) patients, SDAI remissions in 47 
(45%) patients, CDAI remissions in 46 (44%) patients and Boolean remissions in 
39 (38%) patients.   
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Intermittent remissions occurred in 10% to 47% of patients, depending on the 
remission criteria used. Intermittent DAS28ESR remissions were seen in 49 (47%) 
patients, DAS28 CRP remissions in 34 (33%) patients, SDAI remissions in 23 
(22%) patients, CDAI remissions in 24 (23%) patients and Boolean remissions in 
10 (10%) patients. In addition 10 (10%) of patients were in no remission states. 
Comparing agreement between sustained remission states using kappa statistics 
(Table 5.3) showed close agreement between Boolean, SDAI and CDAI remission 
criteria (87%-99%) Once again sustained DAS28ESR remissions had lower levels 
of agreement, particularly with sustained Boolean remissions.  
 
Table 5-3: Agreement Between Sustained Remission Criteria.   
Results Shown For Cohen’s kappa 
 Boolean SDAI CDAI DAS28CRP 
SDAI 88%    
CDAI 87% 99%   
DAS28CRP 77% 89% 90%  
DAS28ESR 63% 71% 72% 80% 
 
5.3.4 Remission And Disease Activity 
The median DAS28 score over 12 months for the whole cohort was 2.06 (IQR 1.32, 
2.71). The median DAS28 scores over 12 months for the no remission group was 
3.75 (IQR 3.47), for DAS28ESR intermittent remission was 2.54 (2.29, 2.84), for 
DAS28ESR sustained remission was 1.31 (0.95, 1.76), for SDAI intermittent 
remission was 1.93 (1.35, 2.30), for SDAI sustained remission was 1.03 (0.67, 
1.41), for Boolean intermittent remission was 1.61 (1.14, 2.07) and for the Boolean 
sustained remission was 0.72 (0.63, 1.30).  






Figure 5-1: The Frequency of Remission in the REMIRA Cohort  
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5.3.5 Radiographic Outcomes 
Paired baseline and 12-month radiographs were available in 98 patients: 14 had 
erosive progression and developed new erosions or showed worsening of existing 
erosions. Seven of these 14 patients were in DAS28 sustained remission, 2 in SDAI 
sustained remission and 2 in Boolean sustained remission. There was no evidence of 
differences in radiographic progression between LDAS and remission groups.  
 
5.3.6 Ultrasound Assessments 
103 patients had baseline ultrasound images (SH and PD); 82 patients had 12-month 
SH images and 76 had 12 month PD images. Inter-observer reliability was good: ICC 
was 0.62 for SH and 0.98 for PD: intraobserver reliability was 0.79 for SH and 0.99 for 
PD. The ultrasound findings are summarized in Table 5.4. The median baseline SH, 
baseline PD, 12-month SH and PD were 11.7, 2.0, 11.5 and 0.7 respectively. The 
numbers (%) of patients without PD signal were 10 at baseline and 9 at 12 months. All 
patients in the cohort had evidence synovial hypertrophy at baseline and 12 months 
(ie SH score >1). 
 
There were no differences between baseline SH and PD, no remission and any the 
remission groups (Table 5.5). No remission patients had more 12-months SH 
compared to remission groups (Table 5.5). There was a similar trend for 12-month 
PD, though this difference was not statistically significant (p values 0.051 – 0.074). 
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Table 5-4 Baseline And Follow Up Ultrasound Scores 
SH = synovial hypertrophy, PD = power Doppler.  Scores from 0 -36 
 
 Median IQR 
Baseline Total SH 11.7 8 – 14.3 
Baseline Total PD 2 1-4.3 
Twelve Month Total SH 11.5 8.3 – 14.7 




Table 5-5 Ultrasound Summary In no Remisson (NR) and sustained Remission Groups  
Showing baseline and 12 Month synovial hypertrophy (SH) and power doppler (PD) scores in No Remission and sustained remission 
groups. Median Values (IQR) Shown, The level of significance is determined Mann-Whitney U test (LDAS vs each remission groups) 
 










Baseline SH 13.3 (10.0, 17.0) 11.5 (7.8, 15.0) 0.22 12.3 (8.0, 14.3) 0.32 8.7 (7.0, 12.0) 0.105 
Baseline PD 2.8 (1.7, 7.3) 2.0 (1.0, 3.7) 0.18 1.7 (0.7, 4.7) 0.13 1.5 (1.0, 2.0) 0.075 
12 Month SH 15.0 (12.5, 18.2) 10.3 (8.3, 14.7) 0.013 10.3 (8.0, 14.0) 0.005 9.3 (8.0-11.67) 0.004 
12 Month PD 2.8 (1.2, 13.2) 1.0 (0.3, 3.3) 0.051 1.0 (0.3, 3.3) 0.051 1 (0.33 – 2.67) 0.074 
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5.3.7 Ultrasound Predictors Of Radiographic Progression 
The role of ultrasound parameters as predictors of radiographic progression was next 
assessed (Table 5.6). Both SH and PD at baseline were found to be predictors of 
radiographic progression at 12 months (OR 1.15 and 1.58 respectively). At 12 months, 
only PD was a predictor (OR 1.10). 
 
 
Table 5-6: Ultrasound Predictors of Radiographic Progression  
Using Univariate logistic regression, PD = Power Doppler Signal, SH = Synovial 
Hypertrophy 
 
Ultrasound Variables Odds Ratio (95% CI) P Value 
Total SH baseline 1.15 (1.03, 1.29) 0.017 
Total SH 12 months 1.06(0.96, 1.18) 0.255 
Total PD baseline 1.58 (1.03, 2.42) 0.036 
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5.3.8 Baseline Clinical Predictors Of Sustained Remission 
Logistic regression analysis showed predictors of sustained DAS28ESR remission at 
baseline included ethnicity (OR 0.06, 95% CI 0.12, 0.30), ESR (OR 0.66, 95% CI 0.51, 
0.84), CRP (OR 0.49 95% CI 0.31, 0.78), TJC (OR 0.26, 95% CI 0.12, 0.55), patient 
global assessment (OR 0.90 95% CI 0.85, 0.96) and physician global assessment (OR 
0.83 95% CI 0.75, 0.92). These findings are summarised in Table 5.7 
 
The predictors of sustained SDAI remission are shown in Table 5.8. These included 
ethnicity (OR 0.10 95% CI 0.02 - 0.58), baseline ESR (OR 0.85 95% CI 0.77- 0.95), 
baseline CRP (OR 0.55 95% CI 0.33 - 0.90), baseline TJC (OR 0.07 95% CI 0.01 - 0.62), 
baseline patient global assessment (OR 0.82 95% CI 0.69 - 0.96), baseline physician 
global assessment (predicts perfectly). With regards to baseline physician global 
assessment, all patients in sustained SDAI remission had a score of 0 whereas the 
score in the NR group ranged from 5-30.  
 
The predictors of sustained Boolean remission are shown in Table 5.9. These included 
erosive disease at baseline (OR 13.50 95% CI 1.20, 152.21) and patient global 
assessment (OR 0.84 95% CI 0.73, 0.98). Baseline ESR, TJC and physician global 
assessments predicted perfectly. In the sustained Boolean remission group, the 
baseline ESR range were between 0-8, TJC 0 and Physician physician global 
assessment 0 whereas in the NR group, the baseline ESR range were between 10-37, 
TJC1-3 and Physician physician global assessment  5-30.  
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Table 5-7 Clinical, Serological and Radiological Predictors of DAS28ESR SR 
Using univariate logistic regression, SR = sustained remission, *where Afrocarribean/Asain = 1, Caucasian = 0  
 
LDAS vs DAS28ESR SR OR (95% CI) Standardised OR p value 
ACPA positivity 0.88 (0.196, 3.94) - 0.87 
Afrocarribean/Asian vs Caucasian * 0.06 (0.12, 0.301) - 0.001 
Age 0.97 (0.92, 1.02) 0.65 0.256 
Disease duration 1.00 (0.99, 1.01) 0.93 0.835 
Erosive baseline 1.63  (0.41, 6.52) - 0.489 
Female 0.89 (0.22, 3.55) - 0.868 
Baseline ESR 0.66 (0.51, 0.84) 0.02 0.001 
Baseline CRP 0.49 (0.31, 0.78) 0.05 0.003 
Baseline TJC 0.26 (0.12, 0.55) 0.25 <0.0001 
Baseline SJC 0.63 (0.30, 1.33) 0.46 0.224 
Baseline PtGA 0.90 (0.85, 0.96) 0.15 0.001 
Baseline PhGA 0.83 (0.75, 0.92) 0.09 <0.0001 
RF IgA positivity 1.14 (0.25, 5.09) - 0.571 
RF IgM positivity 2.10 (0.19, 23.09) - 0.096 
Total PD baseline 0.88 (0.75, 1.02) 0.53 0.091 
Total SH baseline 0.89 (0.75, 1.07) 0.59 0.227 
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Table 5-8 Clinical, Serological and Radiological Predictors of SDAI SR 
Using univariate logistic regression, SR = sustained remission, *where Afrocarribean/Asain = 1, Caucasian = 0 
 ** empty = one of the 4 groups on crosstab had no data. 
 
LDAS vs SDAI SR OR Standardised OR p value 
ACPA positive 0.64 (0.13, 3.25) - 0.593 
Afrocarribean/Asian vs Caucasian * 0.10 (0.02, 0.58) - 0.01 
Age 0.98 (0.93, 1.04) 0.77 0.51 
Disease duration 1 (1, 1) 0.92 0.82 
Erosive baseline 2.33 (0.51, 10.64) - 0.27 
Erosive progression 1.22 (0.14, 10.95) - 0.859 
Female 1.25 (0.27, 5.77) - 0.775 
Baseline ESR 0.85 (0.77, 0.95) 0.25 0.004 
Baseline CRP 0.55 (0.33, 0.90) 0.09 0.017 
Baseline TJC 0.07 (0.01, 0.62) 0.07 0.017 
Baseline SJC 0.26 (0.07, 0.89) 0.10 0.032 
Baseline PtGA 0.82 (0.69, 0.96) 0.02 0.015 
Baseline PhGA Predicts perfectly 
RF IgA positivity 1.09 (0.22, 5.45)  0.916 
RF IgG positivity Empty** (, ) - - 
RF IgM positivity 3.14 (0.17, 57.08) - 0.44 
Total PD baseline 0.79 (0.58, 1.06) 0.30 0.112 
Total SH baseline 0.89 (0.72, 1.10) 0.59 0.29 
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Table 5-9 Clinical, Serological and Radiological Predictors of Boolean SR 
Using univariate logistic regression, SR = sustained remission,*where Afrocarribean/Asain = 1, Caucasian = 0, **omitted = no sustained 
Boolean remission patients were IgG positive 
 
LDAS vs Boolean SR OR Standardised OR p value 
ACPA positive 0.11 (0.01, 1.34) - 0.083 
Afrocarribean/Asian vs Caucasian * Empty - - 
Age 1.00 (0.94, 1.08) 1.05 0.93 
Disease duration 1.02 (0.99, 1.04) 1.63 0.278 
Baseline ESR Predicts perfectly 
Baseline CRP 0.60 (0.33, 1.08) 0.13 0.09 
Baseline TJC Predicts perfectly 
Baseline SJC **omitted 
Baseline PtGA 0.84 (0.73, 0.98) 0.04 0.029 
Baseline PhGA Predicts perfectly 
Erosive baseline 13.50 (1.20, 152.21) - 0.035 
Female 0.67 (0.11, 3.92) - 0.654 
RF IgA positivity 0.67 (0.10, 4.36) - 0.672 
RF IgG positivity **omitted 
RF IgM positivity 1.29 (0.07, 24.38) - 0.867 
Total PD baseline 0.64 (0.36, 1.15) 0.11 0.137 
Total SH baseline 0.83 (0.65, 1.05) 0.42 0.118 
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5.4 Discussion 
In this cohort of RA patients with low disease activity, baseline remission rates varied 
from 30% (Boolean remission) to 66% (DAS28 ESR remission). 47%, 33%, 22%, 23% 
and 10% of patients achieved sustained DAS28ESR, DAS28 CRP, SDAI, CDAI and 
Boolean remission over 12 months of follow up, respectively. 10% of patients were in 
NR. 13.5% of patients developed erosive progression. There were no differences in 
baseline PD and SH scores between NR and any of the remission groups. NR patients 
had significantly more SH at T12 compared to all 3 remission groups. There was a 
similar trend for PD at T12 but this did not reach significance (p value range 0.051 – 
0.074).  
 
4 other studies have reported on sustained remission.  The BARFOT study group 
reported on sustained remission of early RA patients over 4 visits over 8 years of 
follow-up (Svensson et al. 2013). This study reported sustained DAS28, SDAI and 
Boolean remission rates of 14%, 5% and 3% respectively over 8 years.  In the UK 
ERAS study, sustained remission as defined by DAS28 in 3 visits over 5 years was 11% 
(Jayakumar et al. 2012). A study of patients with established RA (BRASS cohort) 
patients reported only a ‘minority’ of patients in sustained remission regardless of the 
criteria used (Prince et al. 2012). The CORRONA database assessed patients with early 
RA with sustained CDAI remission in at least 2 consecutive visits which ranged from 
60-180 days apart. The remission rate was 7%.  The REMIRA study was unique since 
it was restricted to low disease activity states only. Our remission rates were 
therefore higher than these. Other remission cohorts also reported on sustained 
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remission rates. Cohen et al reported that 22.4% of patients achieved DAS remission 
(DAS <1.6) both at 3 years and 5 years and Molenaar et al reported 53% of patients 
were in ACR remission at baseline and at 2 years (Cohen et al. 2007, Molenaar et al. 
2004). Both these studies reported remission 2 years apart. The definition of 
sustained remission was more stringent in the REMIRA study where patients had to 
be in sustained remission at all time points over 1 year.  
 
Very few studies have explored predictors of sustained remission. The BRASS cohort 
reported that more males and patients with <5 years disease duration maintained 
remission in the first year but the survival curves were not significantly different 
(Prince et al. 2012). They found no differences between seropositive and seronegative 
patients. The ERAS study also explored predictors of sustained DAS28 remission 
(Jayakumar et al. 2012). Men, <6 months symptoms and TJC <10 were found to be 
independent predictors of sustained remission. Gender was found to be the only 
predictor of CDAI sustained remission (Jawaheer et al. 2012). These cohorts differed 
from the REMIRA cohort where predictors of sustained remission were assessed 
within a unique LDAS cohort. The predictors of sustained DAS28 and sustained SDAI 
remission in this cohort were the same and included ethnicity, ESR, CRP, TJC, patient 
global assessment and physician global assessment. ESR, TJC, patient global 
assessment and physician global assessment were also predictors of Boolean 
remission. In addition, erosions at baseline was also a predictor of Boolean remission. 
Patients who are of Afro-carribean or Asian origin are less likely to achieve sustained 
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remission. One potential explanation of this could be due to drug adherence and there 
is currently a study ongoing to investigate this (Kumar et al. 2013).  
 
There was no difference in radiographic progression between the LDAS and sustained 
remission states. Even in sustained remission, radiographic progression can occur in 
any remission criteria. This has also been shown in another study of radiographic 
progression over 2 years (Lillegraven et al. 2012). The benefit of sustained remission 
on the prevention of radiographic progression is seen 1 year after the period of 
sustained remission (Aletaha et al. 2009a).  There may therefore be a lag between the 
improvement in disease activity and radiographic outcomes, which we would not 
have captured during the 12 months of follow up. 
 
The REMIRA cohort of patients had a very high proportion of patients with the 
presence of power Doppler signal (90%) and SH (100%). This is higher than that 
reported in the literature. Balsa et al reported in their cohort of remission patients 
92% with SH and 42% with the presence of PD (Balsa et al. 2010). Brown et al’s 
cohort showed 85% SH and 60% PD signal (Brown et al. 2006). It is established that 
the presence of a PD signal predicts radiographic progression in low disease activity 
states, however, the role of SH is less clear. Boyesen found SH predicted 1 year MRI 
erosive progression in patients with active disease (Boyesen et al. 2011b). The 
REMIRA sudy has demonstrated for the first time that SH also has a role in predicting 
radiographic progression in LDAS. Synovial hypertrophy was also found to be less in 
all sustained remission groups at the end of the study compared to the LDAS group. 
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This suggests that synovial hypertrophy can be reduced with stringent sustained 
remission.  
 
The fact that ultrasound parameters predicted radiographic progression but not 
sustained remission over time may suggest that radiographic progression may not be 
wholly dependent on joint inflammation (Boers 2008). It has been suggested 
previously that the pathogenesis of RA is split into 2 distinct processes: synovial 
inflammation which leads to pain and swelling and synovial hypertrophy which leads 
to swelling and erosions (Kirwan 2004). In support of this is the finding that anti-TNF 
treatment has been shown to inhibit radiographic progression even in patients who 
are not responding clinically (Smolen et al. 2005).  
 
The REMIRA cohort found no role for ultrasound at predicting sustained remission. 
This was also seen in a recent study where sustained CDAI remission was defined as 
remission at 2 timepoints (Gartner et al. 2013). They suggested that low-grade PD and 
SH signals may not necessarily reflect the presence of active synovitis in RA joints. 
 
The treat-to target approach is the gold-standard treatment for RA. Guidelines 
propose intensive escalation of treatment for patients with active disease. Our study 
confirms that even after reaching remission, strict monitoring is required, as only a 
small proportion of patients achieve sustained remission. The use of clinical variables 
may help to stratify patients who are more likely to stay in sustained remission and 
help in decision making with treatment changes. 
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6 Serum Biomarker as predictors of sustained remission  
6.1 Introduction 
As discussed in the previous chapters, numerous clinical definitions of remission exist 
but there is still an unmet need for objective molecular biomarkers of remission that 
may reflect a state of true biological remission. This is especially important when drug 
tapering or withdrawal are being considered or when assessing the possibility of 
flares. Definitions of clinical remission states may be inadequate since sub-clinical 
synovitis may still be present. Previous studies have shown that patients in clinical 
remission continue to develop radiographic progression (Brown et al. 2008). Power 
Doppler signal has been detected in these patients and it is suggested that some 
patients in clinical remission continue to have subclinical disease activity. Therefore, 
true remission states might better be defined at a molecular level, where patients may 
be deemed free from subclinical disease activity. 
 
The clinical components are subject to intra and inter assessor variability (Uhlig, 
Kvien & Pincus 2009, Marhadour et al. 2010) and can be confounded by co-
morbidities such as fibromyalgia (Leeb et al. 2004) and joint damage. The biomarkers 
within these clinical disease activity measures are non-specific and can be elevated in 
a number of conditions eg age, anaemia, infection and malignancy. It can also be 
normal in patients with active disease (Keenan, Swearingen & Yazici 2008, Sokka, 
Pincus 2009).  
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A multi-biomarker disease activity algorithm using 12 different serum biomarkers has 
been recently validated as an objective measure of disease activity across a range of 
disease activity states (Curtis et al. 2012). These 12 biomarkers evaluate different 
aspects of pathologic pathways implicated in the pathogenesis of RA and can be 
broadly grouped into the following categories: 
 acute-phase response (SAA, hsCRP, IL6), 
 hormones (leptin and resistin),  
 growth factors (VEGF and EGF), adhesion molecules (VCAM1),  
 cartilage-related proteins (YKL-40) and matrix metalloproteinases (MMP1, MMP3)  
 cytokine related proteins (TNFR1) 
 
This biomarker set has been rigourously evaluated in large numbers of patients with 
active RA and is now available as an FDA approved assay (Vectra-DA) of disease 
activity in the United States. While levels of these analytes are altered in the serum of 
RA patients with active inflammation, it remained to be determined whether the 
biomarker set would have more discriminatory value at low ends of the disease 
spectrum than the conventional ESR or CRP level. 
 
We also opted to include 2 further biomarkers which we felt were important in 
assessing disease activity in RA: CXCL10 and calprotectin. 
 
CXCL10 has been detected in synovial fluid, synovial tissue and serum of RA patients 
(Hanaoka et al. 2003).  Serum levels have also found to be raised in active disease and 
significantly reduced in response to treatment (Kuan et al. 2010). A phase 2 clinical 
  175 
trial using an anti-CXCL10 monocloncal antibody (MDX-1100) has reported increased 
ACR20 response rate at week 12 compared to placebo group in active RA patients who 
have failed Methotrexate treatment (Yellin et al. 2012).  
 
Calprotectin is expressed in RA synovial tissue (Youssef et al. 1999) and high 
concentrations have been found in synovial fluid and blood of RA patients (Berntzen 
et al. 1991). The protein has been described as a good measure of disease activity and 
joint inflammation in RA (Madland et al. 2002). Moreover, Calprotectin was found to 
be an independent predictor of radiograph damage cross-sectionally and 
longitudinally (Hammer et al. 2007, Hammer et al. 2010). 
 
The role of calprotectin in the remission state has been explored in juvenile idiopathic 
arthritis (JIA) patients. It has been shown to be an important predictor for relapse in 
patients after treatment withdrawal (Foell et al. 2010, Gerss et al. 2012) . In early RA, 
normalisation of calprotectin levels have been reported in patients with treatment. It 
was found to be a predictive marker for improvement in swollen joints (Andres 
Cerezo et al. 2011). 
 
In this present study, we studied a cohort of clinically similar group of patients with 
low disease activity states (LDAS) including remission. We aimed firstly to define a 
molecular signature of point remission and sustained remission and secondly to 
explore the role of these biomarkers in predicting sustained remission. This work was 
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undertaken as part of a collaboration with investigators at Crescendo Biosciences, 
following a short secondment to their unit in San Francisco. 
 
6.2 Methods and Patients 
6.2.1 REMIRA cohort and clinical assessments 
This has been discussed in Chapter 5.   
6.2.2 Serum biomarkers 
Sera were collected at all study visits using standard serum separator tubes according 
to the manufacturer’s instructions. The sera were frozen at -80 Celsius within 6 hours 
of blood sampling. Due to limited resources, 3 timepoints were used to measure the 
serum biomakers. Baseline, 3 months and 6 months were chosen as predictors of 
sustained remission at 12 months. 3 patients declined blood sampling therefore 101 
patients have available serum. All 14 biomarkers were measured by Crescendo 
Bioscience laboratories.  
 
The development of the MBDA score was discussed in the introduction (1.7.8). The 
concentrations of 12 serum proteins—serum amyloid A (SAA), IL-6, TNF receptor 
superfamily member 1A (TNF-R1), VEGFA, MMP1, human cartilage glycoprotein 39 
(YKL40), MMP3, epithelial growth factor (EGF), vascular cell adhesion molecule 1 
(VCAM1), leptin, resistin and CRP—were measured by customized immunoassays, 
quantified on a Sector Imager 6000 (Meso Scale Discovery, Gaithersburg, MD, USA) 
and transformed to the power 0.1 to achieve approximately normal distributions. 
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CXCL10 and Calprotectin were measured using commercially available ELISA kits 
according to the manufacturers’ protocols. The Calprotecitin assay was from 
Buhlmann (MRP 8/14 ELISA Product Code EK-MRP8/14). For CXCL10, a modified 
version of the R&D Systems Human CXCL10/IP-10 Quantikine ELISA (Product Code: 
DIP100) was used. For this ELISA assay, in-house manufactured pre-diluted standards 
and controls were used. A 2-fold dilution of samples was carried out. The rest of the 
procedure was performed per the manufacturers protocol 
 
6.2.3 RA reference cohort for the MBDA score 
The RA reference cohort was called InFoRM (Index for Rheumatoid Arthritis 
Measurement), an observational study across multiple centers in North America 
(collected by Crescendo).  Any patients of age 18-90 that were diagnosed of RA by 
ACR1987 criteria and able to consent were eligible to participate. There were 
approximately 1000 patients enrolled.  All of them received routine care. The 
reference cohort consisted of 512 patients that had clinical characteristics 
representative of the entire study population.  They were used in one of the steps for 
training Vectra DA algorithm.  The average age was 59, and 76% were female.  The 
mean SJC28 and TJC28 were 4.3 and 5.5, respectively.  
 
6.2.4 Statistical analysis 
STAT 11.2 (StataCorp, College Station, TX, USA) was used for statistical analysis. 
Remission at baseline was defined as DAS28ESR <2.6, SDAI ≤3.3, or MBDA score ≤ 25 
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(range 0-100) at baseline. Low disease activity states (LDAS) is defined as no 
remission by any clinical criteria. Sustained remission (SR) is defined as achieving 
remission at all time-points, intermittent remission (IR) is defined as achieving 
remission in at least 1 time-point but not all. No remission  (NR) is defined as not 
achieving remission at any time-point by any criteria. Individual variables were 
assessed descriptively as median values and interquartile ranges (IQR). The difference 
between remission and non-remission was assessed using Mann-Whitney test and 
between NR/IR/SR remission using Kruskall-Wallis test. Pairwise comparisons were 
also made using Mann-Whitney U test. All reported p values are 2-sided.  
 
Agreement between the different remission criteria was assessed using Cohen’s kappa 
test. The area under the curve from the receiver-operating characteristic (ROC) was 
used to assess the different remission criteria ability to discriminate between patients 
in Boolean remission and non-remission at baseline or none and sustained remission 
over the 1 year follow-up.  
 
Time-integrated values were calculated using area under the curve (AUC). These were 
computed using GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA) using the 
trapezoidal method. The last observation carried forward method was used to handle 
missing data. AUC values were calculated for all the 14 biomarkers and the MBDA 
score for the first 3 visits (6 months). 
 
Univariate logistic regression models were used to estimate the associations between 
variables as potential predictors of sustained remission. The odds ratio and its 95% 
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confidence interval (95% CI) represent the increased or decreased risk associated 
with a 1-unit change in the predictor variable for continuous variables. For 
dichotomous variables, the odds ratio represents the risk associated with having the 
characteristic compared with not having it. In continuous variables, it can be difficult 
to intepret the actual differences amongst variables because variables can be scaled in 
different units; for example, a 1-unit change in 1 biomarker in g/ml is not 
comparable with another 1-unit change in ng/ml. The standardized odds ratio, or the 
odds ratio per 1-SD change, allows comparison among predictor variables using 
common units.  Standardised OR is defined as Exp(B x SD) where B = B co-efficient 
and SD = standard deviation. 
 
6.3 Results 
6.3.1 Patient Cohort  
The patient characteristics of the REMIRA cohort has been described in the previous 
chaper.  
 
6.3.2 Biomarker summary 
Serum samples were available in 101 REMIRA patients. Table 6.1 summarised the 
median values (IQR) of all 14 biomarkers at baseline and area under the curve values 
(AUC). Figure 6.1 shows the distribution of the normalised biomarker levels of the 12 
biomarkers from the MBDA panel at baseline. This was calculated using the median 
values according to a reference RA cohort whose disease spans the whole spectrum of 
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disease activity. Within the REMIRA cohort, SAA levels were the lowest and EGF was 
the highest when compared to the reference cohort. EGF is reported as being inversely 
correlated to disease activity (through personal communication with Crescendo 
Bioscience). With the exception of EGF, the median values of the REMIRA cohort were 
below 1 showing that it is lower end of the RA range. Figure 6.2 is a heatmap showing 
the percentile of the biomarkers at baseline. This demonstrates that on a molecular 
level, there is marked heterogeneity within this cohort of patients inspite of their 
relatively homogenous  clinical phenotype. 
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Table 6-1 : Summary of MBDA and Individual Biomaker Levels 
Within the REMIRA cohort (n=101). Median values (IQR) of Biomarkers at baseline and 
AUC over the first 6 months 
 
Biomarker Median Baseline values (IQR) Median AUC(IQR) 
MBDA (0-100) 29 (18- 40) 180 (126 – 229) 
EGF (pg/ml) 254.44 (181.71-367.09) 1687 (1148 – 2153) 
IL6 (pg/ml) 9.25 (5.86 – 16.30) 63 (40-96) 
Leptin (ng/ml) 9.33 (3.81 – 27.69) 64 (26 – 172) 
MMP1 (ng/ml) 6.39 (4.55 – 9.30) 41 (28 – 56) 
MMP3 (ng/ml) 26.11 (17.25 – 39.16) 157 (111 – 215) 
Resistin (ng/ml) 7.37 (5.97 – 8.79) 46 (39 – 59) 
SAA (g/ml) 1.70 (0.94 – 3.45) 11 (5 – 23) 
hsCRP (mg/L) 2.36 (1.10 – 6.27) 17 (7 – 36) 
TNFR1 (ng/ml) 1.51  (1.32 – 2.02) 10 (8-12) 
VCAM1 (ng/ml) 559.91 (462.50 -671.61) 3065 (2607 – 3664) 
VEGF (pg/ml) 267 (176 – 408) 1548 (1104-2640) 
YKL-40 (ng/ml) 61.55 (41.33 – 97.96) 364 (238 – 698) 
Calprotectin (ng/ml) 2289.55 (1507.45 – 3792.78) 14106 (11324 – 18251) 
CXCL10 (pg/ml) 204.89 (143.84 - 331.36) 1293 (918 - 1968) 
 





Figure 6-1: Normalised Median Biomaker Levels  
Median (IQR) Biomaker levels (error bars 5-95 centiles). Normalised by median values of reference cohort.  
Dotted line across 1 is the median value of the reference cohort   







Figure 6-2: The REMIRA Cohort Biomarker Levels as Percentile Levels (n = 70). 
Each column represents a patient, each row a biomarker. Patients are arranged in order of increasing disease activity and biomarkers are 
arranged in order of increasing medican conentrations relative to reference cohort. (median percentile shown in brackets).  Figure generated in 
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6.3.3 Agreement between MBDA remission and clinical remission criteria 
Agreement between the clinical remission criteria have been discussed in the 
previous chapter. Table 6.2 shows the agreement between MBDA remission and 
the clinical remission criteria at baseline ranging from 61% to 66%. The weakest 
agreement is with DAS28CRP and best is with DAS28ESR. The agreement of 
sustained MBDA remission over 6 months with the different sustained remssion 
criteria (over 1 year) is better than point remission ranging from 75% to 81% 
(Table 6.3). The worst agreement is with DAS28CRP and the best is with Boolean.  
 
Table 6-2: Agreement Between the Clinical Remission Criteria and MBDA 
Using Cohen’s kappa test. 
 
 Boolean SDAI CDAI DAS28CRP DAS28ESR 
SDAI 85%     
CDAI 84% 99%    
DAS28CRP 70% 86% 87%   
DAS28ESR 60% 69% 69% 80%  
MBDA 66% 64% 63% 61% 65% 
 
 
Table 6-3 Agreement Between Sustained Remission and MBDA  
Using Cohen’s kappa test. *MBDA score – sustained remission over 3 timepoints in the 
first 6 months 
 
 Boolean SDAI CDAI DAS28CRP DAS28ESR 
SDAI 88%     
CDAI 87% 99%    
DAS28CRP 77% 89% 90%   
DAS28ESR 63% 71% 72% 80%  
MBDA* 81% 77% 77% 75% 79% 
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6.3.4 Perfomance of MBDA remission 
The perfomance of the MBDA score at differentiating between remission and non-
remission states using the different clinical remission criteria are shown in table 
6.4. AUROC ranged from 0.62 for CDAI to 0.71 for DAS28 ESR. Table 6.5 shows the 
AUROC values for sustained MBDA remission over 6 months at differenting the 
different non-sustained clinical remission and sustained remissin over 1 year. The 
values ranged from 0.58 to 0.71. The MBDA remission was the least effective at 
differentiating between DAS28CRP remission and non-remission and better at 
differentiating between Boolean remission and non-remission. Since CDAI was 
very similar to SDAI, this was excluded from further analysis. In addition, 
DAS28CRP agreement and perfomance were the least discriminatory; therefore 
this was also excluded from further analysis. 
 
Table 6-4: Ability of MBDA to Differentiate Between baseline Remission and NR  
NR= non-remission 
 
Remission Criteria AUROC 95% CI 
DAS28ESR 0.71 0.63 – 0.79 
DAS28CRP 0.63 0.54 – 0.73 
SDAI 0.63 0.54 – 0.73 
CDAI 0.62 0.73 – 0.72 
Boolean 0.66 0.55 – 0.76 
 
 
Table 6-5: Ability of MBDA over 6 months to Differentiate Between SR and NR 
SR= sustained remission, NR= non-remission 
Remission Criteria AUROC 95% CI 
DAS28ESR 0.61 0.55 – 0.68 
DAS28CRP 0.58 0.50 – 0.66 
SDAI 0.64 0.54 – 0.75 
CDAI 0.63 0.53– 0.73 
Boolean 0.71 0.54– 0.87 
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6.3.5 Baseline Biomarker levels and point remission  
Table 6.6 shows the median (IQR) values of all 14 biomakers in the LDAS group 
(not in remission by any clinical remission criteria) and remission groups 
(DAS28ESR, SDAI and Boolean remission). IL6, Leptin, SAA, hsCRP and total MBDA 
score were all significantly lower in all 3 remission groups when compared to 
LDAS group. In addition, TNFR1 and VCAM1 were also significantly lower in 
DAS28ESR group when compared to LDAS.  
 
6.3.6 Baseline biomarker levels and sustained remission. 
The median (IQR) baseline biomarker levels between No remission (NR), 
intermittent remission (IR) and sustained remission (SR) are shown in Table 6.7. 
DAS28, SDAI and Boolean remission groups are shown. CXCL10, IL6, Leptin, SAA, 
hsCRP and MBDA scores were significantly different in all remission criteria 
groups when compared to LDAS. The exception of this is leptin within the SDAI 
groups. Calprotectin was not significantly different in any of the remission groups.  
Figures 6.3 -6.5 and 6.9 show the pairwise comparisons between NR vs IR, NR vs 
SR and IR vs SR for these individual biomarkers and the MBDA score respectively. 
In DAS28 groups, there was no significant difference between NR and DAS28 IR 
groups (Figure 6.3). This may be due to the large error bars in the DAS28 IR group 
suggesting that there is more heterogeneity within this group. In SDAI and Boolean 
groups, there were no significant differences between IR and SR groups. With 
leptin, there was a trend towards a decrease between NR and IR but the p value 
just greater than 0.05 (Fig 6.4 and 6.5). 
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Table 6-6: Baseline Biomarker Values in LDAS and Remission at Baseline 
Comparing low disease activity (LDAS) to DAS28ESR, SDAI and Boolean remission groups at baseline.   
Values in median (IQR), Levels of significance determined by Mann Whitney test. 
 
Biomarkers LDAS DAS28ESR p value SDAI p value Boolean p value 
EGF (pg/ml) 270 (185, 342) 264 (197, 376) 0.653 230 (162, 364) 0.685 256 (184, 373) 0.832 
IL6 (pg/ml) 13 (10, 24) 7 (5, 13) <0.0001 6.61 (4.79, 9.96) <0.0001 6.05 (4.36, 8.72) <0.0001 
Leptin (ng/ml) 16 (5, 35) 7 (4, 16) 0.036 4.96 (3.35,13.52) 0.008 4.96 (3.27, 10.64) 0.01 
MMP1 (ng/ml) 6.01 (4.36, 8.99) 6.56 (5.07, 948) 0.617 7.38 (5.13, 10.05) 0.361 7.07 (5.19, 1.06) 0.404 
MMP3 (ng/ml) 26 (18, 36) 27 (20, 40) 0.804 27 (17, 39) 0.982 27 (17, 41) 0.988 
Resistin (ng/ml) 7.43 (5.97, 11.80) 7.08 (5.91, 8.18) 0.384 7.19 (5.91, 8.70) 0.685 7.52 (5.97, 8.75) 0.693 
SAA (l/ml) 3.19 (1.71, 5.98) 1.20 (6.73, 2.21) <0.0001 1.11 (6.27, 2.04) <0.0001 1.11 (0.64, 1.79) <0.0001 
TNFR1 (ng/ml) 1.76 (1.40, 2.29) 1.45 (1.30, 1.90) 0.027 1.50 (1.33, 1.99) 0.105 1.53 (1.34, 1.98) 0.154 
VCAM1 (ng/ml) 602 (539, 729) 531 (449, 627) 0.018 546 (445, 637) 0.053 558 (462, 646) 0.118 
VEGF (pg/ml) 291 (198, 453) 226 (165, 393) 0.209 247 (177, 403) 0.338 271 (179, 407) 0.575 
YKL40 (ng/ml) 83 (43, 96) 53 (35, 96) 0.121 60 (37, 14) 0.535 60 (35, 105) 0.332 
hsCRP (mg/ml) 5.10 (1.69, 13.20) 1.46 (0.63, 2.87) <0.0001 1.56 (0.68, 2.61) <0.0001 1.46 (0.46, 2.51) <0.0001 
MBDA score (0-100) 37 (25, 50) 22 (16, 33) <0.0001 21 (16, 32) <0.0001 18 (15, 31) <0.0001 
Calprotectin (ng/ml) 2998 (1978, 5130) 1998 (1450, 3331) 0.011 1937 (1451, 3160) 0.011 1848 (1450, 3190) 0.017 
CXCL10 (pg/ml) 256 (195, 416) 175 (127, 236) <0.0001 183 (133, 245) 0.001 184 (132, 231) 0.001 
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Table 6-7 Baseline biomarker values in NR and remission over 12 months 
Comparing no remission by any criteria (NR) to DAS28ESR, SDAI and Boolean intermittent (IR) and sustained remission (SR) groups. 
Values in median (IQR), Levels of significance determined by Kruskall-Wallis test. 
 









EGF (pg/ml) 358 (227, 417) 233 (180, 334) 256 (188, 371) 0.376 246 (184, 356) 249 (145, 362) 0.374 239 (184, 356) 264 (145, 397) 0.398 
IL6 (pg/ml) 14 (11, 31) 12 (6, 21) 7 (4, 11) 0.001 8.45 (5.97, 13.61) 6.12 (4.20, 10.21) 0.008 6.65 (4.80, 11.09) 6.79 (4.24, 9.33) 0.009 
Leptin (ng/ml) 23 (8, 62) 14 (5, 34) 6 (3, 15) 0.003 7.39 (3.70, 24) 4.65 (3.27, 13.94) 0.081 6.97 (3.55, 2.26) 4.45 (2.97, 8.83) 0.045 
MMP1 (ng/ml) 5.24 (3.68, 8.90) 6.56 (4.87, 9.32) 6.18 (4.47, 9.16) 0.613 7.43 (5.46,10.47) 6.32 (4.49, 8.51) 0.421 6.31 (5.07, 10.47) 7.15 (4.60, 8.51) 0.745 
MMP3 (ng/ml) 30 (17, 42) 23 (17, 34) 27 (19, 41) 0.524 27 (20, 41) 26 (16, 33) 0.491 27 (17, 40) 25 (15, 45) 0.935 
Resistin (ng/ml) 11 (6, 14) 7 (6, 9) 7 (6, 8) 0.274 6.98 (5.67, 7.92) 7.99 (5.84, 9.88) 0.073 7.02 (5.84, 8.80) 8.149 (7.58, 9.88) 0.148 
SAA (ug/ml) 3.89 (2.24, 16.50) 1.88 (1.15, 4.37) 1.18 (0.66, 2.32) 0.001 1.76 (0.67, 3.15) 1.14 (0.63, 2.06) 0.013 1.434 (0.70, 2.13) 1.08 (6.28, 2.21) 0.016 
TNFR1 (ng/ml) 1.66 (1.39, 2.03) 1.58 (1.33, 2.08) 1.47 (1.31, 1.94) 0.638 1.41 (1.20, 1.79) 1.50 (1.35, 2.03) 0.368 1.48 (1.34, 2.14) 1.73  (1,37, 2.03) 0.884 
VCAM1 (ng/ml) 577 (469, 651) 583 (418, 710) 546 (463, 626) 0.697 541 (465, 645) 557 (458, 671) 0.896 557 (418, 646) 545 (462, 685) 0.835 
VEGF (pg/ml) 403 (247, 519) 245 (177, 384) 261 (171, 408) 0.299 232 (177, 398) 275 (150, 408) 0.276 210 (159, 393) 208 (137, 310) 0.112 
YKL40 (ng/ml) 95 (53, 124) 58 (41, 91) 59 (40, 102) 0.59 53 (38, 70) 61 (32, 134) 0.351 62 (35, 98) 60 (48, 135) 0.642 
hsCRP (mg/ml) 5.91 (3.31, 11.70) 3.01 (1.45, 7.76) 1.46 (0.71, 2.76) 0.002 1.69 (1.04, 3.57) 1.46 (0.46, 2.55) 0.014 2.27 (0.78, 3.23) 1.30 (0.21, 2.55) 0.016 
MBDA score 41 (32, 52) 34 (20, 45) 23 (16, 33) <0.0001 28 (18, 35) 20 (15, 37) 0.012 25 (17, 37) 17 (15, 40) 0.015 
Calprotectin (ng/ml) 3278 (2020, 5470) 2377 (1641, 3825) 2007 (1452, 3332) 0.23 2007 (1531,3132) 1962 (1348,3190) 0.203 2055 (1504,3793) 2945 (1783,3190) 0.347 
CXCL10 (pg/ml) 297 (229, 379) 232 (162, 395) 183 (124, 234) 0.002 175 (131, 28) 220 (133, 258) 0.046 184 (139, 240) 228 (103, 258) 0.025 
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Figure 6-3 Baseline Biomarkers Values in NR, DAS28 IR and SR Groups 
A = Calprotectin (ng/ml), B = Leptin (ng/ml), C = SAA (g/ml), D = hsCRP (g/ml), E = CXCL10 (pg/ml), F = IL6 (pg/ml). Values expressed as 
medians with IQR. NR = no remission by any criteria, IR = intermittent remission, SR = sustained remission. Levels of significance determined by 
Mann-Whitney test (NR vs IR, IR vs SR, NR vs SR). ns =  P > 0.05, * =  P ≤ 0.05, **  = P ≤ 0.01, *** =  P ≤ 0.001, **** =   P ≤ 0.0001 
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Figure 6-4: Baseline Biomarkers Values in NR, SDAI IR and SR Groups 
A = Calprotectin (ng/ml), B = Leptin (ng/ml), C = SAA (g/ml), D = hsCRP (g/ml), E = CXCL10 (pg/ml), F = IL6 (pg/ml). Values expressed as 
medians with IQR. NR = no remission by any criteria, IR = intermittent remission, SR = sustained remission. Levels of significance determined by 
Mann-Whitney test (NR vs IR, IR vs SR, NR vs SR). ns =  P > 0.05, * =  P ≤ 0.05, **  = P ≤ 0.01, *** =  P ≤ 0.001, **** =   P ≤ 0.0001 
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Figure 6-5: Baseline Biomarkers Values in NR, Boolean IR and SR Groups. 
A = Calprotectin (ng/ml), B = Leptin (ng/ml), C = SAA (g/ml), D = hsCRP (g/ml), E = CXCL10 (pg/ml), F = IL6 (pg/ml). Values expressed as 
medians with IQR. NR = no remission by any criteria, IR = intermittent remission, SR = sustained remission. Levels of significance determined by 
Mann-Whitney test (NR vs IR, IR vs SR, NR vs SR). ns =  P > 0.05, * =  P ≤ 0.05, **  = P ≤ 0.01, *** =  P ≤ 0.001, **** =   P ≤ 0.0001 
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6.3.7 AUC biomarker levels and sustained remission 
The values of the biomarkers over 6 months were combined into a time-integrated 
value using AUC. The median (IQR) AUC values between NR, IR and SR are shown 
in Table 6.8 and Figures 6.6 - 6.9. AUC values for Calprotectin CXCL10, IL6, Leptin, 
SAA and hsCRP and MBDA scores were all significantly different between these 
groups using all 3 remission criteria (Table 6.8). Again, the exception was with 
leptin AUC levels in the SDAI groups and calprotectin in the Boolean groups where 
the p values were just over 0.05. Pairwise comparisons showed similar trends as 
with baseline biomarker values (Figures 6.6 - 6.9).  
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Table 6-8 AUC Biomarkers Values Between NR, IR and SR groups 
Values expressed as medians with IQR. NR= no-remission by any criteria, IR = intermittent remission, SR = sustained remission. 
 Kruskall-Wallis test preformed. 
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Figure 6-6 AUC Biomarker Values in NR, DAS28 IR and SR Groups 
A = Calprotectin (ng/ml), B = Leptin (ng/ml), C = SAA (g/ml), D = hsCRP (g/ml), E = CXCL10 (pg/ml), F = IL6 (pg/ml). Values expressed as 
medians with IQR. NR = no remission by any criteria, IR = intermittent remission, SR = sustained remission. Levels of significance determined by 
Mann-Whitney test (NR vs IR, IR vs SR, NR vs SR). ns =  P > 0.05, * =  P ≤ 0.05, **  = P ≤ 0.01, *** =  P ≤ 0.001, **** =   P ≤ 0.0001 
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Figure 6-7 AUC Biomarker Values in NR, SDAI IR, SR Groups 
A = Calprotectin (ng/ml), B = Leptin (ng/ml), C = SAA (g/ml), D = hsCRP (g/ml), E = CXCL10 (pg/ml), F = IL6 (pg/ml). Values expressed as 
medians with IQR. NR = no remission by any criteria, IR = intermittent remission, SR = sustained remission. Levels of significance determined by 
Mann-Whitney test (NR vs IR, IR vs SR, NR vs SR). ns =  P > 0.05, * =  P ≤ 0.05, **  = P ≤ 0.01, *** =  P ≤ 0.001, **** =   P ≤ 0.0001 
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Figure 6-8 AUC Biomarker Values in NR, Boolean IR and SR Groups. 
A = Calprotectin (ng/ml), B = Leptin (ng/ml), C = SAA (g/ml), D = hsCRP (g/ml), E = CXCL10 (pg/ml), F = IL6 (pg/ml). Values expressed as 
medians with IQR. NR = no remission by any criteria, IR = intermittent remission, SR = sustained remission. Levels of significance determined by 
Mann-Whitney test (NR vs IR, IR vs SR, NR vs SR). ns =  P > 0.05, * =  P ≤ 0.05, **  = P ≤ 0.01, *** =  P ≤ 0.001, **** =   P ≤ 0.0001 
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Figure 6-9 MBDA Scores  in  LDAS, IR and SR states 
A-C = baseline MBDA, D-F = AUC MBDA, A&D = DAS28, B&E + SDAI, C&F = Boolean. Level of signifiance determined by Mann-Whitney U test.  
Values expressed as medians with IQR. NR = no remission by any criteria, IR = intermittent remission, SR = sustained remission. Levels of significance 
determined by Mann-Whitney test (NR vs IR, IR vs SR, LDAS vs SR). ns =  P > 0.05, * =  P ≤ 0.05, **  = P ≤ 0.01, *** =  P ≤ 0.001, **** =   P ≤ 0.0001 
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6.3.8 Serum biomarkers as predictors of sustained remission (over time) 
Predictors of sustained DAS28ESR (Table 6.9)  
Baseline calprotectin, CXCL10, hsCRP, leptin, SAA, TNFR1, VCAM1 and MBDA 
scores are predictors of sustained DAS28ESR remission (Standardised ORs range 
from 0.01 – 0.62). Time-integrated values of Calprotectin, CXCL10, hsCRP, Resistin, 
SAA, TNFR1, VCAM1 and MBDA score are also predictors (standardized ORs range 
from 0.13 – 0.58). Since all the standardized ORs are less than 1, it means that the 
lower the biomarker level, the more likely that the patient will be in sustained 
remission.  
 
Predictors of sustained SDAI (Table 6.10)  
Baseline Calprotectin, hsCRP, leptin, resistin, SAA and MBDA are predictors of 
sustained SDAI remission (Standardised ORs range 0.03 – 0.45). Calprotectin AUC, 
hsCRP AUC, Resistin AUC, SAA AUC and MBDA AUC are also predictors 
(Standardised ORs 0.11 – 0.48).  
 
Predictors of sustained Boolean remission (Table 6.11)  
Baseline MBDA score was the only predictor of sustained Boolean remission 
(Standardised OR 0.34). hsCRP AUC and MBDA AUC were the only time-integrated 
values which were predictors of sustained Boolean remission. 
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Table 6-9: Biomarker Predictors of Sustained DAS28 Remission 
Univariate logistic regression assessing baseline serum biomarkers levels and time-
integrated values of serum biomarkers over the first 6 months as predictors of 
sustained DAS28ESR remission over 1 year. 
 
LDAS vs DAS28 SR OR Standardised OR p value 
Baseline Calprotectin 1 (1, 1) 0.42 0.004 
Baseline CXCL10 1 (1, 1) 0.31 0.009 
Baseline hsCRP 1 (1, 1) 0.38 0.004 
Baseline IL6 1 (1, 1) 1.04 0.865 
Baseline leptin 1 (1, 1) 0.54 0.012 
Baseline SAA 1 (1, 1) 0.01 0.008 
Baseline MBDA score 1 (1, 1) 0.36 <0.0001 
Calprotectin AUC 1 (1, 1) 0.19 <0.0001 
CXCL10 AUC 1 (1, 1) 0.48 0.006 
HsCRP AUC 0.98 (0.96, 0.99) 0.39 0.005 
IL6 AUC 1 (1, 1) 0.77 0.248 
Leptin AUC 1 (1, 1) 1.23 0.635 
SAA AUC 0.95 (0.92, 0.98) 0.13 0.003 
MBDA AUC 1 (1, 1) 0.34 <0.0001 
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Table 6-10: Biomarker Predictors of Sustained SDAI Remission 
Univariate logistic regression assessing baseline serum biomarkers levels and time-
integrated values of serum biomarkers over the first 6 months as predictors of 
sustained SDAI remission over 1 year. 
 
 
LDAS vs SDAI SR OR Standardised OR p value 
Baseline Calprotectin 1 (1, 1) 0.34 0.029 
Baseline CXCL10 1 (1, 1) 0.25 0.076 
Baseline hsCRP 1 (1, 1) 0.36 0.019 
Baseline IL6 1 (1, 1) 0.97 0.932 
Baseline leptin 1 (1, 1) 0.45 0.01 
Baseline SAA 1 (1, 1) 0.03 0.008 
Baseline MBDA score 0.91 (0.84,0.96) 0.28 0.007 
Calprotectin AUC 1 (1, 1) 0.11 0.002 
CXCL10 AUC 1 (1, 1) 0.60 0.205 
hsCRP AUC 0.98 (0.96, 1) 0.48 0.042 
IL6 AUC 1 (1, 1) 0.75 0.249 
Leptin AUC 1 (1, 1) 1.11 0.838 
SAA AUC 0.95 (0.92, 0.99) 0.15 0.008 
MBDA AUC 0.98 (0.96, 0.99) 0.24 0.004 
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Table 6-11 Biomarker predictors of Sustained Boolean Remission 
Univariate logistic regression assessing baseline serum biomarkers levels and time-
integrated values of serum biomarkers over the first 6 months as predictors of 
sustained Boolean remission over 1 year. 
 
 
LDAS vs Boolean SR OR Standardised OR p value 
Baseline Calprotectin 1 (1, 1) 0.42 0.214 
Baseline CXCL10 1 (1, 1) 0.41 0.405 
Baseline hsCRP 1 (1, 1) 0.03 0.057 
Baseline IL6 0.99 (0.94, 1.04) 0.56 0.607 
Baseline leptin 1 (1, 1) 0.08 0.17 
Baseline SAA 1 (1, 1) 0.00 0.183 
Baseline MBDA score 0.92 (0.85, 1.00) 0.34 0.044 
Calprotectin AUC 1 (1, 1) 0.20 0.061 
CXCL10 AUC 1 (1, 1) 0.38 0.239 
HsCRP AUC 0.92 (0.84, 1.00) 0.03 0.044 
IL6 AUC 1 (1, 1) 0.68 0.397 
Leptin AUC 0.97 (0.92, 1.02) 0.00 0.194 
SAA AUC 0.87 (0.75, 1.01) 0.00 0.06 
MBDA AUC 0.98 (0.97, 1.00) 0.31 0.034 
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6.4 Discussion 
Reliable assessment of remission is important for the optimal management of 
patients with RA. Imaging studies have shown that majority of patients in 
remission, whether the administered therapy was a DMARD or a biological agent, 
have some evidence of active subclinicl inflammation. (Brown et al. 2006, Saleem 
et al. 2009). These findings indicate that patients in clinical remission have 
subclinical disease despite displaying few clinical signs and symptoms. This 
highlights the need for identifying new measures to supplement clinical 
assessment of remission status. The REMIRA study demonstrates a panel of novel 
biomarkers which could be used to address this.  This cohort of patients, whilst  
being clinically similar in phenotype, demonstrates surprising heterogeneity at the 
molecular level. Despite this heterogenity, we identified several individual 
biomarkers which were able to define remission states. MBDA and some of its 
analaytes (hsCRP, SAA, IL6, Leptin), Calprotectin and CXCL10 were able to 
differentiate between LDAS and all 3 point remission criteria. In addition, TNFR1 
and VCAM1 were able to differentiate between LDAS and DAS28ESR point 
remission. MBDA, hsCRP, SAA, IL6, leptin, CXCL10 at baseline or over 6 months 
were able to predict the frequency of remission over 12 months.  Calprotectin over 
6 months but not at baseline were able to predict the frequency of remission over 
12 months indicating that under some circumstances, it maybe beneficial to 
capture multiple readings to inform outcome more accurately. It should also be 
emphasized that, since these analytes were measured in serum as opposed to 
synovium or synovial fluid, the data indicate that it is possible to discriminate 
between low disease activity states by measuring inflammatory responses at a 
systematic rather than local level.  
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The MBDA score and the individual biomarkers which have been shown to be of 
significance as a biomaker are discussed below:  
 
6.4.1 MBDA score 
A significant association between the MBDA score and DAS28-CRP has been 
previously shown in a heterogeneous group of RA patients with a wide range in 
autoantibody status, disease activity and RA treatment (Curtis et al. 2012). The 
MBDA score was able to consistently distinguish patients in different categories of 
clinical disease activity. The performance of the MBDA score was assessed using 
the AUROC previously for classifying patients into low verus moderate or high 
disease activity using DAS28CRP. This showed AUROC of 0.77 and 0.70 
respectively (Curtis et al. 2012). No comparisons were made in remission. The 
REMIRA study shows that the baseline MBDA score interestingly preformed the 
least well with baseline DAS28CRP. The agreement of sustained MBDA remission 
with the sustained clinical remission is better over time than point remission. This 
suggests that a trend over time is more valuable to obtain the true picture of a 
clinical state than just a cross-sectionally snapshot. The baseline median MBDA 
score was below the remission threshold (<25) with all 3 point clinical remission 
and sustained remission. Further work is under way to determine whether this 
current MBDA set points for remission should be lowered. 
 
6.4.2 Acute phase response biomarkers (hsCRP and SAA) 
hsCRP and SAA have been shown in this study to be important biomarkers. They 
were all highly significanty different when comparing LDAS with all 3 point 
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remission criteria. Baseline levels and time-integrated values over 6 months were 
able to predict sustained remission over 1 year with all 3 remission criteria.  
 
During active inflammation, synovial inflammation is mirrored by a systemic 
acute-phase response in which marked biosynthetic changes in the liver alter 
plasma protein concentrations (Steel, Whitehead 1994). Both SAA and CRP are key 
acute phase response markers. Serum amyloid A (SAA) proteins are a family of 
apoliproteins.  SAA mRNA is expressed in RA synovium and not in healthy controls 
(O'Hara et al. 2000). SAA exists as constitutive (c-SAA) and acute-phase isoforms 
(A-SAA). A-SAA induces angiogenesis, leukocyte recruitment, and chemokine and 
MMP expression in RA (Mullan et al. 2006). Similar to CRP, levels of SAA increase 
within hours after inflammatory stimulus, and the magnitude of increase may be 
greater than that of CRP. SAA levels correlate better with disease activity in early 
disease compared to ESR and CRP. This seems to be more specific in RA than other 
forms of inflammatory arthritis (Cunnane et al. 2000). It correlates with the 28-
joint swollen joint count and was independently associated with 1-year 
radiographic progression (Connolly et al. 2012). 
 
CRP correlates with disease activity, radiologic progression and treatment 
response (Nakamura 2000). Conventional CRP assays are not able to differentiate 
low levels of inflammation therefore the use of hsCRP assays is more valuable at 
low levels of disease activity. It correlated better with other disease activity 
measures when compared to ESR (Dessein, Joffe & Stanwix 2004). The mean 
hsCRP level of apparently healthy men is <2mg/L (Ridker et al. 1997). The median 
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hsCRP levels of patients in remission in this study were below this threshold with 
all 3 remission criteria suggesting that the levels normalise in remission.  
 
Our study also showed that SAA preformed better than hsCRP at predicting 
sustained DAS28 or SDAI remission. The signifiance for predicting Boolean 
remission was just over the >0.05 threshold.  
 
6.4.3 IL-6 
IL-6 is a pro-inflammatory cytokine that stimulates the hepatic synthesis of acute 
phase proteins. It has a central role in the pathogensis of RA (Park, Pillinger 2007). 
IL-6 levels are elevated in RA patients compared to healthy controls (Knudsen et 
al. 2008) and multiple studies have shown the efficacy and safety of anti-IL6 
blockade in the treatment of RA. (Schoels et al. 2013). Its role as a biomarker has 
been shown. It correlates not only with clinical variables of disease activity, such 
as joint counts and global disease activity scores, but also for the composite 
measures of disease activity (DAS, DAS-CRP, CDAI, and SDAI) (Milman, Karsh & 
Booth 2010). Several studies have demonstrated decreases in IL-6 levels in 
response to treatment including anti-TNF (Braun-Moscovici et al. 2006), 
Leflunomide (Litinsky et al. 2006) and Methotrexate (Crilly et al. 1995). The 
REMIRA study further supports its use as a biomarker in the low disease activity 
cohort. It preformed well as a biomarker for differentiating between remission and 
LDAS as well as predicting sustained remission. This was not confirmed with 
logistic regression analysis.  
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6.4.4 Leptin 
Leptin is a 16-kDa protein secreted by white adipose tissue and therefore is also an 
adipokine. It resembles IL-6 and is a member of the cytokine superfamily. It is 
present in the synovial fluid (Bokarewa et al. 2003). Higher levels have been found 
in RA patients compared to healthy controls in some studies (Bokarewa et al. 2003, 
Otero et al. 2006) but not in others (Hizmetli et al. 2007, Popa et al. 2005). Its use 
as a biomarker is still controversial. Studies have shown conflicting results: Anders 
et al., 1999 showed no difference between low and moderate disease activity, 
although the number of patients in each group were small (Anders et al. 1999). 
Leptin has also been shown to be inversely correlated with active chronic 
inflammation (Popa et al. 2005). Lee et al., 2007 showed higher serum leptin levels 
in RA patients with high disease activity, correlated well with disease activity, and 
decreased significantly when disease was well controlled (Lee et al. 2007). The 
REMIRA study is the first to demonstrate a role of leptin in defining remission 
amongst patients with low disease activity and furthermore, its role as a predictor 
of sustained remission. The strength of this study is the larger numbers of patients 
studied and also at multiple timepoints.  
 
Leptin acts via the leptin receptor, which is a member of the IL6 receptor-related 
cytokine receptors. It exerts a pro-inflammatory effect on synovial fibroblasts 
(Tong et al. 2008) and chondrocytes (Gomez et al. 2011). The action of leptin in RA 
is not only targeted to articular tissue, it also exerts direct effects on activation, 
proliferation, maturation of, and production of inflammatory mediators by a 
variety of immune cells (Lam, Lu 2007). In particular, leptin is able to modulate 
regulatory T cells, which are potent suppressors of autoimmunity. Leptin sustains 
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Th1 immunity by promoting effector T cell proliferation and by constraining Treg 
cell expansion (De Rosa et al. 2007).  
 
6.4.5 Calprotectin 
Calprotectin is released from activated leucocytes during inflammation. Several 
studies have shown correlation between serum levels of calprotectin with ESR, 
CRP as well as swollen joint count (Brun et al. 1992, Andres Cerezo et al. 2011). 
Acute phase proteins are released from the hepatcoytes during inflammation 
whereas calprotectin is released from the activated leucocytes which is derived 
from inflamed synovium. It therefore differs from acute phase proteins by directly 
reflecting the amount of activated leucocytesin the inflamed joints. There is 
evidence of a strong association between the decrease in calprotectin level and 
improvements in swollen joint counts (Brun et al. 1992, Andres Cerezo et al. 
2011). This provides further evidence of its use as a suitable biomarker which 
gives information about the extent of local inflammation in affected joints. The use 
of calprotectin as a biomarker has been investigated in JIA patients who are in 
remission. It has been shown to have a role in predicting flares in patients after 
treatment withdrawal (Foell et al. 2010, Gerss et al. 2012). This biomarker informs 
about the activation status of innate immunity at the molecular level and thereby 
has a role in identifying patients who are in remission. 
 
6.4.6 CXCL10 
CXCL10 and its receptor CXCR3 play important roles in leukocyte homing to 
inflamed tissues and in the perpetuation of inflammation. High levels of serum 
levels of CXCL0 have been found in active RA and significantly reduced with 
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response to treatment (Kuan et al. 2010). The REMIRA study has also showed that 
lower levels of CXCL10 was associated with lower levels of disease activity.  
 
6.4.7 Implications for clinical practice 
In an era where treatments are increasingly targeted at a molecular level, it is 
important that monitoring treatment responses evolve to reflect such specific 
therapies. This study has demonstrated that novel laboratory biomarkers, beyond 
ESR, play important roles in defining remission states and predicting sustained 
remission.  
 
This chaper has shown that low disease activity states are heterogenous on a 
molecular level. It follows from this that more than 1 biomarker is likely to be 
required to accurately identify patients in remission. Several factors with different 
mechanisms of action have been identified in this study. Sustained remission was 
associated with lower baseline MBDA scores as well as lower concentrations of IL-
6, SAA, hsCRP and leptin, indicating that presence of subclinical inflammation may 
play an important role even at low levels of disease activity. It was not possible to 
compare the different remission groups directly as the patients overlapped in 
these groups. However, it is apparent that levels of the leptin, IL-6, SAA, hsCRP and 
MBDA scores were lower with the more stringent criteria of remission at baseline 
and over time. This was not mirrored for CXCL10 and calprotectin levels. 
 
The study also explored the use of serial serum measurements will have a role in 
the clinical setting. Having 3 readings over a 6 month period seems to have more 
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predictive power with some of the biomarkers. This suggests that stability of the 
molecular signature is important to predict clinical outcome.  
 
In conclusion, even at the low end of the disease activity, the data indicate that the 
MBDA score and some of its analytes can differentiate between small changes in 
disease activity. These findings highlight the importance of close follow-up of 
patients who have achieved low disease activity or clinical remission and the 
potential value of repeated measurements and assessments to evaluate stability of 
phenotypes over time. It is proposed that molecular markers of inflammation may 
be included in the evaluation of patients with low disease activity states to 
facilitate therapy decisions such as drug tapering or treatment withdrawal.  
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7 Impact of remission on health related quality of life  
7.1 Introduction 
Pain, fatigue and disability are all characteristic features of RA. Over time the 
disability associated with RA can have considerable impacts on health-related 
quality of life (HRQoL) (Scott, Smith & Kingsley 2005, Scott et al. 2000). One 
important aim of treatment is to maximise HRQoL.  
Several instruments have been used to assess HRQoL in RA patients. These include 
generic tools eg SF36 (Medical outcomes study 36-Item Health Survey forms), 
EuroQol and Functional Assessment of Chronic Illness Therapy (FACIT-F) as well 
as the disease-specific tool Health assessment questionnaire (HAQ). Although, it is 
well-established that RA therapies decrease disability (Ma, Kingsley & Scott 2010) 
and improve HRQoL (Kimel et al. 2008, Kosinski et al. 2002), the direct 
relationship between remission and HRQoL outcomes are less well established 
(Kekow et al. 2010). 1 study has reported on the benefit of remission over low 
disease activity states cross-sectionally (Radner, Smolen & Aletaha 2014), but the 
impact of sustained remission on HRQoL have not been reported in detail.  
 
This study evaluated the REMIRA cohort to explore the relationship between 
baseline remission, sustained remission and HRQoL.  
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7.2 Methods and Patients 
7.2.1 REMIRA cohort 
This has been described previously in chapter 5. 
7.2.2 Clinical assessments 
Clinical assessments have been described previously in chapter 5.  
 
Patient reported outcome measures 
Health Assessment Questionnaire Disability Index (HAQ-DI) ranged from 0-3 with 
higher scores indicating more disability. The Medical Outcomes Study 36-Item 
Short-Form Health Survey (SF36) assesses health-related quality of life. There are 
8 domains: physical function (PF), physical role (RP), bodily pain (BP), general 
health perception (GH), vitality (VT), social function (SF), emotional role (RE) and 
mental health (MH). These domains are then generated into two summary 
measures: the physical component score (PCS; including PF, RP, BP and GH) and 
the mental component score (MCS including VT, SF, RE and MH). Both range from 
0-100. Norm-based scoring algorithms were used for the subscales, for which 
scores have a mean of 50 and a SD of 10. EuroQol also known as EuroQol is a 
standardized instrument for use as a measure of health outcome. There are 5 
domains which can be combined to a total of 243 health states. Each health state 
can be associated with a numeric score on which full health has a value of 1, death 
has a value of 0 and unconscious is -0.402. In addition, the EuroQol VAS which is a 
20cm vertical VAS that generates a self-rating of health-related quality of life.  The 
Functional Assessment of Chronic Illness Therapy (FACIT-F, (Yellen et al. 1997)) is 
a 13 item questionnaire that assesses self-reported fatigue (range 0-52). With 
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SF36, EurQol and FACIT-F, the greater the score, the better the outcome. These 
outcomes were all measured 3-monthly for the length of the study. 
 
7.2.3 Statistical analysis 
STATA 11.2 (StataCorp, College Station, TX, USA) was used for statistical analysis. 
Point remission at baseline is defined as DAS28ESR <2.6, DAS28CRP <2.32, SDAI ≤ 
3.3 and CDAI ≤ 2.8. ACR/EULAR Boolean remission was defined as TJC, SJC, CRP 
(mg/dl) and patient VAS (0-10cm) all ≤1. Sustained remission (SR) is defined as 
achieving remission at all visit time-points, intermittent remission (IR) is defined 
as achieving remission in at least 1 visit time-point but not all. No remission (NR) 
is defined as not achieving remission at any visit time-point. Individual variables 
were assessed descriptively as median values and interquartile ranges (IQR).  
 
To assess the impact of remission on HRQoL over 1 year, time-integrated values 
were calculated using area under the curve (AUC). These were computed using 
GraphPad Prism software using the trapezoidal method. Last observations carried 
forward method was used to handle missing data. Comparisons of these HRQoL 
measures between remission vs non-remission at baseline and between NR vs IR, 
IR vs SR and NR vs SR were performed using Mann-Whitney test. Generalised 
estimating equation analysis (GEE) was used to estimate the effect of different 
remission groups over the timepoints during 12 months of follow-up. This analysis 
was limited to DAS28 as the number of patients in the other 2 sustained remission 
criteria were too small for meaningful analysis.   
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7.3 Results 
7.3.1 Impact Of Initial Point Remission Status On HRQoL 
Patients meeting one of the three remission criteria at baseline (DAS28ESR, SDAI 
or Boolean) were compared with patients in LDAS states. With all remssion 
criteria patients had significantly better baseline FACIT-F, SF36, HAQ and Euroqol 
scores if they were in remission compared to patients in LDAS states (Table 7.1)  
 
Patients in remission at baseline continued to have significantly better outcomes in 
all HRQoL outcomes measured over the ensuing 12 months. This was shown by 
comparing AUCs for HRQoL in patients in initial remission with LDAS patients. 
This finding was consistent across all 3 remission criteria (Table 7.1); it included 
HAQ, EuroQol, EuroQol VAS and SF36. 
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Table 7-1 Baseline and AUC HRQoL between LDAS and Baseline Remission  
Comparing low disease activity state at baseline (LDAS) with baseline DAS28ESR, SDAI and Boolean remission  
All values are reported as median (IQR). * Mann-Whitney test. HRQoL = Health related quality of life, FACIT –F = Functional assessment of chronic 
illness therapy – Fatigue, SF36 = short form 36, PCS = physical component score, MCS = mental component score, HAQ = health assessment 













FACIT-F 35 (31, 38) 43 (38, 47) <0.0001 46 (42, 50) <0.0001 46 (43, 50) <0.0001 
SF36 PCS 39 (34, 43) 48 (40, 53) <0.0001 51 (46, 55) 0.001 52 (48, 55) <0.0001 
SF36 MCS 49 (41, 53) 54 (47, 58) 0.021 57 (51, 58) <0.0001 57 (51, 58) 0.002 
HAQ 0.75 (0.5,1.38) 0 (0, 0.5) <0.0001 0 (0, 0.125) <0.0001 0 (0, 0.125) <0.0001 
Euroquol 0.69 (0.59,0.76) 0.80 (0.69, 1.00) 0.024 1.00 (0.80, 1.00) <0.0001 1.00 (0.80, 1.00) <0.0001 
Euroqol VAS 70 (60, 80) 81 (75, 93) 0.002 90 (80, 95) <0.0001 90 (80, 95) <0.0001 
FACIT-F AUC 414 (349, 488) 537 (455 575) <0.0001 553 (492, 589) <0.0001 569 (488, 594) 0.001 
SF36 PCS AUC 467 (430, 512) 588 (513 638) <0.0001 622 (554, 695) <0.0001 622 (585, 655) <0.0001 
SF36 MCS AUC 552 (500, 648) 618(557, 674) 0.005 649 (583, 691) 0.001 663 (597, 689) 0.007 
HAQ AUC 10.3 (4.0,14.1) 1.2 (0, 6.6) <0.0001 0.3 (0, 1.8) <0.0001 0.43 (0, 188) <0.0001 
Euroquol AUC 8.7 (7.7, 9.3) 9.9 (8.7, 11.4) <0.0001 10.6 (9.5,11.7) <0.0001 11.1 (9.6, 12.0) <0.0001 
 
 
  215 
Changes in outcome measures over time for patients meeting different point 
remission criteria compared to LDAS are summarized in Tables 7.2-7.6.  
 
When assessing the outcomes at each time point over the 12 month period of study, 
the median HAQ within the LDAS group ranged from 0.75 to 1, whereas the median 
HAQ was significantly lower in the DAS28, SDAI and Boolean point remission groups 
at each time point (0-0.125, 0 and 0 respectively, Table 7.2). The median EuroQol in 
the LDAS group ranged from 0.69 - 0.76. These were lower than DAS28ESR (0.80 - 
0.81), SDAI (0.85 – 1) and Boolean (0.94 - 1) point remission groups at all time points 
(Table 7.3). The median FACIT-F was also significantly higher at all time points in 
DAS28 (44-47), SDAI (46-48) and Boolean (47-49) point remission groups compared 
to LDAS group (34-36) (Table 7.4).  
 
The median SF36 PCS of the LDAS group was 38.48 – 41.47. This was significantly 
lower at all time points than DAS28 remission (47.78 – 49.40), SDAI (50.90 – 52.95) 
and Boolean (52.04 – 53) (Table 7.5). The median SF36 MCS in the LDAS group was 
45.36 – 50.08. This was lower significantly lower only at T0 and T12 in the DAS28 
groups (53.54 – 54.06). The median SF36 MCS in the SDAI group was 54.55-57 and  
55.04-56.67 in the Boolean group. In both these groups, these were not significantly 
different at T6 compared to the LDAS group (Table 7.6). 
 
Although it was not possible to compare between the remission groups, there is a 
trend of  greater improvement with increasing stringency of the remission criteria.  
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Table 7-2 HAQ Scores At Each Time Point By LDAS and Remission Groups 




LDAS DAS28 SDAI Boolean 
0 0.75 (0.50, 1.38) 0 (0, 0.50)* 0 (0, 0.13)* 0 (0, 0.13)* 
3 0.75 (0.25, 1.06) 0 (0 , 0.63)* 0 (0, 0.13)* 0 (0, 0.13)* 
6 0.81 (0.31, 1.13) 0.06 (0, 0.56)* 0 (0, 0.13)* 0 (0, 0.13)* 
9 0.94 (0.38, 1.50) 0.13 (0, 0.38)* 0 (0, 0.13)* 0 (0, 0.25)* 
12 1.00 (0.13, 1.25) 0 (0, 0.25)* 0 (0, 0.13)* 0 (0, 0.13)* 
 
p values *= <0.0001, + = <0.001, ‡ = <0.01, # = <0.05 
 
 
Table 7-3 EuroQol Scores At Each Time Point By LDAS and Remission Groups 




LDAS DAS28 SDAI Boolean 
0 0.73 (0.65, 0.78) 0.80 (0.71, 1.00)+ 0.93 (0.80, 1.00)* 1.00 (0.80, 1.00)* 
3 0.76 (0.69, 0.78) 0.81 (0.69, 1.00)+ 1.00 (0.80, 1.00)* 1.00 (0.80, 1.00)* 
6 0.76 (0.69, 0.78) 0.80 (0.73, 1.00)# 0.88 (0.80, 1.00)* 0.94 (0.80, 1.00)* 
9 0.73 (0.59, 0.80) 0.80 (0.73, 1.00)+ 0.85 (0.80, 1.00)* 1.00 (0.80, 1.00)* 
12 0.69 (0.59, 0.80) 0.80 (0.74, 1.00)* 1.00 (0.76, 1.00)* 1.00 (0.80, 1.00)* 
 
*= <0.0001, + = <0.001, ‡ = <0.01, # = <0.05, ns= non-significant  
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Table 7-4 FACIT-F Scores At Each Time Point By LDAS and Remission Groups 




LDAS DAS28 SDAI Boolean 
0 35 (31, 41) 44 (38, 48)* 46 (42, 50)* 47 (43, 50)* 
3 35 (29, 42) 44 (39, 48)* 47 (41, 49)* 48 (42, 49)* 
6 36 (29, 41) 47 (41, 49)* 48 (45, 50)* 48 (46, 50)* 
9 34 (26, 41) 44 (38, 49)* 47 (42, 50)* 49 (42, 51)* 
12 34 (26, 38) 45 (39, 49)* 47 (42, 50)* 48 (43, 50)* 
 
*= <0.0001, + = <0.001, ‡ = <0.01, # = <0.05 
 
Table 7-5 SF36 PCS Scores At Each Time Point By LDAS and Remission Groups 




LDAS DAS28 SDAI Boolean 
0 39.1 (34.1, 43.2) 48.4 (41.1, 53.8)* 51.5 (45.7, 54.8)* 52.3 (47.6, 55.2)* 
3 41.5 (35.8, 44.5) 49.4 (40.1, 53.9)+ 52.9 (46.3, 55.7)* 53.0 (47.6, 56.0)* 
6 40.1 (32.4, 43.5) 48.6 (42.9, 54.7)* 50.9 (46.9, 54.9)* 52.0 (48.5, 56.3)* 
9 38.9 (34.7, 42.0) 47.8 (40.9, 53.3)* 51.7 (45.7, 54.7)* 52.3 (47.1, 54.7)* 
12 38.5 (31.3, 43.7) 49.2 (43.2, 53.5)* 51.7 (44.8, 55.4)* 52.2 (44.8, 55.4)* 
 
*= <0.0001, + = <0.001, ‡ = <0.01, # = <0.05  
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Table 7-6 SF36 MCS Scores At Each Time Point By LDAS and Remission Groups 




LDAS DAS28 SDAI Boolean 
0 48.9 (41.2, 53.5) 54.1 (47.0, 58.1)# 56.67 (50.5, 58.4)‡ 56.7 (50.8, 58.5)‡ 
3 46.8 (40.9 ,52.5) 53.7 (45.2, 57.3)ns 54.8 (46.7, 57.6)# 56.3 (49.0, 57.6)‡ 
6 50.1 (42.9, 57.5) 53.7 (47.0, 57.2)ns 54.5 (48.0, 57.9)ns 55.0 (49.7, 58.1)ns 
9 47.0 (37.4, 54.6) 52.8 (42.9, 56.3)ns 54.6 (50.1, 57.7)‡ 55.8 (49.7, 58.4)‡ 
12 45.4 (35.9, 51.4) 53.5 (42.1, 57.6)# 55.6 (50.6, 58.8)+ 55.6 (51.5, 58.8)‡ 
 
*= <0.0001, + = <0.001, ‡ = <0.01, # = <0.05, ns= non-significant
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7.3.2 Impact of frequency of remission on HRQoL 
Table 7.7-7.11 summarised the levels of HRQoL outcomes achieved at each visit in no 
remission (NR), intermittent remission (IR) and sustained remission (SR) groups. 
They reveal relative stability of these values over time.  
 
The NR group had higher median HAQ (0.875 – 1.5) then DAS28 IR (0.25 – 0.5) and 
DAS28 SR (0- 0.063). This trend was also observed in SDAI IR (0 – 0.25) and SDAI SR 
(0). Boolean IR and Boolean SR were similar (0 vs 0 – 0.125) (Table 7.7). Patients in 
the NR group lower median EuroQol values (0.52-0.66) compared to all 3 IR groups 
(DAS28 IR = 0.76 – 0.8, SDAI IR = 0.80, Boolean IR = 0.85-0.88). All SR groups achieved 
the highest EuroQol (DAS28 SR = 0.80 – 1, SDAI SR = 1, Boolean = SR 1) (Table 7.8). 
Over time, the NR patients achieved lower median FACIT-F values (26-33) compared 
to all 3 IR groups (DAS28 IR = 38-41, SDAI IR = 46-49, Boolean IR = 45-48). All SR 
remission groups achieved the highest FACIT-F (DAS28 SR = 45-47, SDAI SR = 46-49, 
Boolean SR = 47-50) (Table 7.9). Over time, patients in NR group had lower median 
SF36 PCS values (36.73 – 40.83) compared to all 3 IR groups (DAS28 IR = 31.56 – 
43.83, SDAI IR = 44.02 – 47.02, Boolean IR = 50.08 – 51.98). All SR remission groups 
achieved the highest SF36 PCS (DAS28 SR = 49.37 – 52.60, SDAI SR = 51.05 – 54.56, 
Boolean SR = 52.04 – 56.31) (Table 7.10). Over time, NR patients achieved lower 
median SF36 MCS values (39.66 – 46.55) compared to all 3 IR groups (DAS28 IR = 
48.29 – 51.90, SDAI IR = 50.72- 54.43, Boolean IR = 53.34 – 56.85). DAS28 SR and 
SDAI SR groups achieved the better SF36 MCS than IR and NR groups (DAS28 SR = 
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54.18 – 55.86 and SDAI SR = 55 – 57.23), Boolean SR was similar to Boolean IR (54.45 
- 57) (Table 7.11). 
 
When this was combined into time-integrated AUC values, there was a significant 
improvement of all HRQoL between NR, DAS28 IR and DAS28 SR and between LDAS, 
SDAI IR and SDAI SR (Fig 7.1-7.2).  
 
Applying the most stringent Boolean remission criteria, the number of patients 
achieving sustained remission was small (10%). In all HRQoL measures, there were 
significant differences between Boolean NR vs Boolean IR. Interestingly, differences 
between Boolean IR and Boolean SR were not demonstrated in any of the outcomes 
(Fig 7.3).  
 
The spidergrams in Figure 7.4 show the distribution of improvement in the AUC of the 
8 domains of SF36. With DAS28 ESR and SDAI remission criteria, there were 
improvements in all 8 domains with increasing frequency of remission except in the 
GH domain. (Fig 7.4 A and B). There was no difference in the GH domain over time 
between NR and IR (Fig 7.4B). There were no improvements between Boolean IR and 
Boolean SR in all 8 domains (Fig 7C).  
 
GEE analysis showed significant improvement of FACIT-F, EuroQol, SF36PCS and SF36 
MCS between NR and DAS28 SR after correcting for baseline values. There was no 
difference in HAQ (Table 7.7).  
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Table 7-7 HAQ Scores At Each Time Point For NR, IR and SR Groups 
 Shows scores in no remission (NR), intermittent remission(IR) and sustained remission(SR) in three remission groups 
(DAS28, SDAI and Boolean remission) at each visit timepoint. Median scores and interquartile ranges are shown 
 
Visit NR DAS28 IR DAS28 SR SDAI IR SDAI SR Boolean IR Boolean SR 
0 1.25 (0.75, 1.88) 0.50 (0, 0.94) 0 (0, 0.38) 0 (0, 0.63) 0 (0, 0.13) 0 (0, 0.25) 0 (0, 0.13) 
3 0.88 (0.75, 1.44) 0.44 (0, 0.88) 0 (0, 0.38) 0.13 (0, 0.75) 0 (0, 0.25) 0 (0, 0.25) 0.06 (0, 0.44) 
6 1.19 (0.69, 1.56) 0.38 (0, 0.88) 0.06 (0, 0.44) 0.13 (0, 0.75) 0 (0, 0.13) 0 (0, 0.13) 0.13 (0, 0.25) 
9 1.50 (0.75, 1.63) 0.38 (0.13, 1.00) 0.06 (0, 0.31) 0.25 (0, 0.88) 0 (0, 0.13) 0 (0, 0.38) 0 (0, 0.25) 
12 1.38 (0.50, 1.63) 0.25 (0, 1.13) 0 (0, 0.25) 0.13 (0, 0.75) 0 (0, 0) 0 (0, 0.13) 0 (0, 0.13) 
 
 
Table 7-8 EuroQol Scores At Each Time Point For NR, IR and SR Groups 
 Shows scores in no remission (NR), intermittent remission(IR) and sustained remission(SR) in three remission groups 
(DAS28, SDAI and Boolean remission) at each visit timepoint. Median scores and interquartile ranges are shown 
 
 
Visit NR DAS28 IR DAS28 SR SDAI IR SDAI SR Boolean IR Boolean SR 
0 0.66 (0.59 ,0.76) 0.76 (0.69,0.80) 0.80 (0.73, 1.00) 0.80 (0.73, 1.00) 1.00 (0.80, 1.00) 0.85 (0.80, 1.00) 1.00 (0.80, 1.00) 
3 0.74 (0.60 ,0.78) 0.76 (0.69, 0.80) 1.00 (0.76, 1.00) 0.80 (0.73, 1.00) 1.00 (0.81, 1.00) 1.00 (0.80, 1.00) 1.00 (0.81, 1.00) 
6 0.69 (0.55, 0.76) 0.80 (0.73 ,0.80) 0.85 (0.73, 1.00) 0.80 (0.69, 1.00) 1.00 (0.80, 1.00) 0.88 (0.80, 1.00) 1.00 (0.71, 1.00) 
9 0.69 (0.52 ,0.73) 0.76 (0.66, 0.80) 0.81 (0.80, 1.00) 0.80 (0.73, 1.00) 1.00 (0.80, 1.00) 0.85 (0.80, 1.00) 1.00 (1.00,1.00) 
12 0.52 (0.52, 0.69) 0.76 (0.69, 0.80) 0.85 (0.76, 1.00) 0.80 (0.73, 1.00) 1.00 (0.85, 1.00) 0.85 (0.76, 1.00) 1.00 (1.00,1.00) 
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Table 7-9 FACIT-F Scores At Each Time Point For NR, IR and SR Groups 
  Shows scores in no remission (NR), intermittent remission(IR) and sustained remission(SR) in three remission groups 




Visit NR DAS28 IR DAS28 SR SDAI IR SDAI SR Boolean IR Boolean SR 
0 33 (18, 37) 39 (33, 46) 45 (40, 48)* 43 (38, 48) 46 (43, 50)* 45 (42, 50 47 (45, 50)‡ 
3 30 (25, 37) 40 (32, 45) 45 (40, 49)+ 43 (38, 48) 48 (41, 49)+ 48 (42, 49) 47 (41, 51)‡ 
6 32 (24, 42) 41 (35, 47) 47 (42, 49)‡ 45 (39, 49) 48 (46, 50)‡ 48 (45, 50) 48 (46, 51)# 
9 28 (19, 34) 40 (31, 46) 45 (39, 50)+ 45 (38, 49) 49 (43, 50)+ 47 (41, 50) 49 (46, 51)+ 
12 26 (19, 36) 38 (33, 45) 47 (41, 50)+ 45 (37, 47) 49 (47, 51)* 47 (41, 50) 50 (47, 50)+ 
 
 
Table 7-10 SF36 PCS Scores At Each Time Point For NR, IR and SR Groups 
 Shows scores in no remission (NR), intermittent remission(IR) and sustained remission(SR) in three remission groups 
(DAS28, SDAI and Boolean remission) at each visit timepoint. Median scores and interquartile ranges are shown 
 
 
Visit NR DAS28 IR DAS28 SR SDAI IR SDAI SR Boolean IR Boolean SR 
0 36.7 (32.8, 44.4) 43.1 (36.8, 48.0) 49.5 (41.2, 54.2) 47.0 (40.5, 52.4) 51.1 (44.4, 54.8) 52.0 (45.6, 54.5) 52.0 (49.3, 55.2) 
3 39.8 (35.3, 45.2) 43.8 (35.0, 48.4) 52.6 (40.7, 55.1)  44.9 (39.6, 52.7) 53.0 (49.6, 55.5) 52.8 (47.1, 55.5) 53.0 (45.9, 56.0)  
6 40.8 (34.6, 44.8) 43.3 (38.4, 47.6) 49.4 (43.0, 54.9)  46.9 (40.7, 50.1) 54.6 (49.4, 56.4) 50.1 (47.0, 54.7) 56.3 (45.6, 58.9)  
9 34.7 (34.1, 35.9) 41.6 (38.4, 45.4) 48.7 (43.2, 53.8) 44.0 (40.3, 52.6) 52.4 (47.8, 56.6) 50.3 (46.2, 53.9) 53.9 (52.4, 57.2) 
12 36.7 (32.4, 38.5) 41.7 (35.1, 47.6) 50.6 (43.9, 55.5) 45.5 (39.3, 51.4) 54.3 (49.2, 56.7) 51.4 (44.8, 55.0) 56.7 (49.2, 57.6) 
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Table 7-11 SF36 MCS Scores At Each Time Point For NR, IR and SR Groups 
  Shows scores in no remission (NR), intermittent remission(IR) and sustained remission(SR) in three remission groups 
(DAS28, SDAI and Boolean remission) at each visit timepoint. Median scores and interquartile ranges are shown 
 
 
Visit NR DAS28 IR DAS28 SR SDAI IR SDAI SR Boolean IR Boolean SR 
0 46.6 (38.1, 53.2) 50.8 (44.3, 57.4) 55.9 (48.1, 58.2) 53.3 (46.3, 57.5) 57.2 (50.8, 58.5) 56.9 (48.4, 58.2) 55.3 (50.8, 58.1) 
3 42.8 (31.4, 44.7) 51.3 (45.2, 57.5) 54.5 (45.4, 57.5) 52.5 (45.5, 56.7) 57.1 (51.1, 58.4)  54.8 (46.2, 58.4) 56.7 (51.6, 58.5)  
6 42.3 (32.8, 51.9) 51.9 (47.2, 57.2) 54.4 (49.7, 57.8) 53.7 (48.0, 57.2) 57.1 (49.7, 58.3) 55.0 (49.7, 57.8) 54.5 (45.9, 58.1) 
9 40.5 (32.5, 46.7) 48.3 (42.0, 54.6) 54.2 (50.0, 57.1) 51.1 (44.9, 55.6) 56.2 (51.9, 58.8) 53.5 (48.6, 57.4) 56.2 (52.7, 58.1)  
12 39.7 (34.3, 48.5) 48.7 (40.8, 57.1) 54.9 (43.4, 58.5) 50.7 (43.2, 57.4) 55.0 (53.3, 58.8) 53.3 (42.1, 58.6) 57.0 (54.9, 58.8)  
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Figure 7-1 Impact of NR, DAS28 IR and SR on HRQoL over time  
A) HAQ, B) EuroQol, C) FACIT-F, D) SF36 PCS , E) SF36 MCS, Values expressed as medians with min and max range. NR = No Remission by any 
criteria over 1 year), IR = intermittent remission, SR = sustained remission, ns =  P > 0.05, * =  P ≤ 0.05, **  = P ≤ 0.01, *** =  P ≤ 0.001, **** =   P ≤ 
0.0001 using Mann-Whitney test (NR vs IR, IR vs SR, NR vs SR) 
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Figure 7-2 Impact of NR, SDAI IR and SR on HRQoL  
A) HAQ, B) EuroQol, C) FACIT-F, D) SF36 PCS , E) SF36 MCS, Values expressed as medians with min and max range. NR = No Remission by any 
criteria over 1 year), IR = intermittent remission, SR = sustained remission, ns =  P > 0.05, * =  P ≤ 0.05, **  = P ≤ 0.01, *** =  P ≤ 0.001, **** =   P ≤ 
0.0001 using Mann-Whitney test (NR vs IR, IR vs SR, NR vs SR) 
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Figure 7-3 Impact of NR, Boolean IR and SR on HRQoL  
A) HAQ, B) EuroQol, C) FACIT-F, D) SF36 MCS , E) SF36 PCS, Values expressed as medians with min and max range. NR = No Remission by any 
criteria over 1 year), IR = intermittent remission, SR = sustained remission, ns =  P > 0.05, * =  P ≤ 0.05, **  = P ≤ 0.01, *** =  P ≤ 0.001, **** =   P ≤ 
0.0001 using Mann-Whitney test (NR vs IR, IR vs SR, NR vs SR) 
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Figure 7-4. Impact of SR Compared With NR On HRQol 
A) HAQ, B) EuroQol, C) FACIT-F, D) SF36 PCS , E) SF36 MCS, Values expressed as medians with min and max range. NR = No Remission by any 
criteria over 1 year), IR = intermittent remission, SR = sustained remission, ns =  P > 0.05, * =  P ≤ 0.05, **  = P ≤ 0.01, *** =  P ≤ 0.001, **** =   P ≤ 
0.0001 using Mann-Whitney test (NR vs IR, IR vs SR, NR vs SR) 
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Figure 7-5 Spidergrams Showing 8 domains of SF36 in NR, IR and SR 
A) DAS28 remission, B) SDAI remission, C) Boolean Remission, PR = physical functioning, RP = Role-physical, BP = bodily pain, GH = general health, 
VT = vitality, SF = social functioning, RE = Role-emotional, MH = mental health, values expressed as median AUC values  
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Table 7-12 GEE analysis comparison Of HRQoL of no remission and SR  
Comparing no remission (NR) and different sustained remission groups (SR), GEE = General Estimating Equation Analysis 
Adjusted For Baseline HRQoL Values 
 
HRQoL 
NR vs DAS28 Remission NR vs SDAI Remission NR vs Boolean Remission 
Coefficient (95% CI) P value Coefficient (95% CI) P value Coefficient (95% CI) P value 
HAQ -0.27 (-0.56 ,  0.02) 0.065 -0.41 (-0.81, -0.22) 0.038 -0.36 (-0.76, 0.03) 0.07 
Eq5D 0.12 (0.07, 0.18) <0.0001 0.16 (0.103, 0.22) <0.0001 0.19 (0.13, 2.46) <0.0001 
FACIT-F 5.11 (1.13, 8.96) 0.009 9.97 (5.19, 14.76) <0.0001 9.86 (4.82, 14.90) <0.0001 
SF36 PCS 5.03 (2.41, 7.65) <0.0001 8.07 (5.6, 10.53) <0.0001 8.39 (6.49, 10.28) <0.0001 
SF36 MCS 4.22 (1.56, 6.88) 0.002 5.86 (2.53, 9.18) 0.001 7.04 (2.96, 11.05) 0.001 
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7.4 Discussion 
In the REMIRA cohort, significant differences were found in HRQoL outcomes 
within the different levels of low disease activity. The positive impact of point 
remission can be seen with all HRQoL at baseline and over time with all aspects of 
HrQoL outcomes when compared to LDAS. The impact of sustained remission on 
HRQoL is dependent on the remission criteria used. With the more lenient 
DAS28ESR and SDAI remission criteria, all 4 HRQoL outcomes showed 
improvement with increasing frequency of remission over time. With the most 
stringent ACR/EULAR Boolean remission criteria, the effects of intermittent and 
sustained remission were similar across all 4 HRQoL. 
 
HAQ has been shown to be a predictor of remission (Eberhardt, Fex 1998, Gossec 
et al. 2004). This study has shown that HAQ was also significantly lower in all 3 
point remission criteria compared to low disease activity state.  This was also 
shown in the BARFOT study (Svensson et al. 2013). The minimum clinical 
important difference (MCID) has been reported as greater than 0.22 in clinical 
trials (van Riel et al. 2008), however, the change in clinical practice has been 
reported as lower at 0.09 (Pope et al. 2009). The difference between LDAS and 
remission between any of the criteria were larger than the MCID. In the literature, 
HAQ score <0.5 is considered as remission (Molenaar, Voskuyl & Dijkmans 2002). 
However, the REMIRA study has demonstrated that levels achieved were lower 
than this (upper quartile range 0.125-0.5).  The median HAQ were all 0 in the least 
stringent DAS28ESR remission group and the stringent SDAI and Boolean groups 
suggesting that the assessment of HAQ in LDAS may have a floor effect. This may 
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also account for the results of the GEE analysis where there was no difference 
between LDAS and DAS28ESR after correcting for baseline HAQ. Disability and 
different remission criteria were explored in the DREAM cohort using anti-TNF. 
Their reported HAQ levels were higher than those in our study (de Punder et al. 
2012).  This is likely to be due to the fact that the DREAM cohort was more likely to 
have more severe disease given that they were all taking anti-TNF. The REMIRA 
median HAQ value was also lower than the original cut-off for predictive validity of 
the ACR/EULAR Boolean criteria (Felson et al. 2011).  
 
The minimum clinically important change (MCID) of Euroqol is 0.05 and EuroQol 
VAS of >82 is representative of population norms have been used in a previous 
study of RA (van Riel et al. 2008). Although the EuroQol and EurQol VAS values 
were high throughout our whole cohort, there were clinically meaningful 
differences in EuroQol between LDA and remission in all 3 remission criteria 
groups. With the more stringent criteria, EurQol scores were at the maximum 
level. In addition, the median EuroQol VAS (80) in DAS28ESR remission was just 
under the population norm, whereas in both the more stringent criteria SDAI and 
Boolean, their median VAS in the remission groups were higher at 90. There was a 
clear impact of point remission on EuroQol and EuroQol VAS over time. There was 
also a clear difference in better EuroQol with increasing frequency of DAS28ESR 
and SDAI remission. The EuroQol levels between SDAI and LDAS at baseline were 
comparable that found in the literature (Radner, Smolen & Aletaha 2014).  
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SF36 have extensive evidence on reliability and validity. It has demonstrated 
responsiveness to change in patients with RA (Ruta et al. 1998). The advantage of 
using SF36 is that it is compared to norms from a population of subjects with no 
known history of specified illness. The levels found in the REMIRA study were 
comparable to the literature (Radner, Smolen & Aletaha 2014). Across all 3 point 
remission, the SF36 PCS is the same as the population norm whereas the SF36 MCS 
is higher than the population norm. It is interesting to note that SF36 MCS values 
are higher than PCS in both LDA and remission groups. The MCID in both SF36 
MCS and PCS were 3 (Kosinski et al. 2000). This was reached in all 3 remission 
criteria compared to LDA groups. SF36 MCS and PCS improved. GH domain was the 
same between LDAS and DAS28IR as well as SDAI IR. Improvement was only seen 
in sustained remission. This again shows the importance of being in susatained 
remission.  
 
Fatigue is a common symptom in the majority of patients with RA and has been 
recommended to be an outcome measured in RA studies (Kirwan et al. 2007). 
FACIT-F has been validated for use in RA and the MCID has been reported as 3.56 
(Cella et al. 2005). The REMIRA cohort showed that patients in all 3 point 
remission states had clinically significant less fatigue than LDAS patients. This 
impact was seen throughout whole year of follow-up.  
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In all HRQoL measures, there was no difference between intermittent and 
sustained Boolean remission. This suggests that with stringent remission, 
intermittent remission maybe good enough to achieve maximal quality of life. 
 
In conclusion, HRQoL outcomes are the most important outcomes from the patient 
perspective and should be given as much importance as other RA outcomes. Point 
remission allows patients to achieve near normal function with significant impact 
on their disease over time. When considering sustained remission, Boolean 
remission may be ‘over-stringent’ since no differences were found between 
intermittent and sustained remission. This implies that any patients achieving 
Boolen remission is likely to have a better outcome. This study has demonstrated 
that in routine clinical practice, even patients in low disease activity states have 
limited HRQoL and therefore LDAS should not be used as a treatment goal for RA.  
  
8 Discussion 
The findings of this thesis have made a number of novel contributions towards 
understanding of remission in RA. There are three important findings. Firstly, the 
definition of remission and sustained remission have been characterised in detail 
using an extended range of clinical, laboratory and radiological biomarkers. Secondly, 
predictors of remission, both for remission at single time points and also for remission 
sustained over periods of time have been identified; these could guide treatment 
decisions in clinical settings. Thirdly, the study has shown the importance of aiming 
for sustained remission over low disease activity states to maximize the benefits to 
health related quality of life.  
 
8.1 Synopsis of key findings 
The systematic review found that remission is becoming a realistic therapeutic target 
in early RA. Observational studies showed an overall remission rate of 17% with 
modified old ACR remission criteria and 33% with DAS remission criteria. The RCTs 
showed that more patients achieved remission when combination treatments were 
used (random OR 1.69–2.01 compared to DMARD monotherapies). Radiological 
progression was less in patients receiving combination therapies who were in 
remission. Despite this, patients in clinical remission still had ongoing radiological 
progression. This suggests that true remission remains ill-defined using the available 
remission criteria.  
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A model was then created to predict which patients are more likely to achieve 
remission after 24 months of treatment. The Remission Score using simple clinical 
assessments correctly classifies over 70% of patients. The score is equally applicable 
in the clinical trial setting (CARDERA) as well as in the routine practice setting (ERAN 
cohort). Three variables – gender, age and baseline tender joint counts – are all that is 
required. There was a marked difference in the likelihood of remission between 
different groups. Males who are under 50 years of age with less than 6 tender joints 
were the most likely to be in remission at 24 months. The Simplified Remission Score 
is readily applied in routine practice, and is similar in approach to the Simplified 
Disease Activity Index (Gaujoux-Viala et al. 2012). The prediction model had good 
specificity but poor sensitivity. This suggests that other biomarkers are likely to be 
required.  
 
Next, it was assessed whether all patients responded to combination treatment in a 
similar fashion. Early intensive regimes have become the gold standard in the 
treatment of early RA. However, this study showed that the combination approach is 
only superior to monotherapy in certain subsets of patients. Stratifying patients 
according to gender, age, tender joint counts, RF IgM positivity and ACPA positivity 
can predict those subjects more likely to achieve remission states after 24 months of 
intensive treatment.  
 
After establishing which patients are most likely to achieve in remission, the next part 
of the thesis was to explore what happened to patients once they achieved a stable 
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low disease activity states. To address this, patients in stable low disease activity 
states were recruited to the REMIRA cohort and followed up for 1 year. Baseline 
remission rates ranged from 30% (Boolean remission) to 66% (DAS28 ESR 
remission). 47%, 33%, 22%, 23% and 10% of patients achieved sustained DAS28ESR, 
DAS28 CRP, SDAI, CDAI and Boolean remission respectively. 10% of patients did not 
achieve remission by any criteria at any point during the follow-up period (No 
remission group). In total, 13.5% of patients developed erosive progression over the 
follow-up period. There were no differences in power Doppler (PD) signal and 
synovial hypertrophy (SH) at baseline between NR and any of the remission groups. 
NR patients had significantly more SH at T12 compared to all 3 remission groups. 
There was a similar trend for higher PD scores at T12 but this did not reach 
significance (p value range 0.051 – 0.074). Both SH and PD at baseline were predictors 
of radiographic progression in low disease activity states.  
 
True remission should include stability of disease over time and therefore sustained 
remission should be the ultimate aim in therapy. Baseline predictors of sustained 
DAS28 and SDAI remission included ethnicity, ESR, CRP, TJC, Patient global 
assessment and physician assessment. Baseline predictors of sustained Boolean 
remission also included ESR, TJC, Patient global assessment, physician assessment but 
also the presence of erosions at baseline.  
 
Reliable assessment of remission is important for the optimal management of patients 
with RA. Clinical assessments of disease activity have been critised for being too 
subjective. Therefore more objective laboratory markers are required to supplement 
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clinical assessment of remission status. Analysis of serum samples from subjects 
enrolled in the REMIRA study has identified novel biomarkers which may contribue to 
defining low disease activity states. This cohort of patients who are clinically similar 
in phenotype shows marked heterogeneity at the molecular level. Despite this, we 
found several biomarkers which were able to define the different remission criteria. 
MBDA and some of its analaytes (hsCRP, SAA, IL6, Leptin), calprotectin and CXCL10 
were able to differentiate between LDAS and all 3 point remission criteria. In addition, 
TNFR1 and VCAM1 were able to differentiate between LDAS and DAS28ESR point 
remission. MBDA, hsCRP, SAA, IL6, leptin, CXCL10 levels at baseline or over 6 months 
were able to predict the frequency of remission over 12 months.  Calprotectin levels 
over 6 months but not at baseline were able to predict the frequency of remission 
over 12 months.  
 
Lastly, this thesis determined the impact of sustained remission versus low disease 
activity states from a patient’s perspective. The impact of point remission can be seen 
with all HRQoL at baseline and over time with all aspects of HrQoL outcomes. The 
impact of sustained remission on HRQoL is dependent on the remission criteria used. 
With the more lenient DAS28ESR and SDAI remission criteria, all 4 HRQoL outcomes 
showed improvement with increasing frequency of remission over time. With the 
most stringent ACR/EULAR Boolean remission criteria, the effects of intermittent and 
sustained remission were similar across all 4 HRQoL. 
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8.2 Strengths and Limitations 
8.2.1 Systematic review 
Strengths 
This was a comprehensive systematic review using observational studies and RCTs to 
assess the frequency of remission and the impact of treatment. An update was also 




This systematic review has several limitations. One issue is study heterogeneity. The 
studies varied in duration (12-120 months), design (observational and trials), 
treatment approaches (DMARD monotherapy and intensive combination regimens) 
and the classification of remission (ACR and DAS criteria). Most studies used single 
time-points to define remission; this was usually at the end of follow-up. Those 
studies reporting remission rates over prolonged periods recorded fewer remissions. 
Another limitation is focusing on early RA, thereby excluding studies of patients with 
undifferentiated early inflammatory arthritis. The Norfolk Arthritis Register (NOAR) 
exemplifies such studies; it shows there are more remissions in milder forms of 
arthritis (Symmons, Silman 2006). Older “classic” studies going back several decades 
were excluded. Changes in the management of RA over the last 20 years mean these 
historical studies have limited current relevance. In addition, the difference between 
the effects of monotherapies versus combination DMARD therapies may be 
exaggerated due to the choice of DMARD in the monotherapy arm. SSZ is often used as 
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DMARD monotherapy and is considered by some experts to be a ‘weaker’ DMARD in 
comparison to MTX, though the relative efficacy of different DMARDs is a contentious 
issue. There is also controversy over whether patients treated with steroids, 
particularly at high dosages can be considered as being in remission. Some of the RCTs 
did use high dose steroids at the beginning of treatment but these were rapidly 
reduced to 7.5mg. Low dose prednisolone was considered as acceptable and have 
included these in the analysis. In addition, it is important to bear in mind that 
differences between groups of patients are easier to demonstrate when there are high 
potentials for progression as opposed to low potentials for progression; the same is 
true in showing differences between highly effective and relatively ineffective 
treatments. Lastly, the use of Jadad score may be over-simplistic. It has been critised 
for not taking into account of allocation concealment.  
 
8.2.2 Predictors of Remission at 24 months and treatment response 
Strengths 
The strength of the prediction model was that it was created using a large RCT dataset 
and then validated in a cohort study. Unfortunately, since there was no serum 
available in the ERAN cohort, the second part of the study assessing treatment 
response could not be validated with the same method. However, there is 
confirmatory evidence in another publication which used the same dataset. This 
showed again that only ACPA status influences the need for combination DMARDs 
(Seegobin et al. 2014). 
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Limitations 
This study has several limitations. Firstly, it used data collected for other purposes 
and neither the clinical trial nor the observational study were powered to investigate 
remission. A far larger dataset is needed to investigate all the potentially relevant 
factors. Secondly, the treatments used in the RCT - Methotrexate, Ciclosporin and 
short-term high dose prednisolone - are not widely used as initial combinations in 
contemporary RA treatment. The findings in this study might not be generalisable to 
all intensive combination therapies. However, it is a well-recognised combination and 
many RCTs have demonstrated its efficacy. Ciclosporin is infrequently used in RA, 
though there is extensive evidence base for its use, which has been summarised in a 
Cochrane review by Wells et al. (Wells et al. 2000). Although it is both effective and 
relatively safe, other DMARDs like Sulfasalazine and Hydroxychloroquine are usually 
given in combination with Methotrexate. Thirdly, the RCT used fixed treatment 
regimens rather than the treat-to-target approach which is now widely used in early 
RA management. Further research is needed to assess the benefits and risks of “treat-
to-target strategies in ACPA negative disease. Fourthly, DAS28 remission criteria was 
used because it is readily achievable in clinical practice. Stricter remission criteria 
may be preferable in the longer term, such as the ACR/EULAR Boolean remission 
criteria. Fourthly, using a single time point at 2 years as the sole criterion for judging 
remission is insufficiently rigorous and ideally extended periods of remission would 
be a more clinically relevant target. However, a far larger database would be required 
for this purpose. Finally, although the specificity of our remission score is high, its 
sensitivity is relatively poor. The use of a more extended range of clinical and 
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laboratory markers might improve the prediction of remission in future and more 
research is needed in this area. 
 
8.2.3 The REMIRA cohort 
Strengths 
The strength of the REMIRA cohort is firstly that this is a large and unique cohort of 
RA patients with LDAS with detailed clinical assessments and a large biobank of 
biological materials collected serially over time. The second strength of this cohort lies 
in the frequency of follow-ups. Most papers reporting sustained remission over years 
with yearly follow-ups. As this study as demonstrated, in this unique cohort of 
patients with stable LDAS, disease activity can still be dynamic over a year. Therefore, 
the definition of sustained remission in this study which included being in remission 
at every time point 3 months apart for 1 year was very stringent. The original ACR 
remission criteria in the seminal report by Pinals et al in 1981 concluded ‘complete’ 
RA remission indicates the ‘total absence of articular and extraarticular inflammation 
and immunological activities’. Despite advances in therapies, this criteria is still to 
difficult to achieve. Within their criteria, they also incorporated time into the 
definition of remission. They chose 2 consecutive months. Other reports of sustained 
remission opted for much longer periods of remission. Jayakumar et al, 2012 
(Jayakumar et al. 2012) looked at sustained remission over 5 years and Prince et al., 7 
years (Prince et al. 2012). Currently, there is no consensus on what the optimal time 
should be. Within the REMIRA study, 1 year was chosen as it was thought to be a good 
balance between assessing the stability of disease activity and feasibility in clinical 
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practice. The agreement between the sustained remission criteria was slightly better 
than point remission. Thirdly, the strength of the ultrasound aspect of the study is that 
the same ultrasound machine was used for all patients with the same operator. There 
was good inter- and intra-observer agreement between the first and second readers. 
 
Limitations 
The main limitation of the study was related to the small number of patients in 
sustained remission and in the comparator group (NR group). Even though this 
remission cohort is more stringent than other cohorts previously reported (Brown et 
al. 2008), given the low prevalence of Boolean sustained remission and NR group, 
analysis was limited. In particular, multivariate logistic regression was not possible. 
Secondly, radiographic progression was defined as a binary outcome (new or 
worsening erosions). This may not have been a sensitive enough outcome for a cohort 
with similar disease activity. Other scoring methods may have been more suitable. 
However, it was decided that a binary outcome was preferable as there was less 
potential noise. Thirdly, as the patients in the different remission criteria overlapped 
with each other, it was not possible to compare parameters between the groups. 
Fourthly, BMI was not collected for the study and therefore it was not possible to 
correct for BMI when analyzing leptin levels. 
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8.3 Clinical implications of study 
The findings of each chapter have been discussed in detail within the individual 
sections. This section of the general discussion is to the highlight the clinical 
implications of these findings. 
8.3.1 Personalised medicine 
In the era where personalised medicine is becoming a reality, treatment of RA patients 
should be more individualised. This thesis suggests that both the remission score and 
serological status could be used as therapy decision tools. The results suggest that 
initial combination therapy may only be useful in certain subsets of early RA patients. 
It is premature to use the remission score for treatment decisions in routine practice; 
further work is required to validate this approach and to improve its specificity. Other 
biomarkers are likely to be required to achieve a personalised approach for the 
treatment of RA. However, the concept of a predictive remission score would be useful 
to tailor treatment regimes at an individual patient level.  The findings of the study 
challenge the established view that all RA patients should be given intensive 
combination treatment as recommended by NICE guidance. This study favours the 
more cautious approach in the 2013 EULAR guidance.  
  
8.3.2 Clinical and laboratory remission biomarkers  
The thesis has shown several clinical and laboratory remission biomarkers. Table 8.1 
summarised the continuous variables in order of effect size as defined standardized 
ORs. Baseline SAA was the best laboratory predictor of sustained DAS28 and SDAI 
remission whereas physician global assessment scores were the best clinical 
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predictors. It is interesting that similar predictors were found in both sustained 
DAS28 and SDAI remission. Baseline ESR, TJC and PhGA predicted Boolean remission 
perfectly. MBDA score was a predictor in all 3 sustained remission criteria but only a 
few of these biomarkers within the panel were shown to be important in predicting 
sustained remission. Out of the binary variables, ethnicity was a good predictor of 
sustained DAS28 and SDAI remission (ORs= 0.06 and 0.10 respectively) and having 
erosions on x-rays at baseline was a good predictor of boolean remission (OR = 13.50) 
 
The methodology used to create the remission score in Chapter 4 can be applied to 
sustained remission. Once the above variables can be validated as predictors of 
sustained remission, a clinical and extended REMIRA score can be developed, similar 
to the idea of SDAI and CDAI scores.  These will be very useful in clinical practice. 
These scores will be able to inform when patients are likely to remain in stable true 
remission over 1 year. If this can be determined, drug tapering can be considered. 
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Table 8-1: Summary of the predictors of sustained remission. 
The table summarises the continuous clinical and laboratory variables in order of 
standardized Odds ratios. * AUC value is used over baseline value as this 
preformed much better as a predictor.  
 
Remission Type Baseline Variable Standardised OR 
DAS28 
Serum Amyloid A  0.01 
Erythrocyte Sedimentation Rate 0.02 
C-Reactive Protein 0.05 
Physician Global 0.09 
Patient Global  0.15 
Calprotectin AUC* 0.19 
Tender Joint Count 0.25 
CXC motif chemokine 10  0.31 
Multi-biomarker Disease Activity  0.36 
High sensitivity C-Reactive Protein 0.38 
Leptin 0.54 
SDAI 
Physician Global Predicts perfectly 
Patient Global 0.02 
Serum Amyloid A  0.03 
Tender Joint Count 0.07 
C-Reactive Protein 0.09 
Calprotectin AUC* 0.11 
Erythrocyte Sedimentation Rate 0.25 
Multi-biomarker Disease Activity  0.28 
High sensitivity C-Reactive Protein 0.36 
Leptin 0.45 
Boolean 
Erythrocyte Sedimentation Rate Predicts perfectly 
Tender Joint Count Predicts perfectly 
Physician Global Predicts perfectly 
High sensitivity C-Reactive Protein 
AUC* 
0.03 
Patient Global 0.04 
Multi-biomarker Disease Activity  0.34 
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8.3.3 Role of ultrasound in remission 
From the systematic review, it is clear that sub-clinical inflammation is present in a 
significant proportion of RA patients in clinical remission leading to radiographic 
progression. This was confirmed in the REMIRA study. It is established that the 
presence of a PD signal predicts radiographic progression in low disease activity 
states (Brown et al. 2008, 618, Foltz et al. 2012), however, the role of SH is less clear. 
Boyesen found SH predicted 1 year MRI erosive progression in patients with active 
disease (Boyesen et al. 2011). The REMIRA sudy has demonstrated for the first time 
that synovial hypertrophy, as well as power Doppler, has a role in predicting 
radiographic progression in low disease activity states. In addition, synovial 
hypertrophy was also found to be less in all sustained remission groups at the end of 
the study compared to the LDAS group. This suggests that synovial hypertrophy can 
be reduced with stringent sustained remission. The clinical implication of this is 
treatment escalation should be considered in patients with LDAS who have power 
Doppler signal and/or synovial hypertrophy.  
 
More stringent criteria have been shown to be closely associated with less sub-clinical 
synovitis. Balsa et al., 2010, showed the superiority of SDAI over DAS28 remission 
criteria in the assessment of ultrasound-classified remission (Balsa et al. 2010). 
However, this was not substantiated in a paper by Saleem et al., 2011 which showed 
similar PD signal between DAS28, SDAI and Boolean remission (Saleem et al. 2011).  
The REMIRA study also did not find a role for ultrasound as a predictor of sustained 
remission.  
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8.3.4 Aim for remission, not LDAS, to optimise HrQOL 
Chapter 7 established that in clinical practice, in order to optimise quality of life of 
patients with rheumatoid arthritis, the aim of treatment should be to achieve 
sustained DAS28, sustained SDAI or at least intermittent Boolean remission. The 
REMIRA study has shown that disease activity can fluctuate over 1 year. In order to 
achieve sustained remission, it maybe necessary to keep patients under closer follow-
up than may be done in routine practice currently, where patients with LDAS or 
remission states are routinely followed up on a yearly basis.  
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8.4 Future studies 
8.4.1 The use of predictors of sustained remission in drug-tapering  
With the growing number of RA patients reaching remission, the new clinical problem 
is knowing how best to treat these patients once they achieve sustained remission. 
Once remission can be identified with certainty, tapering of DMARD treatment after 
sustained remission should the next goal in treatment. Several papers have been 
published on drug tapering and withdrawal. The BeST study which compared 4 
different treatment regimes in early RA patients: DMARD monotherapy, step up 
DMARD combinations, step-down DMARD combinations and infliximab with 
Methotrexate. When patients achieved remission, DMARDs were tapered and stopped. 
23% of patients achieved drug-free remission during the 5 year follow-up period 
(Klarenbeek et al. 2011). A meta-analysis of DMARDs withdrawal or tapering showed 
that the relative risk of flares in patients remaining on DMARDs compared to patients 
in whom DMARDs were stopped was 0.31 (95% CI 0.16, 0.57) (O'Mahony et al. 2010). 
This suggests that further work is required to establish reliable predictors of 
sustained remission upon drug-tapering.  
 
Currently, a follow-up study to the REMIRA is ongoing which will investigate the 
affects of biologics drug-tapering in patients with LDAS. This study is named: 
Optimising Treatment With Tumour Necrosis Factor Inhibitors In Rheumatoid 
Arthritis: Is Dose Tapering Practical In Good Responders? (OPTTIRA study, Table 8.2). 
This randomised trial will study the following in patients tapering TNF inhibitors and 
controls: 
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a. The risk of disease flares (DAS28 increases ≥0.6). 
b. If flares are reversed by reverting to the original TNF inhibitor dosage. 
c. If either tapering group shows worse key RA assessments including disease activity 
(DAS28) and disability as measured by health assessment questionnaire (HAQ) 
scores. 
 
Ultimately, an RCT should be designed to address DMARDs drug-tapering directly. 
Once predictors of sustained remission are established, a remission alogorithm could 
be established to guide treatment taper. To test the validity of this approach, an RCT 
with 3 treatment arms will be required: 
1) Standard Care Treatment with no tapering of medication 
2) Standard Care treatment with tapering of DMARDs which will be guided by 
clinicians 
2) DMARD drug tapering based on the remission algorithm.  
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 Table 8-2 Protocol for the OPTTIRA Study 
 
TITLE 
Optimising Treatment With Tumour Necrosis Factor Inhibitors In Rheumatoid Arthritis: Is Dose Tapering 
Practical In Good Responders? A “Proof Of Principle” And Exploratory Trial. 
HYPOTHESIS 
Tapering TNF inhibitors (to a minimum of one third of the initial “induction” doses) will not adversely affect 
disease control in established RA patients who have achieved a good response to standard doses of TNF 
inhibitors and are also receiving disease modifying anti-rheumatic drugs (DMARDs). We consider an 
increase of disease activity score (DAS28) ≥0.6 represents a clinical important change. 
TRIAL DESIGN 
Randomised controlled, open label multicentred, proof of principle trial followed by open exploratory phase 
trial in patients with established RA who have achieved a good response to standard doses of TNF inhibitors 
and are also receiving disease modifying anti-rheumatic drugs (DMARDs). Follow-up period =  12 monhths 
INCLUSION CRITERIA 
 RA by American College of Rheumatology and EULAR criteria 
 Etanercept or Adalimumab treatment for at least 6 months (a break of up to 4 consecutive weeks is 
permitted). 
 Taking at least one DMARD  
 Stable clinical response for ≥ 3 months (one DAS28 score ≤ 3.2; no increase in DAS28 > 0.6) 
 Patient considers he or she has achieved a suitable response to TNF inhibitors. 
 Supervising rheumatologist considers further improvements are unlikely on the patient’s current 
treatment regimen. 
 At least 18 years of age. 
 Willing and able to give informed consent. 
EXCLUSION CRITERIA 
 Serious concurrent illness (e.g. terminal cancer). 
 Prednisolone at more than 10mg daily (for doses > 10mg daily, a 4 week washout period is required). 
 Recently received IM/IA steroids (12 weeks washout required) 




Visits at baseline, 3, 6, 9 and 12 months using standard validated questionnaires, and there will be monthly 
telephone calls between visits. X-rays of hands and feet will be taken at baseline, 6 months and 12 months. 
Patients will be monitored via blood tests as set out in current guidelines for all DMARDs and TNF inhibitors. 
BIOMARKER SUB-STUDY 
The study will also include an optional Biomarker Sub-study which will aim to identify patients who are in 
true remission, based on clinical, imaging and laboratory parameters. These parameters will be used to predict 
those subjects most likely to tolerate TNF tapering and/or withdrawal in the OPTTIRA study.Study subjects 
in true remission would be predicted to best tolerate drug withdrawal. 
The Sub-study is optional for participants and blood samples will be collected from experimental groups 1 
and 2 at the baseline assessment and at the 6 month assessment for participants in the control group. 
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8.4.2 Ongoing Research 
The REMIRA study has contributed to the development of 2 new studies: 
a) Towards a cure for early Rheumatoid arthritis (TACERA study, Table 8.3). This is 
longitudinal observational cohort study with early seropostivie RA patients. The aims 
of this study are firstly to apply a combination of clinical and laboratory parameters to 
predict clinical responses to disease modifying drugs in patients with recent onset RA; 
secondly to use laboratory parameters to monitor biological responses to therapy; 
and thirdly define a true biological remission state in patients with early RA. Such an 
approach to therapeutic decision-making means that patients receive the drug 
combinations most likely to induce and sustain remission. The clinical and laboratory 
biomarkers from the REMIRA study have helped with the development of these 3 
aims. 
 
b) Treatment intensities and targets in rheumatoid arthritis therapy (TITRATE) study 
(Table 8.4). This is a RCT comparing the intensive management compared to standard 
care on remission rates at 12 months in rheumatoid arthritis patients with 
intermediate disease activity. The primary endpoint of the study is to assess the 
number of patients in each treatment arm fulfilling the definition of remission as 
measured by DAS28-ESR. The role of the novel biomarkers identified in the REMIRA 
study will also be investigated in this study. 
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Table 8-3 Protocol for the TACERA Study 
 
Study Design 
A longitudinal observational study of an early RA inception cohort over 18 months 
Working Hypothesis 
A suite of immunological assays (“the immunological toolkit”) can be used to accurately predict 
clinical responses to therapy at a molecular and cellular level. We also propose that immune based 
assays can be adapted to define an immune signature associated with a state of sustained clinical 
remission in patients with early RA. This study protocol seeks to recruit a large cohort of patients 
with early RA. Biological samples will be acquired from study subjects and used to develop the 
immunological toolkit, through the identification of baseline biomarker signatures (prior to starting 
therapy), and by documenting the changes in the immune system in response to therapeutic 
intervention. 
Key Inclusion Criteria 
 Diagnosis of early RA using either 1987 ACR or the 2010 ACR/EULAR criteria 
 Positive for serum rheumatoid factor and anti-citrullinated protein autoantibodies (ACPA) 
 Within 12 months of symptom onset 
 Able and willing to give informed consent to provide clinical data and blood samples at 
defined time points for the duration of the study 
 Aged over 18 years 
Key Exclusion Criteria 
 Previous treatment with DMARDS or biologics 
 Corticosteroid treatment for the current episode of inflammatory arthritis within the last 12 
months 
 Pregnant 
 Significant co-morbidities 
Study treatment 
The study is observational an oberservational study where patients will receive routine clinical care 




Visits will comprise a detailed assessment of disease activity (including standard blood monitoring 
for DMARDs, TNF inhibitors or other biological agents, as appropriate) along with completion of a 
number of questionnaires and the provision of additional blood and urine samples for 
immunoanalysis. X-rays of the hands and feet will be taken at Baseline, 12 and 18 months. Where 
Ultrasound scanning is offered as part of routine care participants may have high resolution 
ultrasound scanning (HRUS) of affected joints performed at Baseline, 6, 12 and 18 (optional) months. 
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Table 8-4 Protocol for the TITRATE Study  
 
Study Design 
A pragmatic randomised controlled open trial of the effect of intensive management (IM) compared 
with standard care (SC) on remission rates at 12 months in rheumatoid arthritis patients with 
intermediate disease activity.  
Working Hypothesis 
Patients with established RA (of at least 6 months duration), who currently have intermediate 
disease activity (defined as DAS28-ESR 3.2-5.1 with at least 3 active joints) and are currently 
receiving at least one DMARD, are more likely to achieve remission at 12 months if they receive 
intensive management than if they continue to have standard care.  
Key Inclusion Criteria 
 Aged over 18 years 
 Diagnosis of rheumatoid arthritis for 6 months-10 years 
 Have intermediate disease activity (DAS28-ESR 3.2-5.1 with at least 3 active joints) 
 Have received at least one DMARD for a period of six months or more.  
 
Key Exclusion Criteria 
 Participants who have failed ≥5 DMARDS or have received biologics 
 Have irreversible disability from extensive joint damage 
 Have major comorbidities (e.g., heart failure) 
 Are pregnant, breast-feeding or at risk of conceiving 
 Are unable or unwilling to give informed consent 
 Are currently or have recently participated in another interventional trial or are currently in an 
early RA pathway.  
 
Study treatment 
Intervention group: Intensive Management will involve monthly clinical reviews which will allow 
immediate adjustments of patients’ management in response to their clinical status. Part of the 
management will be the optimal intensive use of standard drug treatments. These will all be given 
within their licensed indication, at licensed doses and routes of administration. Intensive 
management will also involve supportive non-drug interventions which will be individualised to 
meet patients’ specific needs. These non-drug approaches will be combined in a ‘treatment support’ 
programme. They will span psychoeducation, goal-setting and skills teaching to address identified 
problem areas, such as pain, fatigue and low physical activity, and will be outlined in a treatment 
support manual.  
Comparator group: Standard care, which consists of at least one routine clinical review.  
Sample Size 
398  Patients. 
Assessments: 
All patients will be assessed at baseline, 6 months and 12 months. In addition, the intensive group 
will be assessed monthly fro treatment changes according to protocol in the first 6 months.  
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8.4.3 Peripheral blood mononuclear cells signatures of remission (PBMCs)  
Adaptive immunity underpins RA synovitis, shown by its strong HLA-DRB1 
association, confirmed in genome wide association studies, and the efficacy of 
costimulatory blockade and B cell therapies (Cope 2008, Kremer et al. 2003, Edwards 
et al. 2004). But the use of cell based immunoassays for clinical decision making is less 
advanced. There is a need to identify immune cell signatures reflecting disease 
activity; identifying LDA signatures is one possible example. Four subsets of atypical 
CD4+ T lymphocytes are implicated in RA pathogenesis and persistence. Unlike 
conventional Th effector T cells, whose differentiation depends on antigen specific 
TCR ligation, unconventional subsets emerge in response to chronic inflammatory 
cytokine signals: 
 Subset Of Inflammation Related Cells (IRC): these reflect a distinct 
CD45RBbright, CD45RA+, CD45ROdim and CD62L- phenotype; cytokine drive 
may be important for expansion and/or maintenance of IRC (Ponchel et al. 
2002).  
 Cytokine stimulated T cells (Tck): this cell population, identified by Brennan 
and colleagues, resemble RA synovial T cells; they are potent inducers of 
contact-dependent TNF production by monocytes (Brennan et al. 2002, 
Brennan et al. 2008). 
 Antigen Experienced T Cells with reduced expression of TCRz (TCRzdim): 
several groups, including our own, have identified these cells, which migrate to 
inflammatory sites like RA synovia, and accumulate in peripheral blood (PB) 
when migration is blocked in vivo with TNF blockers (Zhang et al. 2007, 
Maurice et al. 1997). 
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Atypical, cytokine driven T cells share the expression of cell surface antigens 
associated with abnormal or terminal differentiation, persistence of effector function 
and enhanced migratory competence. Exclusion of IRC and TCRzdim T cells from 
peripheral tissues and their accumulation in PB is linked to remission (Burgoyne et al. 
2008). Interestingly, persistence of IRC in RA patients achieving remission predicted 
disease flares in >70% patients within 18 months. Their persistence implies 
incomplete suppression of synovitis, undetectable using conventional clinical 
assessments. These results suggest that: 
1) Effector T cell subsets: these accumulate in PB in response to DMARD or 
biological therapy, as a consequence of endothelial cell de-activation and 
inhibition of cell migration. 
2) Increased atypical T cells: will identify patients with erosive disease likely to 
flare on tapering DMARDs 
3) Low numbers of unconventional T cells in PB: should predict stable LDA 
without erosive progression. 
 
Distinguishing these subsets of patients could help define patients in ‘immunological’ 
remission. During the REMIRA study, PBMCs were collected at all timepoints and 
stored in liquid nitrogen. It is likely that immunophenotyping using flow-cytometry 
will also contribute to a more accurate definition of true remission and hence in turn, 
play a role in predicting sustained remission 
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8.4.4 Gene expression profiling to predict flares 
This technology has evolved from studying selected gene sets to whole genome 
screening where all genes expressed are sampled at single time points. Microarray 
technology permits the acquisition of comprehensive profiles (gene expression 
signatures) unique to a tissue or cell type.  This unbiased approach also: (i) identifies 
the coordinated expression of large panels of known genes; (ii) provides insights into 
common pathways of gene regulation; (iii) may identify unique patterns of novel 
genes; (iv) facilitates the identification of novel therapeutic targets in distinct patient 
subsets. No published studies report comprehensive analysis of remission-specific 
gene expression signatures in RA, with the exception of a recent study of spontaneous 
(drug free) remission in a cohort of pregnant RA patients (Haupl et al. 2008). Pregnant 
RA patients had similar PB gene expression profiles to healthy women in the third 
trimester, showing that in drug free remission biological signatures normalise in RA 
patients. Identifying related signatures in RA patients with LDA states would be a key 
advance as it could identify patients suitable for treatment tapering or withdrawal.  
 
The REMIRA cohort will be used to explore the role of gene expression in predicting 
flares. Baseline samples of patients who flared during follow-up were compared to 
patients who have remained in sustained remission. These samples were matched for 
age, gender, treatment and disease activity at baseline. Transcriptomic data on over 
70 samples have been acquired so far. Analysis is ongoing currently.  
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8.4.5 Health economics of sustained remission.  
Whilst the impact of sustained remission on the quality of life was evaluated in this 
study, its cost-effectiveness has not been explored. A systematic review showed that 
treatment strategies leading to maintenance of physical function and keeping patients 
at work are cost effective even when including biological agents (Schoels et al. 2010). 
A recent study by Radner et al showed that patients in point remission had better 
work productivity, lower indirect and direct costs when compared to LDAS state 
(Radner, Smolen & Aletaha 2014). HAQ and EuroQol have been used to calculate cost-
effectiveness of biological therapies in NICE guidance (NICE 2009). Therefore, a 
similar approach can be taken to assess the cost-effectiveness of keeping patients in 
sustained remission.  
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9 Conclusions 
Remission is the ultimate goal when treating patients with RA. The seminal report by 
Pinals et al in 1981 suggested that “complete” RA remission should indicate the “total 
absence of articular and extraarticular inflammation and immunological activities”. 
Since that time, there have been uncertainties on how best to define remission states. 
This thesis had made contributions to knowledge about how to define remission and 
also have important implications for clinical practice.  
 
The impact of the length of time in remission has been demonstrated. True remission 
implies stability over time. The treat-to-target approach is the gold-standard 
treatment for RA. Guidelines propose close monitoring of patients are required for 
intensive escalation of treatment for patients with active disease. This thesis study 
shows that even after reaching remission, strict monitoring is required, as only a small 
proportion of patients achieve sustained remission.  
 
Targeted treatment should take into account the relative chance of entering state of 
sustained remission. Not all patients have the same likelihood of achieving remission.  
In an era where treatments are increasingly targeted at a molecular level, it is 
important that monitoring treatment responses progresses to reflect such specific 
therapies. Laboratory biomarkers, beyond ESR and CRP, are likely to play crucial roles 
in defining disease activity and remission in the future. This thesis has identified 
several novel serum biomarkers that could differentiate small changes in disease 
activity even at the low end of the disease activity. Molecular markers of inflammation 
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may be included in the evaluation of patients with low disease activity states to define 
remission states. The use of clinical predictors and as well as these novel biomarkers 
may help to stratify patients who are more likely to stay in sustained remission and 
help in decision making with treatment changes.  
 
With the growing emphasis on personalised medicine, this thesis brings us one step 
closer to achieving individualised care. Ultimately, these findings can be used to define 
true remission and allow treatment to be tapered. This in turn will reduce the cost and 
toxicity of treatment, benefiting the NHS and patients alike. 
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1. Clinical and serological predictors of remission in Rheumatoid Arthritis is 
dependent on treatment regimes. Ma MHY, Scott IC, C Dahanayake, Cope AP 
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2. ACPA-positive and ACPA-negative rheumatoid arthritis differ in their 
requirements for combination DMARDs and corticosteroids: secondary 
analysis of a randomized controlled trial. Seegobin SD, Ma MH, Dahanayake C, 
Cope AP, Scott DL, Lewis CM, Scott IC Arthritis Res Ther. 2014 Jan 16;16 
3. Randomised controlled trial of tumour-necrosis-factor inhibitors against 
combination intensive disease modifying anti-rheumatic drugs in established 
rheumatoid arthritis: The TACIT trial  DL Scott, F Ibrahim, V Farewell,  AG 
O'Keeffe,  MHY Ma,  D Walker,  M Heslin, A Patel, G Kingsley. Accepted for 
publication to HTA 
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Young A, Scott DL.J Rheum 39 (3):470-5. Also published in Clinical highlights 
for Rheumatologists March 2012 Volume 1, Issue 3 Page 1  
6. Safety of combination therapies in early RA: a systematic comparison between 
combination DMARDs and TNF inihibitors with Methotrexate.  Ma MHY, Cope 
AC, Scott DL. Int. J. Clin. Rheumatol. 2010 5(5), 547–554 
7. Remission in Early Rheumatoid Arthritis. Ma MHY, Scott IC, Kingsley GH, Scott 
DL. J Rheum 2010 37:1444-53 
 
Reviews  
1. Editorial: Adding New Perspectives To The Kaleidoscope Of Remission Criteria 
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11.2 Presentations at conferences 
2014 BSR conference, Liverpool, Poster presentation 
 The REMIRA study: The impact of sustained remission on health-related 
quality of life in rheumatoid arthritis patients with low disease activity state.  
2013  EULAR conference, Madrid. Poster: A multi-biomarker disease activity 
(VECTRADA algorithm) score and components are associated with sustained 
clinical remission in rheumatoid arthritis: The REMIRA study.  
2013 BSR conference, Birmingham. Poster presentations: 
1. Rheumatoid Factor IgA  (RF IgA) and Anti-cyclic citrullinated peptides 
antibodies (ACPA) – predictors of radiographic progression. 
2. Systematic review comparing combination DMARD therapy with anti-TNF 
plus Methotrexate in drug resistant Rheumatoid Arthritis 
3. Serological status - a predictor of response to intensive therapy in 
Rheumatoid Arthritis (Guided poster) 
2013 Spring Meeting for Clinician Scientists in Training (Guided poster): Serological 
status - a predictor of response to intensive therapy in Rheumatoid Arthritis  
2013 Best Practice in RA management, London (talk): What happens to patients in 
remission? 
2012 BSR (Glasgow, Guided poster): Biomarker signatures in RA patients with LDA: 
The REMIRA study 
2011  ACR conference (Chicago, USA, Poster): Biomarker signatures in RA patients 
with LDA: The REMIRA study 
2011 BSR conference (Brighton, UK, Poster): Persisting Remission is essential to 
achieve low HAQ score in RA. 
2010  ACR conference (Atlanta, USA, Poster) Safety of combination therapies in early 
RA: a systematic comparison between combination DMARDs and TNF 
inihibitors with Methotrexate.   
2010  BSR Conference (Birmingham, UK): Talk: Treatment decisions in RA: Are we 
undertreating the elderly? 
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11.3 Jadad score 
Items Score 
Was the study described as randomized? 0/1 
Was the method used to generate the sequence of 
randomization described and was it appropriate? 
0/1 
Was the study described as double-blind? 0/1 
Was the method of doble-blinding described and 
was it appropriate?  
0/1 
Was there a description of withdrawals and 
dropouts 
0/1 
Deduct 1 point if the method used to generate 
sequence of randomised was described but 
inappropriate 
0/-1 
Deduct 1 point if the study was described as double-
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11.4 MBDA algorithm. 














All biomarker concentrations are in pg/ml.   
EGF = epidermal growth factor; IL-6 = interleukin-6; MMP = matrix metalloproteinase; 
PPG = predicted patient global; PSJC = predicted swollen joint count; PTJC = predicted 
tender joint count; SAA = serum amyloid A; TNF-R1 = tumor necrosis factor receptor 
superfamily member 1A ; VCAM-1 = vascular cell adhesion molecule 1; VEGF-A = 
vascular endothelial growth factor-A; YKL-40 = human cartilage glycoprotein 39. 
 
  
11.5  Example of the follow-up page on the REMIRA ACCESS database 
 
  308 









Date:   
  
11.7 Patient information leaflet for the REMIRA study (Healthy controls) 
THE REMIRA STUDY - DEFINING LOW DISEASE ACTIVITY STATES 
IN RHEUMATOID ARTHRITIS USING CLINICAL, IMAGING AND BIOLOGICAL MEASURES 
 
PRINCIPLE INVESTIGATORS: PROF DAVID SCOTT AND PROF ANDREW COPE 
 
You are being invited to take part in this research project. Before you decide, it is 
important for you to understand why the research is important and what it will 
involve. Please take time to read the following information carefully. Talk to your 
family and friends about the study if you wish. Please ask us if there is anything that is 
not clear or if you would like more information. Take time to decide whether or not 
you wish to take part.  
 
What is the purpose of the study? 
The treatment of Rheumatoid Arthritis has improved dramatically in recent years. The 
use of earlier and more intensive therapy means that the disease can now be 
controlled much more effectively. The aim of current treatment strategies is to induce 
a ‘Low Disease Activity State’ (LDAS), where there is minimal joint inflammation, 
which means minimal tender and swollen joints.  Minimal joint inflammation is good 
as it reduces joint damage and disability.  However, the way we currently measure 
disease activity in patients with RA in the clinic is not ideal for patients in LDAS. The 
aim of this study is to improve disease activity scoring systems for LDAS by using a 
combination of clinical, imaging (such as X-ray and ultrasound) and blood markers. 
This is important because some RA patients continue to develop joint damage in spite 
of low disease activity scores. This study will try to identify those patients who will 
develop further joint damage by measuring their white blood cells, the activity of 
genes that we think are involved in the disease process and by genetic testing. We 
hope in the future that we will be able to use the results of these blood tests to identify 
those patients with true LDAS in whom we can safely reduce therapy, as well as those 
patients likely to develop joint damage who would need to continue, or even, intensify 
therapy.  
 
Why have I been invited to participate? 
You are a healthy person with no evidence of rheumatoid arthritis. Your immune cells 
and genes function normally. We would like to compare immune cells and activity of 
genes in healthy individuals with RA patients. The differences and similarities will 
provide vital information of the different disease activity states in RA.  
 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you do, you will be asked to 
sign a consent form to show you have agreed to take part. You are still free to 
withdraw at any time and without giving a reason.  
 
What will happen if I take part? 
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If you agree to take part, no more than 50ml of blood will be taken for research 
purposes. This will take about 10 minutes. You may experience slight discomfort 
and/or minor bruising as a result of giving the blood sample. If you wish to stop at any 
time during the donation, you are able to do so.  
 
What are the possible benefits of taking part? 
There will not be a direct benefit to you following your participation, but the 
information we get might help to develop new management approaches for patients 
with rheumatoid arthritis.  
 
Will my taking part in this study be kept confidential? 
Yes. We will follow ethical and legal practice and all the information about your 
participation in this study will be kept confidential. Once we have collected the blood, 
all identifiable tags will be replaced by a code. Only the researchers involved in the 
study will be able to view the identifiable data, which are kept in a secure place.  
 
What happens to the results from this study?  
Results from this study may be published in scientific articles or presentations, 
although you may not be made aware of these. You will not be identified in any 
reports of publications.  
 
Will any genetic tests be done? 
As part of this study, participants will have genetic testing done on blood samples to 
see if carrying different genes will influence whether people with arthritis achieve low 
disease activity states.  Genetic tests for other, unrelated conditions will not be tested. 
Using a different technique, we will also compare the activity of a large number of 
genes using a technique called ‘gene expression profiling’. This will measure the 
activity of thousands of genes at once to create a global picture of the function of cells 
in the blood. These tests may help us identify study participants whose disease is in 
remission and provide important clues as to why arthritis continues to cause joint 
damage in a subset of study subjects.   
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should speak to the research 
team who will do their best to answer your question. If you remain unhappy and wish 
to complain formally, you can do this through the formal NHS complaints procedure. 
Details can be obtained from the hospital.  In the unlikely event that something does 
go wrong and you are harmed during the research and this is due to someone’s 
negligence then you may have grounds for a legal action for compensation against the 
NHS Trust administering your care.  You may have to pay your legal costs. The normal 
NHS complaints mechanisms will still be available to you.  
 
Who is organising and funding the research? 
This project is funded by the National Institute of Health and Research (NIHR). 
 
Who has reviewed the study? 
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All research in the NHS is reviewed by an independent group called a Research Ethics 
Committee to protect your safety, rights, well-being and dignity. This study has been 
reviewed by the Wandsworth Research Ethics Committee. Your hospital Research and 
Development Department has also approved this project.  
 
 
We would like to thank you for considering taking part or taking time to read this 
sheet.  
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11.8 Patient information leaflet for the REMIRA study (Remission patients) 
REMIRA STUDY: DEFINING LOW DISEASE ACTIVITY STATES (LDAS) IN 
RHEUMATOID ARTHRITIS USING CLINICAL, IMAGING AND BIOLOGICAL MEASURES. 
 
Principle Investigators: Prof David Scott and Prof Andrew Cope 
 
You are being invited to take part in this research project. Before you decide, it is 
important for you to understand why the research is important and what it will 
involve. Please take time to read the following information carefully. Talk to your 
family and friends about the study if you wish. Please ask us if there is anything that is 
not clear or if you would like more information. Take time to decide whether or not 
you wish to take part.  
 
Part 1 tells you about the purpose of this study and what will happen to you if you 




What is the purpose of the study? 
The treatment of Rheumatoid Arthritis has improved dramatically in recent years. The 
use of earlier and more intensive therapy means that the disease can now be 
controlled much more effectively. The aim of current treatment strategies is to induce 
a ‘Low Disease Activity State’ (LDAS), where there is minimal joint inflammation, 
which means minimal tender and swollen joints.  Minimal joint inflammation is good 
as it reduces joint damage and disability.  However, the way we currently measure 
disease activity in patients with RA in the clinic is not ideal for patients in LDAS. The 
aim of this study is to improve disease activity scoring systems for LDAS by using a 
combination of clinical, imaging (such as X-ray and ultrasound) and blood markers. 
This is important because some RA patients continue to develop joint damage in spite 
of low disease activity scores. This study will try to identify those patients who will 
develop further joint damage by measuring their white blood cells (T cells, B cells and 
monocytes), the activity of genes that we think are involved in the disease process and 
by genetic testing. We hope in the future that we will be able to use the results of these 
blood tests to identify those patients with true LDAS in whom we can safely reduce 
therapy, as well as those patients likely to develop joint damage who would need to 
continue, or even, intensify therapy.  
 
 
Why have I been invited to participate? 
Currently, the treatment you are receiving seems to be working very well and your 
disease is under good control.  You fulfil the criteria for ‘Low Disease Activity’.  
 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you do, you will be asked to 
sign a consent form to show you have agreed to participate. You are still free to 
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withdraw at any time and without giving a reason. A decision to withdraw at any time 
or a decision not to take part, will not affect the standard of care you receive.  
 
What will happen if I take part? 
You will be monitored in the outpatient’s clinic for 1 year while you continue with 
your current treatment. You will be seen initially at the start of the study, and then 
three monthly until 12 months. The activity of your arthritis will be assessed in detail 
and you will be asked to complete questionnaires about the way in which the arthritis 
is affecting your life. We will also take blood tests during these visits. We will take no 
more than 50ml of blood (less than half a tea cup full) during each visit; these blood 
samples will be taken at the same time as the samples we take for routine monitoring 
of your treatment. Ultrasound scans of your joints will also be carried out some of 
these visits (similar to those used during pregnancy to visualise the foetus). At the 
beginning and end of the study, we will also carry out X-rays of your hands and feet. In 
total, these visits will last about 2 hours.  These tests will help us to establish whether 
there has been any damage to your joints during this period of LDA.  
 
What are the advantages of taking part? 
You will be monitored more closely than routine care. In particular, the use of 
ultrasound and certain blood tests are not currently available to all patients in routine 
clinical practice. In the future, the aim will be to make these technologies available to 
all our patients if it is proven to be useful. 
 
What are the possible disadvantages and risks of taking part? 
Your arthritis treatment will not be altered because of this study, so there are no real 
disadvantages or risks from taking part in the trial.  
 
 
Ionising Radiation (Medical Exposure) Regulations – IRMER 
While all patients with a new diagnosis of Rheumatoid Arthritis will have X-rays taken 
of their hands and feet at the beginning of their treatment, it has become standard 
practice for patients to have X-rays carried out annually to monitor their treatment. 
Therefore, we will use these X-rays in this study to monitor progression of joint 
damage. The dose you will receive from the two sets of x-rays is very small and 
equivalent to 3 days of natural background level of radiation. 
 
What happens when the research study stops? 
All participants will continue with their routine clinical care. 
 
Will my taking part in this study be kept confidential? 
Yes. We will follow ethical and legal practice and all the information about your 
participation in this study will be kept confidential. The details are in Part 2. 
 
Part 2 
What if there is a problem? 
If you have a concern about any aspect of this study, you should speak to the research 
team who will do their best to answer your question. If you remain unhappy and wish 
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to complain formally, you can do this through the formal NHS complaints procedure. 
Details can be obtained from the hospital.  In the unlikely event that something does 
go wrong and you are harmed during the research and this is due to someone’s 
negligence then you may have grounds for a legal action for compensation against the 
NHS Trust administering your care.  You may have to pay your legal costs. The normal 
NHS complaints mechanisms will still be available to you.  
 
Will my taking part in this study be kept confidential? 
If you join the study, some parts of your medical records and the information collected 
for the study will be analysed by our team.  The research team will have a duty of 
confidentiality to you as a study participant.  We will do our best to meet this duty. All 
information that is collected about you during the course of the research will be kept 
strictly confidential, and any information about you that leaves the hospital will have 
your name and address (except your postcode) removed so that you cannot be 
recognised.  
 
Involvement of your GP 
We will notify your GP about your participation in the trial.  
 
What will happen to any samples I give? 
Only researchers and their designated collaborators involved in this study will have 
access to your blood samples. Upon collection, we will isolate blood serum, white 
blood cells, RNA and DNA from your blood using special techniques in the laboratory. 
These will then be analysed in the laboratory using a variety of different methods. We 
may need to store the samples for up to 10 years until we can perform a complete 
analysis. It is likely that new tests, not specified in this sheet, may become available 
for studying low disease activity. We therefore seek your permission to use your 
samples in future studies relating to disease activity. At the end of the 10 year period, 
all samples will be destroyed.  
 
Will any genetic tests be done? 
As part of this study, participants will have genetic testing done on blood samples to 
see if carrying different genes will influence whether people with arthritis achieve low 
disease activity states.  Genetic tests for other, unrelated conditions will not be tested. 
Using a different technique, we will also compare the activity of a large number of 
genes using a technique called ‘gene expression profiling’. This will measure the 
activity of thousands of genes at once to create a global picture of the function of cells 
in the blood. These tests may help us identify study participants whose disease is in 
remission and provide important clues as to why arthritis continues to cause joint 
damage in a subset of study subjects.   
 
What will happen to the results of the research study? 
The overall results of the trial will be collected by the Chief Investigators. We intend to 
present and publish the findings to inform others about this trial. This will take at 
least 4 years from the beginning of the trial. When the results are published, we will 
be happy to make them available to all those who took part. No individual study 
participant will be identified in any report or publication from this study.  The results 
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Who is organising and funding the research? 
This project is funded by the National Institute of Health and Research (NIHR) 
Doctoral Research Fellowship (DRF) awarded to Dr Margaret Ma. 
 
 
Who has reviewed the study? 
All research in the NHS is reviewed by an independent group called a Research Ethics 
Committee to protect your safety, rights, well-being and dignity. This study has been 
reviewed by the Wandsworth Research Ethics Committee. Your hospital Research and 
Development Department has also approved this project.  
 
We would like to thank you for considering taking part or taking time to read this 
sheet.  
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11.9 Patient information leaflet for the REMIRA study (Active RA controls) 
THE REMIRA STUDY - DEFINING LOW DISEASE ACTIVITY STATES 
IN RHEUMATOID ARTHRITIS USING CLINICAL, IMAGING AND BIOLOGICAL MEASURES 
 
PRINCIPLE INVESTIGATORS: PROF DAVID SCOTT AND PROF ANDREW COPE 
 
You are being invited to take part in this research project. Before you decide, it is 
important for you to understand why the research is important and what it will 
involve. Please take time to read the following information carefully. Talk to your 
family and friends about the study if you wish. Please ask us if there is anything that is 
not clear or if you would like more information. Take time to decide whether or not 
you wish to take part.  
 
What is the purpose of the study? 
The treatment of Rheumatoid Arthritis has improved dramatically in recent years. The 
use of earlier and more intensive therapy means that the disease can now be 
controlled much more effectively. The aim of current treatment strategies is to induce 
a ‘Low Disease Activity State’ (LDAS), where there is minimal joint inflammation, 
which means minimal tender and swollen joints.  Minimal joint inflammation is good 
as it reduces joint damage and disability.  However, the way we currently measure 
disease activity in patients with RA in the clinic is not ideal for patients in LDAS. The 
aim of this study is to improve disease activity scoring systems for LDAS by using a 
combination of clinical, imaging (such as X-ray and ultrasound) and blood markers. 
This is important because some RA patients continue to develop joint damage in spite 
of low disease activity scores. This study will try to identify those patients who will 
develop further joint damage by measuring their white blood cells, the activity of 
genes that we think are involved in the disease process and by genetic testing. We 
hope in the future that we will be able to use the results of these blood tests to identify 
those patients with true LDAS in whom we can safely reduce therapy, as well as those 
patients likely to develop joint damage who would need to continue, or even, intensify 
therapy.  
 
Why have I been invited to participate? 
You have rheumatoid arthritis and your disease is still active. Whilst your doctors are 
trying to reduce your disease activity, we would like to take a blood sample from you 
and to compare your immune cells and gene activity to someone with low disease 
activity. The differences and similarities will provide vital information of the different 
disease activity states in RA.  
 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you do, you will be asked to 
sign a consent form to show you have agreed to take part. You are still free to 
withdraw at any time and without giving a reason.  
 
What will happen if I take part? 
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If you agree to take part, no more than 50ml of blood will be taken for research 
purposes. This will take about 10 minutes. You may experience slight discomfort 
and/or minor bruising as a result of giving the blood sample. If you wish to stop at any 
time during the donation, you are able to do so.  
 
What are the possible benefits of taking part? 
The information from the study may help to develop new management approaches for 
patients with rheumatoid arthritis. This will benefit you in the future when your 
disease is under better control. 
 
Will my taking part in this study be kept confidential? 
Yes. We will follow ethical and legal practice and all the information about your 
participation in this study will be kept confidential. Once we have collected the blood, 
all identifiable tags will be replaced by a code. Only the researchers involved in the 
study will be able to view the identifiable data, which are kept in a secure place.  
 
What happens to the results from this study?  
Results from this study may be published in scientific articles or presentations, 
although you may not be made aware of these. You will not be identified in any 
reports of publications.  
 
Will any genetic tests be done? 
As part of this study, participants will have genetic testing done on blood samples to 
see if carrying different genes will influence whether people with arthritis achieve low 
disease activity states.  Genetic tests for other, unrelated conditions will not be tested. 
Using a different technique, we will also compare the activity of a large number of 
genes using a technique called ‘gene expression profiling’. This will measure the 
activity of thousands of genes at once to create a global picture of the function of cells 
in the blood. These tests may help us identify study participants whose disease is in 
remission and provide important clues as to why arthritis continues to cause joint 
damage in a subset of study subjects.   
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should speak to the research 
team who will do their best to answer your question. If you remain unhappy and wish 
to complain formally, you can do this through the formal NHS complaints procedure. 
Details can be obtained from the hospital.  In the unlikely event that something does 
go wrong and you are harmed during the research and this is due to someone’s 
negligence then you may have grounds for a legal action for compensation against the 
NHS Trust administering your care.  You may have to pay your legal costs. The normal 
NHS complaints mechanisms will still be available to you.  
 
Who is organising and funding the research? 
This project is funded by the National Institute of Health and Research (NIHR). 
 
Who has reviewed the study? 
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All research in the NHS is reviewed by an independent group called a Research Ethics 
Committee to protect your safety, rights, well-being and dignity. This study has been 
reviewed by the Wandsworth Research Ethics Committee. Your hospital Research and 
Development Department has also approved this project.  
 
 
We would like to thank you for considering taking part or taking time to read this 
sheet.  
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11.10 Consent Form - Remission Patients 
 
 
Title of Project: TREATMENT DECISIONS IN RHEUMATOID ARTHRITIS: DEFINING LOW 
DISEASE ACTIVITY STATES USING CLINICAL, IMAGING AND BIOLOGICAL MEASURES. 
 
Principle Investigators: Prof David Scott and Prof Andrew Cope 
1. I confirm that I have read and understood the Patient Information Sheet 
dated 21/12/09 for the above study. I have had the opportunity to consider 
the information, ask questions and have these answered satisfactorily.  
 
2. I understand that my participation is voluntary and that I’m free to withdraw 
at any time without giving any reasons, without my medical care or legal 
rights being affected. 
 
3. I understand that relevant sections of my medical notes and data collected 
during the study may be used by the research team from King’s College 
London and their designated collaborators, from regulatory authorities or 
from the NHS, where it is relevant to my taking part in this research. I give 
permission for these individuals for have access to my records. 
 
4. I understand that my blood samples will be used for purposes of laboratory 
research, including gene testing, by the research team and their designated 
collaborators. 
 
5. I consent for my samples to be used in future research studies.  
 
6. I agree to my GP being informed of my participation in the study. 
 





Name:  __________________________ 
 
Signature:  __________________________ 
 
Date:  __________________________ 
PERSON TAKING CONSENT 
 
Name:  _________________________ 
 
Signature:  _________________________ 
 




11.11 Consent Form – Healthy Controls 
 
 
Title of Project: REMIRA STUDY - DEFINING LOW DISEASE ACTIVITY STATES 
IN RHEUMATOID ARTHRITIS USING CLINICAL, IMAGING AND BIOLOGICAL MEASURES 
 
Principle Investigators: Prof David Scott and Prof Andrew Cope 
 
8. I confirm that I have read and understood the Patient Information Sheet 
dated 25/01/10 V1 for the above study. I have had the opportunity to 
consider the information, ask questions and have these answered 
satisfactorily.  
 
9. I understand that my participation is voluntary and that I’m free to withdraw 
at any time without giving any reasons, without my medical care or legal 
rights being affected. 
 
10. I understand that my blood samples will be used for purposes of laboratory 
research, including gene testing, by the research team and their designated 
collaborators. 
 
11. I consent for my samples to be used in future research studies.  
 
12. I agree to be contacted about participation in future studies 
 





Name:  __________________________ 
 
 
Signature:  __________________________ 












PERSON TAKING  CONSENT 
 
Name:  _________________________ 
 
 
Signature:  _________________________ 








11.12 Consent Form - Active RA controls 
 
 
Title of Project: REMIRA STUDY - DEFINING LOW DISEASE ACTIVITY STATES 
IN RHEUMATOID ARTHRITIS USING CLINICAL, IMAGING AND BIOLOGICAL MEASURES 
 
Principle Investigators: Prof David Scott and Prof Andrew Cope 
 
14. I confirm that I have read and understood the Patient Information Sheet 
dated 25/01/10 V1 for the above study. I have had the opportunity to 
consider the information, ask questions and have these answered 
satisfactorily.  
 
15. I understand that my participation is voluntary and that I’m free to withdraw 
at any time without giving any reasons, without my medical care or legal 
rights being affected. 
 
16. I understand that my blood samples will be used for purposes of laboratory 
research, including gene testing, by the research team and their designated 
collaborators. 
 
17. I consent for my samples to be used in future research studies.  
 
18. I agree to be contacted about participation in future studies 
 






Name:  __________________________ 
 
 
Signature:  __________________________ 










PERSON TAKING  CONSENT 
 




Date:  _________________________ 
  
11.13 SF-36 questionnaire 
 
Your Health and Well-Being 
 
 
This survey asks for your views about your health.  This information will 
help keep track of how you feel and how well you are able to do your 
usual activities.  Thank you for completing this survey! 
For each of the following questions, please mark an  in the one box that 
best describes your answer. 
1. In general, would you say your health is: 
 
Excellent Very good Good Fair Poor 
     
  1  2  3  4  5 
 




now than one 
year ago 
Somewhat better 
now than one 
year ago 
About the 
same as one year 
ago 
Somewhat 
worse now than 
one year ago 
Much worse 
now than one 
year ago 
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3. The following questions are about activities you might do during a 
typical day.  Does your health now limit you in these activities?  If so, 
how much? 
 










   
 
 a  Vigorous activities, such as running, lifting  
 heavy objects, participating in strenuous  
 sports  .................................................................... 1 ................... 2 ................... 3 
 
b   Moderate activities, such as moving a table,  
  pushing a vacuum cleaner, bowling, or  
 playing golf ........................................................... 1 ................... 2 ................... 3 
 
c   Lifting or carrying groceries .................................. 1 ................... 2 ................... 3 
 
d  Climbing several flights of stairs ........................... 1 ................... 2 ................... 3 
 
e  Climbing one flight of stairs ................................... 1 ................... 2 ................... 3 
 
f  Bending, kneeling, or stooping ............................... 1 ................... 2 ................... 3 
 
g Walking more than a mile ...................................... 1 ................... 2 ................... 3        
 
h Walking several hundred yards .............................. 1 ................... 2 ................... 3        
 
i Walking one hundred yards .................................... 1 ................... 2 ................... 3        
 
j  Bathing or dressing yourself ................................... 1 ................... 2 ................... 3        
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4. During the past 4 weeks, how much of the time have you had any of 
the following problems with your work or other regular daily 
activities as a result of your physical health? 
 











      
a  Cut down on the amount of time you spent  
on work or other activities ....................................... 1 ......... 2 ........ 3 ......... 4 ......... 5 
b  Accomplished less than you would like .................. 1 ......... 2 ........ 3 ......... 4 ......... 5 
 
c  Were limited in the kind of work or other  
    activities ................................................................. 1 ......... 2 ........ 3 ......... 4 ......... 5 
d  Had difficulty performing the work or other  
  activities (for example, it took extra effort)  ........... 1 ......... 2 ........ 3 ......... 4 ......... 5 
 
5. During the past 4 weeks, how much of the time have you had any of 
the following problems with your work or other regular daily 
activities as a result of any emotional problems (such as feeling 
depressed or anxious)? 











      
a  Cut down on the amount of time you spent  
 on work or other activities ..................................... 1 .......... 2 ......... 3 ......... 4 ........ 5  
b  Accomplished less than you would like ................ 1 .......... 2 ......... 3 ......... 4 ........ 5 
 
c  Did work or other activities less carefully  
 than usual ............................................................... 1 .......... 2 ......... 3 ......... 4 ........ 5 
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6. During the past 4 weeks, to what extent has your physical health or 
emotional problems interfered with your normal social activities with 
family, friends, neighbors, or groups? 
Not at all Slightly Moderately Quite a bit Extremely 
     
 1  2  3   4  5 
 
7. How much bodily pain have you had during the past 4 weeks? 
None Very mild Mild Moderate Severe Very Severe 
      
 1  2  3  4  5  6 
 
8. During the past 4 weeks, how much did pain interfere with your 
normal work (including both work outside the home and housework)? 
Not at all A little bit Moderately Quite a bit Extremely 
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9. These questions are about how you feel and how things have been with 
you during the past 4 weeks.  For each question, please give the one 
answer that comes closest to the way you have been feeling.  How 
much of the time during the past 4 weeks... 












     
 
a   Did you feel full of life? ...................................... 1 .......... 2.......... 3 .......... 4.......... 5  
b  Have you been very nervous? ............................. 1 .......... 2........... 3 .......... 4.......... 5  
 c  Have you felt so down in the dumps  
 that nothing could cheer you up? ........................ 1 .......... 2........... 3 .......... 4.......... 5  
d  Have you felt calm and peaceful? ....................... 1 .......... 2........... 3 .......... 4.......... 5  
 
e  Did you have a lot of energy? ............................. 1 .......... 2........... 3 .......... 4.......... 5  
 
f  Have you felt downhearted and  
 depressed? ........................................................... 1 .......... 2........... 3 .......... 4.......... 5  
 
g  Did you feel worn out? ....................................... 1 .......... 2........... 3 .......... 4.......... 5  
 
h  Have you been happy? ........................................ 1 .......... 2........... 3 .......... 4.......... 5  
 
i  Did you feel tired? ............................................... 1 .......... 2........... 3 .......... 4.......... 5  
 
 
10.  During the past 4 weeks, how much of the time has your physical 
health  or emotional problems interfered with your social activities 
(like visiting friends, relatives, etc.)? 
All of the 
time 
Most of the 
time 
Some of the 
time 
A little of the 
time 
None of the 
time 
     
 1  2  3   4  5 
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a  I seem to get sick a little easier  
 than other people .................................... 1 ............ 2 ........... 3 ........... 4 ........... 5   
b  I am as healthy as anybody I know ........ 1 ............ 2 ........... 3 ........... 4 ........... 5 
c  I expect my health to get worse .............. 1 ............ 2 ........... 3 ........... 4 ........... 5  
d  My health is excellent ............................ 1 ............ 2 ........... 3 ........... 4 ........... 5  
 
 
THANK YOU FOR COMPLETING THESE QUESTIONS! 
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11.14 FACIT-F form 
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11.15 Health assessment questionnaire 
We are interested in learning how your illness affects your ability to function in daily life. Please feel free to add any 
comments at the end of this form. Please tick one response which best describes your usual abilities over the past 
week 
       Without    With     With    Unable 
     Any      Some     Much   To Do 
  difficulty Difficulty Difficulty       
1. DRESSING AND GROOMING   
Are you able to: 
 
a. Dress yourself, including tying 
shoelaces and doing buttons? 
 



























Are you able to: 
 
a. Stand up from an armless  
straight chair? 
 



























Are you able to: 
 
a. Cut your Meat? 
 
b. Lift a full cup or glass to your 
mouth? 
 
c. Open a new carton of milk 








































Are you able to: 
 
a. Walk outdoors on flat ground? 
 






















Please tick any aids or devices that you usually use for any of these activities: 
  
Cane (W)  Walking frame (W)  Built-up or special utensils (E)  
Crutches (W)  Wheelchair (W)   Special or built-up chair (R)  
Devices used for dressing (buttonhooks, zipper pull, shoe horn)     
Other (specify)………………………………………………………………………………. 
  
Please tick any categories for which you usually need help from another person: 
Dressing and Grooming   Eating    
Rising     Walking    
Please tick the one response which best describes your usual abilities over the past 
week 

















Are you able to: 
 
a. Wash and dry your entire body? 
 
b. Take a bath? 
 
































Are you able to: 
 
a. Reach and get down a 5lb object 
(e.g. a bag of potatoes) from just 
above your head? 
 
b. Bend down to pick up clothing 
































Are you able to: 
 
a. Open car doors? 
 













































Are you able to: 
 
a. Run errands and shop? 
 
b. Get in and out of a car? 
 
c. Do chores such as vacuuming  































Please tick any aids or devices that you usually use for any of these activities: 
Raised toilet seat (h)  bath seat (h)  bath rail (h)     
Long handled appliances for reach (r)  Jar opener (for jars previously opened) (g)  
Please tick any categories for which you usually need help from another Person: 
 
Hygiene   Gripping and opening things  
Reach    Errands and housework   
 
  331 
11.16 EuroQol/EQ-5D 
 
By placing a tick in one box in each group below, please indicate which statements best 
describe your own health state today. 
 
 
1. Mobility (please tick one box) 
 
 I have no problems in walking about 
 I have some problems walking about 
 I am confined to bed 
 
 
2. Self-care (please tick one box) 
 
 I have no problems with self-care 
 I have some problems washing or dressing myself 
 I am unable to wash or dress myself 
 
 
3. Usual activities e.g. work, study, housework, family or leisure activities 
    (please tick one box) 
 
 I have no problems with performing my usual activities 
 I have some problems performing my usual activities 
 I am unable to perform my usual activities 
 
4. Pain/Discomfort (please tick one box) 
 
 I have no pain or discomfort 
 I have moderate pain or discomfort 
 I have extreme pain or discomfort 
 
5. Anxiety/Depression (please tick one box) 
 
 I am not anxious or depressed 
 I am moderately anxious or depressed 
 I am extremely anxious or depressed 
 
6. Compared with my general level of health over the past 12 months, my 
    health state today is (please tick one box) 
 
 Better 
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VISUAL ANALOGUE SCALE. 
 
 
To help people say how good or bad a health state is, we 
have drawn a scale (rather like a thermometer) on which 
the best state you can imagine is marked 100 and the 
worst state you can imagine is marked 0. 
 
We would like you to indicate on this scale how good or 
bad your own health is today, in your opinion. Please 
do this by drawing a line from the box below to 
whichever point on the scale indicates how good or bad 
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11.17 Summary of REMIRA study 
  
 
